var title_f18_56_19328="Duplication cyst Endosc";
var content_f18_56_19328=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Duplication cyst in the esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of esophageal compression (arrow) due to a duplication cyst.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Lee Krinsky, DO and Kenneth Binmoeller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_56_19328=[""].join("\n");
var outline_f18_56_19328=null;
var title_f18_56_19329="Calculator: Blatchford score for gastrointestinal bleeding";
var content_f18_56_19329=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"BlatchfordScore_form\" name=\"BlatchfordScore_form\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Blatchford score for gastrointestinal bleeding",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <div id=\"calc_input\">",
"      <center>",
"       <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Blood Urea Nitrogen",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"BlatchfordScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &lt;18.2 mg/dL (&lt;6.5 mmol/L) (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"BlatchfordScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &gt;=18.2 and &lt;22.4 mg/dL (&gt;=6.5 and &lt;8 mmol/L) (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"BlatchfordScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &gt;=22.4 and &lt;28 mg/dL (&gt;=8 and &lt;10 mmol/L) (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"BlatchfordScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &gt;=28 and &lt;70 mg/dL (&gt;=10 and &lt;25 mmol/L) (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"BlatchfordScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &gt;=70 mg/dL (&gt;=25 mmol/L) (6 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Hemoglobin",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"BlatchfordScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Male &gt;=13 gm/dL (&gt;130 gm/L) (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"BlatchfordScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Male &gt;=12 and &lt;13 gm/dL (&gt;=120 and &lt;130 gm/L) (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"BlatchfordScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Male &gt;=10 and &lt;12 gm/dL (&gt;=100 and &lt;120 gm/L) (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"BlatchfordScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Female &gt;=12 gm/dL (&gt;120 gm/L) (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"BlatchfordScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Female &gt;=10 and &lt;12 gm/dL (&gt;=100 and &lt;120 gm/L) (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"BlatchfordScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Male or female &lt;10 gm/dL (&lt;100 gm/L) (6 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Systolic BP",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"BlatchfordScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &gt;=110 mmHg (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"BlatchfordScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           100-109 mmHg (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"BlatchfordScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           90-99 mmHg (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"BlatchfordScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &lt;90 mmHg (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Other Markers",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"BlatchfordScore_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Heart rate &gt;=100 per minute (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"BlatchfordScore_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Melena at presentation (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"BlatchfordScore_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Syncope at presentation (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"BlatchfordScore_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Hepatic disease present (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"BlatchfordScore_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Cardiac failure present (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <div id=\"calc_result\">",
"      <span class=\"medCalcFontCCTabBold\">",
"       Total Criteria Point Count:",
"      </span>",
"      <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"      </center>",
"     </div>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       A score of zero is associated with a low risk of the need for endoscopic intervention.",
"      </li>",
"      <li>",
"       Please see appropriate UpToDate topic reviews for further information.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage.",
"        <i>",
"         Lancet",
"        </i>",
"        . 2000 Oct 14;356(9238):1318-21.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
";",
"BlatchfordScore_fx();",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_56_19329=[" ",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function BlatchfordScore_fx() {",
"with(document.BlatchfordScore_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1[0].checked){",
"Score = Score + 0;",
"}",
"if (cc1[1].checked){",
"Score = Score + 2;",
"}",
"if (cc1[2].checked){",
"Score = Score + 3;",
"}",
"if (cc1[3].checked){",
"Score = Score + 4;",
"}",
"if (cc1[4].checked){",
"Score = Score + 6;",
"}",
"if (cc2[0].checked){",
"Score = Score + 0;",
"}",
"if (cc2[1].checked){",
"Score = Score + 1;",
"}",
"if (cc2[2].checked){",
"Score = Score + 3;",
"}",
"if (cc2[3].checked){",
"Score = Score + 0;",
"}",
"if (cc2[4].checked){",
"Score = Score + 1;",
"}",
"if (cc2[5].checked){",
"Score = Score + 6;",
"}",
"if (cc3[0].checked){",
"Score = Score + 0;",
"}",
"if (cc3[1].checked){",
"Score = Score + 1;",
"}",
"if (cc3[2].checked){",
"Score = Score + 2;",
"}",
"if (cc3[3].checked){",
"Score = Score + 3;",
"}",
"if (cc4.checked){",
"Score = Score + 1;",
"}",
"if (cc5.checked){",
"Score = Score + 1;",
"}",
"if (cc6.checked){",
"Score = Score + 2;",
"}",
"if (cc7.checked){",
"Score = Score + 2;",
"}",
"if (cc8.checked){",
"Score = Score + 2;",
"}",
"cctotal.value = Score;",
"}",
"}",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f18_56_19329=null;
var title_f18_56_19330="Patient information: Congenital adrenal hyperplasia (The Basics)";
var content_f18_56_19330=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/19/11570\">",
"         Patient information: Adrenal crisis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/58/31650\">",
"         Patient information: Early puberty (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/1/30738\">",
"         Patient information: Normal sexual development (puberty) (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Congenital adrenal hyperplasia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/congenital-adrenal-hyperplasia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H102065245\">",
"      <span class=\"h1\">",
"       What is congenital adrenal hyperplasia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Congenital adrenal hyperplasia, also called CAH, is a genetic disorder that affects a pair of organs in the body called the &ldquo;adrenal glands.&rdquo; The adrenal glands are located just above the kidneys. They make a lot of different hormones.",
"     </p>",
"     <p>",
"      There is more than one type of CAH. This article is about the most common type, called &ldquo;classic CAH.&rdquo; Classic CAH is usually diagnosed soon after birth.",
"     </p>",
"     <p>",
"      In classic CAH, 3 main hormones can be out of balance:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Aldosterone",
"        </strong>",
"        &ndash; This hormone helps control the amount of salt and fluid in the body. People with classic CAH often make",
"        <strong>",
"         too little",
"        </strong>",
"        aldosterone.",
"       </li>",
"       <li>",
"        <strong>",
"         Cortisol",
"        </strong>",
"        &ndash; This hormone helps control how the body uses sugar. People with classic CAH often make",
"        <strong>",
"         too little",
"        </strong>",
"        cortisol.",
"       </li>",
"       <li>",
"        <strong>",
"         Androgens",
"        </strong>",
"        &ndash; Androgens are also known as &ldquo;male hormones.&rdquo; People with classic CAH generally make",
"        <strong>",
"         too much",
"        </strong>",
"        of these hormones.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H102065252\">",
"      <span class=\"h1\">",
"       What are the symptoms of congenital adrenal hyperplasia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms are different depending on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        How severe the condition is",
"       </li>",
"       <li>",
"        Whether the person with CAH is male or female",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Babies with severe CAH do not make enough aldosterone or cortisol. This can cause a serious condition called &ldquo;adrenal crisis,&rdquo; which makes babies very sick. Babies with adrenal crisis have low blood sugar and low blood pressure, and they do not gain weight as they should.",
"     </p>",
"     <p>",
"      Girls with CAH have another problem. They are born with genitals that look like somewhat like those of a boy. That&rsquo;s because they make too much male hormone.",
"     </p>",
"     <p>",
"      In children of either sex, if CAH is not found and treated early, puberty can happen earlier than it is supposed to. This can cause the child to be shorter than expected because he or she stops growing too soon.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H102065259\">",
"      <span class=\"h1\">",
"       Is there a test for congenital adrenal hyperplasia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Today most newborn babies in the US and many other countries have a blood test to check for classic CAH. The test is done as part of the routine newborn screening tests.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H102065266\">",
"      <span class=\"h1\">",
"       How is congenital adrenal hyperplasia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main treatment is pills that contain the hormones that the adrenal gland does not make enough of. This includes:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines called &ldquo;steroids,&rdquo; which replace missing cortisol",
"       </li>",
"       <li>",
"        A medicine called",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?37/11/38069?source=see_link\">",
"         fludrocortisone",
"        </a>",
"        (brand name: Florinef&reg;), which replaces missing aldosterone",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Having just the right amount of these medicines is very important in making sure that children grow normally and go through puberty at a right time. The doctor will decide on the right amount of hormone pills by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Doing blood tests every so often to check hormone levels",
"       </li>",
"       <li>",
"        Measuring the child&rsquo;s growth",
"       </li>",
"       <li>",
"        Doing X-ray studies once in a while to check how the bones are growing",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some children with CAH also need to take salt tablets or eat extra salt. As they get older, they can often stop taking these extra sources of salt if the doctor says that it is safe to stop.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H102065273\">",
"      <span class=\"h1\">",
"       What can be done about abnormal genitals in girls?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Girls with abnormal genitals can have surgery to make them look more like girls without CAH. But surgery is not always needed and it does not need to happen right away.",
"     </p>",
"     <p>",
"      If your daughter has abnormal genitals, your doctor can put you in touch with a team of CAH experts. These experts can help you figure out what is best for your daughter. You will have to decide whether she should have surgery and, if so, when. These decisions can be hard. The people on the treatment team can help you understand your choices and the pros and cons of each option. Make sure you have a treatment team with a lot of experience with this type of problem.",
"     </p>",
"     <p>",
"      If your daughter does not have surgery right away, you can still treat her as you would any daughter. Her genes and the organs inside her body are like those of any girl. With the right treatments, she should be able to get pregnant some day, if she wants to.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H102065280\">",
"      <span class=\"h1\">",
"       Are there problems I should watch for?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Children with CAH sometimes have a serious problem called &ldquo;adrenal crisis.&rdquo; This can happen if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The child is sick, especially if he or she is vomiting, or has fever or an infection",
"       </li>",
"       <li>",
"        The child stops taking his or her medicine",
"       </li>",
"       <li>",
"        The child has surgery",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your child&rsquo;s doctor will tell you what to do if your child gets sick. If your child has a high fever or is vomiting, you might need to give your child higher doses of the medicines he or she normally takes. In some cases, you might even need to give your child a shot and take him or her to the emergency room. It is important to do this right away to prevent an adrenal crisis.",
"     </p>",
"     <p>",
"      An adrenal crisis usually comes on suddenly. The symptoms of an adrenal crisis can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Loss of appetite",
"       </li>",
"       <li>",
"        Vomiting",
"       </li>",
"       <li>",
"        Belly pain",
"       </li>",
"       <li>",
"        Weakness",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Confusion",
"       </li>",
"       <li>",
"        Passing out",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H102065287\">",
"      <span class=\"h1\">",
"       What will my child&rsquo;s life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your child will need help and support to understand and cope with CAH. It is a life-long condition, so your child will need to take medicines for the rest of his or her life. Still, treatment is effective, so most children with CAH have a fairly normal life.",
"     </p>",
"     <p>",
"      Girls with CAH who have abnormal genitals often have to sort out how they feel about their appearance and identity. Some feel like they relate more to boys. Others feel like regular girls. Offer your daughter support, without judgement, as she figures this out.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H102065343\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/1/30738?source=see_link\">",
"       Patient information: Normal sexual development (puberty) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/58/31650?source=see_link\">",
"       Patient information: Early puberty (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/19/11570?source=see_link\">",
"       Patient information: Adrenal crisis (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?18/56/19330?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16935 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-49B032D4AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_56_19330=[""].join("\n");
var outline_f18_56_19330=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102065245\">",
"      What is congenital adrenal hyperplasia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102065252\">",
"      What are the symptoms of congenital adrenal hyperplasia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102065259\">",
"      Is there a test for congenital adrenal hyperplasia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102065266\">",
"      How is congenital adrenal hyperplasia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102065273\">",
"      What can be done about abnormal genitals in girls?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102065280\">",
"      Are there problems I should watch for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102065287\">",
"      What will my child&rsquo;s life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102065343\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/19/11570?source=related_link\">",
"      Patient information: Adrenal crisis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/58/31650?source=related_link\">",
"      Patient information: Early puberty (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/1/30738?source=related_link\">",
"      Patient information: Normal sexual development (puberty) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_56_19331="Vitamin A and vitamin D (systemic): Patient drug information";
var content_f18_56_19331=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Vitamin A and vitamin D (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/23/371?source=see_link\">",
"     see \"Vitamin A and vitamin D (systemic): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14731099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      A&amp;D Jr. [OTC];",
"     </li>",
"     <li>",
"      D-Natural-5 [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F14727437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692172",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vitamins are needed for growth and good health.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F14727157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703133",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to vitamin A, vitamin D, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F14727159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F14727440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14727160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F14727439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F14727158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F14727161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86237 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-4B2100FB5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_56_19331=[""].join("\n");
var outline_f18_56_19331=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14731099\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14727437\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14727157\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14727159\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14727440\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14727160\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14727439\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14727158\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14727161\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/23/371?source=related_link\">",
"      Vitamin A and vitamin D (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/21/13650?source=related_link\">",
"      Vitamin A and vitamin D (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/17/41235?source=related_link\">",
"      Vitamin A and vitamin D (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_56_19332="Nodular lymphoid hyperplasia High I";
var content_f18_56_19332=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular lymphoid hyperplasia in Sj&ouml;gren's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power photomicrograph shows heterogenous foci of lymphocytes and plasma cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Colby TV, Koss MN, Travis WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_56_19332=[""].join("\n");
var outline_f18_56_19332=null;
var title_f18_56_19333="Local palliation for advanced gastric cancer";
var content_f18_56_19333=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Local palliation for advanced gastric cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/56/19333/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/56/19333/contributors\">",
"     Johanna Bendell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/56/19333/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/56/19333/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/56/19333/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/56/19333/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/56/19333/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with gastric cancer will require palliative treatment at some point in the course of their disease. Approximately 50 percent of patients already have advanced incurable disease at the time of initial presentation, and even those who undergo potentially curative resection have high rates of distant as well as local recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33018?source=see_link&amp;anchor=H19#H19\">",
"     \"Invasive gastric cancer: Surgery and prognosis\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Palliative treatments for advanced gastric cancer can be either local or systemic. While cytotoxic chemotherapy is the most effective treatment modality for patients with metastatic disease, it is frequently inadequate for palliation of local symptoms such nausea, pain, obstruction, perforation, or bleeding from a locally advanced or locally recurrent primary tumor, which require multidisciplinary management using endoscopic, surgical, radiotherapeutic or other approaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44202?source=see_link\">",
"     \"Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will focus on local palliative treatments for patients with locally advanced unresectable or metastatic gastric cancer. Chemotherapy for locally advanced unresectable or metastatic esophageal and gastric cancer is discussed elsewhere, as is endoscopic palliation for dysphagia in patients with locally advanced or recurrent esophageal cancer and primary surgical treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44202?source=see_link\">",
"     \"Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42006?source=see_link\">",
"     \"Endoscopic palliation of esophageal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33018?source=see_link\">",
"     \"Invasive gastric cancer: Surgery and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34282?source=see_link\">",
"     \"Surgical oncologic principles for management of resectable esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THERAPEUTIC OPTIONS FOR LOCAL PALLIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic options to control symptoms of local disease progression such as nausea, pain, bleeding and obstruction include palliative surgical resection, surgical bypass (gastrojejunostomy), radiation therapy, and endoscopic techniques. All forms of palliative therapy must take into account the overall prognosis of the patient in order to avoid excessive morbidity and mortality or lengthy hospital stays in those with a limited life span.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Palliative resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palliative gastrectomy may provide symptomatic relief of pain, nausea, bleeding, obstruction, and perforation, and possibly prolong survival [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19333/abstract/1-9\">",
"     1-9",
"    </a>",
"    ], although this has not been seen in all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19333/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. More extensive procedures such as radical gastrectomy are associated with high rates of perioperative morbidity, they provide no survival benefit, and they are rarely indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19333/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A benefit for palliative gastrectomy over gastrojejunostomy alone was suggested in a retrospective series of 75 patients with advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19333/abstract/3\">",
"     3",
"    </a>",
"    ]. Palliative resection was associated with a significantly longer duration of symptom relief (14.6 versus 5.9 months), with a lower operative mortality rate (15 versus 25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19333/abstract/3\">",
"     3",
"    </a>",
"    ]. Similarly, in another report of 51 patients who underwent palliative resection or bypass, the mean survival after surgery was higher in patients undergoing resection (9.5 versus 4.2 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19333/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A significant problem with these reports is selection bias; those patients who were candidates for surgical resection may have had a smaller disease burden and better performance status and prognosis than those who received only a bypass procedure, or no surgical intervention at all. These issues were addressed in a retrospective study that attempted to stratify patients with advanced gastric cancer who were not candidates for curative resection according to presurgical disease extent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19333/abstract/2\">",
"     2",
"    </a>",
"    ]. The median survival for patients undergoing palliative resection was significantly longer as compared to those who had bypass, exploratory laparotomy only, or no surgery at all (8 versus 3.5, 2.8 and 2.4 months, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19333/abstract/2\">",
"     2",
"    </a>",
"    ]. When patients were stratified into three groups according to the extent of disease spread (local, distant, or local plus distant), the benefit of a bypass procedure was limited to those with localized disease while the advantage of palliative resection was apparent in all groups.",
"   </p>",
"   <p>",
"    Another less invasive surgical option is laparoscopic gastrojejunostomy. Multiple case reports and small studies report successful palliation of malignant gastric outlet obstruction using this minimally invasive approach. A small retrospective comparison of patients who had palliative laparoscopic (n = 10) versus open (n = 10) gastrojejunostomy showed a similar mean surgery time but less intraoperative blood loss (23 versus 142 mL) and a shorter length of stay (8 versus 124 days) for the laparoscopically-treated group [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19333/abstract/14\">",
"     14",
"    </a>",
"    ]. However the differences were not statistically significant, likely because of the small sample size.",
"   </p>",
"   <p>",
"    In current practice, palliative resection for patients with metastatic gastric cancer is only rarely performed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19333/abstract/15\">",
"     15",
"    </a>",
"    ]. It is reserved for extreme cases where less invasive methods, such as palliative radiation therapy with or without chemotherapy, endoscopic procedures such as ablation, stenting, or J-tube placement to establish a route for enteral nutrition cannot be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nonsurgical palliation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of nonsurgical measures have been evaluated for palliation of obstructive symptoms or uncontrolled bleeding, which may be acute or chronic. Medical therapies such as antacids and H2-antagonists are often of little benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Endoscopic stent placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;For palliation of obstructive symptoms, endoscopic placement of a stent provides a less invasive alternative to surgery for symptom palliation and may possibly be more effective in symptom relief. Published experience with enteral stenting for gastroduodenal obstruction is derived mostly from case series and small comparative trials. The available data suggest that enteral stenting has a similar success rate as surgical palliation (with approximately 90 percent of patients improving clinically) but is associated with less morbidity, procedure-related mortality, and cost. Furthermore, stenting may achieve a better quality of life compared with other forms of palliation (such as non-oral feeding through a jejunostomy tube), although they have not been directly compared in controlled trials.",
"   </p>",
"   <p>",
"    In a review of two randomized trials of endoscopic stenting versus palliative gastrojejunostomy, six comparative studies, and 36 retrospective series, there were no statistically significant differences between the two procedures in terms of efficacy or complications [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19333/abstract/16\">",
"     16",
"    </a>",
"    ]. However, stenting was associated with a trend toward shorter hospital stay, a higher clinical success rate and a faster relief of obstructive symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19333/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients who received stents did require reintervention more frequently than did surgically-treated patients.",
"   </p>",
"   <p>",
"    This subject is addressed in further detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37895?source=see_link\">",
"     \"Enteral stents for the palliation of malignant gastroduodenal obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;External beam radiation therapy (RT) has a well-defined role in the control of pain, bleeding, or obstruction in patients with localized but unresectable gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19333/abstract/17\">",
"     17",
"    </a>",
"    ]. A retrospective review of 37 patients with gastric cancer treated with palliative RT (median dose, 35 Gy) revealed that rates of control of bleeding,",
"    <span class=\"nowrap\">",
"     dysphagia/obstruction,",
"    </span>",
"    and pain were 70, 81, and 86 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19333/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients who received chemotherapy in addition to RT had a trend towards improved median overall survival (6.7 versus 2.4 months, p = 0.08), although the possibility of selection bias cannot be excluded. Local control was inferior at radiation doses of less than 41 Gy.",
"   </p>",
"   <p>",
"    Two other studies evaluating palliative chemoradiotherapy have also demonstrated durable palliation of dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19333/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no controlled studies that directly compare RT or chemoradiotherapy with endoscopic or surgical techniques for symptomatic palliation. However, responses to RT are not as immediate as with stenting or surgical palliation. Furthermore, while control of bleeding may be possible with low RT doses that are not associated with significant side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19333/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], doses above 40 Gy (which may be associated with significant adverse effects) are often required for palliation of obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Endoscopic laser therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic laser treatment can effectively palliate dysphagia due to obstruction in 75 to 93 percent of patients with esophageal or gastric cardia tumors (",
"    <a class=\"graphic graphic_figure graphicRef79793 \" href=\"UTD.htm?4/45/4817\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19333/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42006?source=see_link\">",
"     \"Endoscopic palliation of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of endoscopic procedures have been used for the control of tumor-induced hemorrhage; there are no controlled studies to compare their relative efficacy. Laser photocoagulation can be effective, particularly for large tumors with diffuse bleeding, although the equipment is expensive and not widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19333/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. An alternative that is being used increasingly is argon plasma coagulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34695?source=see_link\">",
"     \"Argon plasma coagulation in the management of gastrointestinal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31210540\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of patients with gastric cancer will require palliative treatment at some point in the course of their disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cytotoxic chemotherapy is the most effective treatment modality for metastatic disease, but may be inadequate for palliation of local symptoms such nausea, pain, obstruction, perforation, or bleeding from a locally advanced or locally recurrent primary tumor. Many patients require multidisciplinary management using endoscopic, surgical, radiotherapeutic or other approaches. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Therapeutic options for local palliation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although effective, palliative resection for patients with metastatic gastric cancer is only rarely performed and reserved for extreme cases where less invasive methods cannot be used. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Palliative resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with obstructive symptoms, we recommend endoscopic placement of a stent or external beam radiation therapy (RT) rather than palliative surgery (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Endoscopic stenting has a similar success rate as surgical palliation (with approximately 90 percent of patients improving clinically) but is associated with less morbidity, procedure-related mortality, and cost. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Endoscopic stent placement'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      RT can control pain, bleeding, and obstruction in patients with localized but unresectable gastric cancer, but responses may be delayed. Furthermore, while control of bleeding may be possible with low RT doses that are not associated with significant side effects, doses above 40 Gy are often required for palliation of obstruction. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Another option to palliate dysphagia due to obstruction in patients with esophageal or gastric cardia tumors is endoscopic laser ablation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Endoscopic laser therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/1\">",
"      Meijer S, De Bakker OJ, Hoitsma HF. Palliative resection in gastric cancer. J Surg Oncol 1983; 23:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/2\">",
"      Bozzetti F, Bonfanti G, Audisio RA, et al. Prognosis of patients after palliative surgical procedures for carcinoma of the stomach. Surg Gynecol Obstet 1987; 164:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/3\">",
"      Ekbom GA, Gleysteen JJ. Gastric malignancy: resection for palliation. Surgery 1980; 88:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/4\">",
"      Kasakura Y, Ajani JA, Mochizuki F, et al. Outcomes after emergency surgery for gastric perforation or severe bleeding in patients with gastric cancer. J Surg Oncol 2002; 80:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/5\">",
"      Doglietto GB, Pacelli F, Caprino P, et al. Surgery: independent prognostic factor in curable and far advanced gastric cancer. World J Surg 2000; 24:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/6\">",
"      Hanazaki K, Sodeyama H, Mochizuki Y, et al. Palliative gastrectomy for advanced gastric cancer. Hepatogastroenterology 2001; 48:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/7\">",
"      Monson JR, Donohue JH, McIlrath DC, et al. Total gastrectomy for advanced cancer. A worthwhile palliative procedure. Cancer 1991; 68:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/8\">",
"      Zhang JZ, Lu HS, Huang CM, et al. Outcome of palliative total gastrectomy for stage IV proximal gastric cancer. Am J Surg 2011; 202:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/9\">",
"      Chang YR, Han DS, Kong SH, et al. The value of palliative gastrectomy in gastric cancer with distant metastasis. Ann Surg Oncol 2012; 19:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/10\">",
"      Kahlke V, Bestmann B, Schmid A, et al. Palliation of metastatic gastric cancer: impact of preoperative symptoms and the type of operation on survival and quality of life. World J Surg 2004; 28:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/11\">",
"      Ouchi K, Sugawara T, Ono H, et al. Therapeutic significance of palliative operations for gastric cancer for survival and quality of life. J Surg Oncol 1998; 69:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/12\">",
"      Kikuchi S, Arai Y, Kobayashi N, et al. Is extended lymphadenectomy valuable in palliatively gastrectomized patients with gastric cancer and simultaneous peritoneal metastasis? Hepatogastroenterology 2000; 47:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/13\">",
"      Kokkola A, Louhimo J, Puolakkainen P. Does non-curative gastrectomy improve survival in patients with metastatic gastric cancer? J Surg Oncol 2012; 106:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/14\">",
"      Guzman EA, Dagis A, Bening L, Pigazzi A. Laparoscopic gastrojejunostomy in patients with obstruction of the gastric outlet secondary to advanced malignancies. Am Surg 2009; 75:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/15\">",
"      Sarela AI, Yelluri S, Leeds Upper Gastrointestinal Cancer Multidisciplinary Team. Gastric adenocarcinoma with distant metastasis: is gastrectomy necessary? Arch Surg 2007; 142:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/16\">",
"      Jeurnink SM, van Eijck CH, Steyerberg EW, et al. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. BMC Gastroenterol 2007; 7:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/17\">",
"      Tey J, Back MF, Shakespeare TP, et al. The role of palliative radiation therapy in symptomatic locally advanced gastric cancer. Int J Radiat Oncol Biol Phys 2007; 67:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/18\">",
"      Kim MM, Rana V, Janjan NA, et al. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol 2008; 47:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/19\">",
"      Harvey JA, Bessell JR, Beller E, et al. Chemoradiation therapy is effective for the palliative treatment of malignant dysphagia. Dis Esophagus 2004; 17:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/20\">",
"      Burmeister BH, Denham JW, O'Brien M, et al. Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study. Int J Radiat Oncol Biol Phys 1995; 32:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/21\">",
"      Hashimoto K, Mayahara H, Takashima A, et al. Palliative radiation therapy for hemorrhage of unresectable gastric cancer: a single institute experience. J Cancer Res Clin Oncol 2009; 135:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/22\">",
"      Asakura H, Hashimoto T, Harada H, et al. Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate? J Cancer Res Clin Oncol 2011; 137:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/23\">",
"      Norberto L, Ranzato R, Marino S, et al. Endoscopic palliation of esophageal and cardial cancer: neodymium-yttrium aluminum garnet laser therapy. Dis Esophagus 1999; 12:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/24\">",
"      Freitas D, Gouveia H, Sofia C, et al. Endoscopic Nd-YAG laser therapy as palliative treatment for esophageal and cardial cancer. Hepatogastroenterology 1995; 42:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/25\">",
"      Wu KL, Tsao WL, Shyu RY. Low-power laser therapy for gastrointestinal neoplasia. J Gastroenterol 2000; 35:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/26\">",
"      Barr H, Krasner N. Interstitial laser photocoagulation for treating bleeding gastric cancer. BMJ 1989; 299:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19333/abstract/27\">",
"      Mathus-Vliegen EM, Tytgat GN. Laser photocoagulation in the palliative treatment of upper digestive tract tumors. Cancer 1986; 57:396.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2521 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-213.131.41.98-64F77B4D5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_56_19333=[""].join("\n");
var outline_f18_56_19333=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31210540\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THERAPEUTIC OPTIONS FOR LOCAL PALLIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Palliative resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nonsurgical palliation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Endoscopic stent placement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Endoscopic laser therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31210540\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2521\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2521|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/45/4817\" title=\"figure 1\">",
"      Parts of the stomach",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34695?source=related_link\">",
"      Argon plasma coagulation in the management of gastrointestinal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44202?source=related_link\">",
"      Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42006?source=related_link\">",
"      Endoscopic palliation of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37895?source=related_link\">",
"      Enteral stents for the palliation of malignant gastroduodenal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33018?source=related_link\">",
"      Invasive gastric cancer: Surgery and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34282?source=related_link\">",
"      Surgical oncologic principles for management of resectable esophageal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_56_19334="Esophageal lichen planus";
var content_f18_56_19334=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Esophageal lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 527px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Endoscopy showing erosions.",
"    <br>",
"     (B) Stricture and erosions.",
"     <br>",
"      (C) Stricture.",
"      <br>",
"       (D) Bulla formation in the esophagus.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Copyright &copy; Grant Anhalt, MD, Dermatlas;",
"        <a href=\"file://www.dermatlas.org\" target=\"_blank\">",
"         file://www.dermatlas.org",
"        </a>",
"        .",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_56_19334=[""].join("\n");
var outline_f18_56_19334=null;
var title_f18_56_19335="Loa loa life cycle";
var content_f18_56_19335=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Loa loa life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwAg0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOI/4WFFP4y1nw1pfh/W9SvtI8n7XJbm2SNRKgdSDLMhPB7Dsfak8G/ESw1/U9bsb0WumXFhrM+j20ct2pa8aLGWRSFOcH7o3Y9aydL+GMD/FXxb4n8Q2Gi6lZ6l9kawWeETS27RRhWJDphSSBgqT0GcVxHjf4e61ongzxfqVqjXeuyeKP+Eg0UabC9xKjNIoAZdox8pbd1XjqaAPedO1Ow1OOeTTb61u44JWgla3mWQRyL95GIJwwyMg8iuT8TfFTwdoOhahqZ1yw1EWO3zbbT7uGacksFwE3jnJ7kdDT/A3g5fDfwwt/DskUV3ctaOLsSSlFuJ5ATJucAkAsxG4AkDHXFebxfB/xW3g7xL4cGswWuiXlmkOn6ZLfPepbyrKsm7zWhjZV+UjaFP3s84AoA9Vh+IPhGSxsLqTxNotvHfRCWBZr+FGcZKnHzc4YFTjOCCO1X9Z8VeHtElii1rXtJ06WVPMjS7vI4S6/3gGIyPevJvG3w78eeJtOSxk1DTYtObR/sH9npqtzFDFcq2BMSkI85SoHyOAAT325PHeOPBOv6BZ6lZWFpJrV9qvhyw0h0t7O7fyZIgiExyiExFCU3EO8ZHUjoCAfRN94r8O2E1pFfa9pNtLdqr2yTXkaNMrfdKAn5gexHWn3HifQbbWU0i41vS4tWchUsnu41nYnoBGTuOe3FeMz/BrVJdQvLm4isdWs9U0yztbiyvNVu7NbeWCJEGRACs6ZXdtbGD0I5J29P+HHiLTPiFFrGgXkOiaZLdLNqUUWpS3KX6KAMGB4QEZhnnzGxnjOBQB7FRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACMdqknoBmvPbX4s6Fc+DfDviWO01MWGu6iumW0bRx+YkrO6AuN+AuY25BJ6cV6DICyMo6kEV4FpPwLuLDwJ4NsVt/DyeJNJ1mO/vtRjQhpoFlkfYJfL3scMgw2B8vXgUAezt4o8Pqrs2uaUFS7+wMTdx4W5/54nniTg/J19qh/4TPwv9re1/4STRftKM6ND9ui3qyffBXdnK9x2715BqXwg8Sy3eoW9rc6MdNuPFyeJUmknlWUJ826IoIyM88HdzjtU9v8H9djuLCR7rSiIPGkniN/3kmTbMUwg+T/WfKeOn+1QB6xN4x8MQ6XDqU3iPRY9OncxxXTX0QikYdVV92CRg8A0tx4w8NW1vaz3HiLRooLqNpreSS+iVZkX7zIS2GA7kcCvKNO+GPjXStLey0/WLOO1m8Q3Op3Nrb389p9otpAmyPz4498ZBVshRg7utU/AfwX8QaBqnhKe/u9Jlh0gakJ1jlkYsLhGVNu5BnBPOce2aAPeLC+tNQsorywuoLq0lXfHPBIHR19Qw4Irj/E3xU8HaDoWoamdcsNRFjt8220+7hmnJLBcBN45ye5HQ1W+F/gu+8K/CG28K6x9ivryKG5jkSKZ1hlEkkjBd+3coIcAkLkc4Brg4vg/4rbwd4l8ODWYLXRLyzSHT9MlvnvUt5VlWTd5rQxsq/KRtCn72ecAUAeqw/EHwjJY2F1J4m0W3jvohLAs1/CjOMlTj5ucMCpxnBBHar2r+LPDmizxw6zr+kafNInmIl1eRxMy/3gGYZHvXk/jb4d+PPE2nJYyahpsWnNo/2D+z01W5ihiuVbAmJSEecpUD5HAAJ77cnhvG3gXxDoel6/pFhZy61fa1o+lWDi3s7tvIktljRtkvk+UyNsJO6RCOMjIwQD6TvPFPh+xu7a1vdd0q3uroK0EMt5Gjyg9Cik5YHtilk8T6DFrK6PJrelpqzkKtk13GJyTyAI87v0rxy/8Agzqc2raxNPHp+s2GrW9qHt73Vby0FvLCgUZSAFZkBGQGKkYABHJO9pXw98RaX8SX1rRbyLRtHur2S61G3TU5LsX2c4PkvCojds8kSNjtnAoA9cooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPNtNGr3+janrV54u8R28UWpX8C22nWNrPsjivJYUVE+yvI3yovdj1NYNvrd/rfwj1fxr4d8Z+KlS3sru4givrTTgS8Kv99VtzwWTs2celdp4Fe8j8H6i+mwW9xeDWNW8uK4mMMbH+0bjq4RyPwU1w2j+FNa8E/s6+LNA14aczW2k6g8U9lcPIJA8crncrRptxkDgtn2oA9F+Ivir/hDvDf8Aav2e3n/0mC2xc3P2eJPNkVN7ybW2qu7JODwK57TPiQG1aH+1ZdEXSHsmuPtWlXj6hHv+0Rwr+9CKMZcg/LhcZLYzjsvEug2viKxt7W9knSOG7gvFMJAJeGRZFByDwSoz7dxWd4r8Kwax/aN2qLPe3GlTaYsFw+2B1chvmIUsOQORnA7ZoA2LHWLG+/tA2s+8WEzW9w2xlCSKoZgCRhsBhkjIzkdQQOW0nx5bR+GdK1XxGxgl1hXurG0s7OaeYW+Ay7kjDsSEZS7ABQWxx31fDOk2XhTwnp2kXt3G5OIpZ55ADdXEpJc5PVndmOOpzXGaj4D8Qr4a0Sz0u5gTVNHhn023vUv/ACN9kwVVEga2lBYhI9wAGCuVcZoA6uP4g+GpZLFYr+V1vY7eSKVbSYxKJwDD5kmzbEX3DAcqeRxzVc/E/wAJLDczSanLHDbwzTtJJZXCIyRMFkKMUxJtJAITJFYml/BzRLWTRbueTzNQsbSzt5nNnazLObeNUVszQu6ZCgfIy9u/Nat98MdDvtIttNupb6S1gt722UeYoJW6YNISdvUEDbjGO+aANjV/GWh6TcT297dS/aYZordoIbWaaRpJEZ0VURSXJVGPyg4AOcVNrXiO10vw0daeG6kiYRiG38lo5pZJGCxxhHClWZmVcNjBPOK5e5+H2mXTahp994iv7zUNSMV1cfbI7GeSRIgY1PlPAUCjcASE6455Odj/AIRnRtS8IL4YivrieDTTDB58dyHubeaLZIjF+dsg+RsEdxxg4oAw/E/jXxL4f0+CbVNAsbNrq5tre3khvHvvmklUOjRLGjlxH5jAJuBK4BNbcfxC8NTNZLb3tzcPeI8kSQWNxIwVJPLcuqoTHtbg78Ywc9DS23gxBqthqOp65rOq3NlcG5i+2PCED+U8Q+SONFGFkboAc4Jziq+ieFdL8KXbHTbsz6tcWLW1tDfXCL5u2SSZj8qZ+Z5yXYA4G3j1ALk3j3w3FawXH9oNLHPbwXMQgtpZWdJjiLCopJZ+cJjccE44OGT/ABA8O280EVxdXcMkojLLLp9whg3vsTzsx/udzcDzNue3FYujfC+ysvANv4ce7eLcyy3ssVvBOtwwXAQrcRyr5agKFGMgIvPXMlr8LdKszst9Q1Z7JjbyTWEs6NDcyQKqxtIdnmfwJlQwU7R8tAGqvxD8MG8vLZtSaM2huBLLLbTRw5gz5yrKyBGZACSFYnAJ6Cq9740Ux6Rf6dDcHSp9QisLr7bp9xaygzELE8fmquV3sgPykHd1BXBy/CXw2k0/w/Zw6xrd7c6pHA4DosDRWk0xLTtCrQ4bcWYZlDnaT0yaXSfA1lFo2i2Ph6/iudBGqJq1zPvT940ZVo0iSFFiVfMRCdoUDaeCWJAB6NRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzV34B8HXl1NdXnhPw/Pczu0kssunQu8jsclmYrkkkkkmov+FceB/+hN8N/wDgrg/+JqfUtbuk8X2mj2McPlJZyX97JKpJCZ2RomCMMzbjk5ACdOeK9j4pudR+HeneJ7O00+A3VnFeyRahfm3hgRkDNumEbfdB67QPpQB1deY+M4tQsfidaavbvrxt/wCxpoY4tOs1mSWZZFYROxify9w/iYqMqORyDrDxpc3Xwj1Lxfa2UVvcwafd3cMMjmWJmiD7WDDaXjbYGBwpKsDxmtEeNdJgvLOw1GS6tr24UbGksLhIJH8vzCqTFPLY7QxwGJ4I6g0AePw6n4/1mCdJtM1O/NrqGmXenrqNs8J375PMV3FrB8q7U3EIQufvEEVp+IPEXxAFrpZ0xtWgV7N3mmuNLcMt4HIMTxRWk5MSjG0rt3DOJWPNemad4+8N6jHayW2oP5N1bvdQSy200UcsSIruyu6BThXGQDkYYdVYAi8eeH5Lqxge4vLf7cqvbTXWn3EEMoMXmgCV4wmdgJxuyMEEZBFAHO+DNV8Sz+PtQtNZk1O4sMTNGUsmt7SAB1CpmW2RnbBIDJNIGwxIUYqhrPiHxcnxTtLPTbXWV0YX8UFwktrvt2gMfzSoy2uAu4jlrjcCD8mOnd+HPFujeIp5IdKuJnlSJZ9s1rNAXiYkLInmKu9CQfmXI96qzePfDkN/c2kt/Islv5wd/sk3lFoVLSosuzY7qFYlFYsNp44NAHGfFNtYsvGaajor65BOuhzxW8mm6YbtZbjzVZIZCYnVFOMknb0+8KzYJfFOmXurPPHrGlWt9rMs95daXpv2yYMLC1CCNDHJujMiyKXCnlMZHJrrNT+K+gwW1tNp6X98ZLu2t3iFhcpIsc5bZMqGLc6kK20qMMRgHNbI8e+HftxtDeTpKC6lnsp1j3rGZGj8wps8wKCTHncMEYyKAPP217x+WsTex6ta6i1rYtBZ2ulrLbXUjt/pH2mXY3kkDtvTHUbulTeGZNf1T4jaHd64Nbae2/tFLiCbTfJs7MFlEQil8seYGVQcmR847dK7y58V2114L1bXtCZp47WzkuIXnt5Y45SIvMUjcF3r05U46jOQcZmm/EfSr3TbKRJcXrtapPBPbXEDDz8hWjUxFpASrBSPlOPvDrQBjeNpfGp1nWpND1HVLW0tZNOjtYLewilSYTShLh8tGzNsU7uCAuMnisTxHq3xE0+IWlpNqU1tFqF3A2pfYv37xqsRgJWK0mBUlpQWWEA7ANy9+u0H4paJqHhuw1S+h1Gyluw5W1Gn3UzkJyzIFiy6KCMuo2jIBOa6ubX9Li07Tr97tPseoyQx2syqWWVpseXggcBsjBPHIoA8nl8TeO/+Es8PQJbat5JksI9Q22T/AGSZZETzpI82m5FBY53zIylTlMCvQPhRaXFj8PNEtr2Ca3uI4SHimQo6nc3UHkVY1Hxz4bsAvnapHJvjEsf2aN7jzAZPKATyw25i/wAoUZYkHjg4LLxv4fvWgS3vmMk0VxMsb28qOqwFRKGVlBRlLL8rAHngGgDpKK5GL4jeF5by2to9QmZ7j7PscWU/lL9oVWhDybNiFwy4DEcnHXis4+PBrHi2w0bwtJFJHc2d9Kbu5spxCZYWiVPLc7FlTLvu2E9ByO4B39FYvgzWj4h8MafqkkP2eaePE0IORHKpKuoPcBlYZraoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiisLx1eXGn+D9YurN2initnZZV6xccuP90Zb8KAEvfFel215NaQtc315CcSw2Nu9w0Z9HKAhT7Eg1B/wmmmRLu1GHUtNTOPMvbGWKMfV9u0fiRWJ4e8P6dqN3qmnXBkGm6VMtrb6bFMyRhDGj+dJtIMjOWY7mJH47idr/AIQ3T7cbtGuL/SZgchrS5bZn3jfdGfxWgDobW4gu7eOe1mjngkG5JI2DKw9QRwaw/G2qX2nWVjb6SYE1DUrxLKGadSyQlgzM5UEbsKjYXIycDOK5O60XxHoFzJeaRawPOfmeXTgEiuen+vtGYDJ/56RPv9iPlOtdXY8Y+BpZrzw9rkN5FKuLJNtvdwzowxJC8rIh253B8gEAjBOVoAJW1zwxrGj/AG3XJta03UbkWUyXdvDHLDIyMVeMxIgK5XBVgThs7uMHt68r+FsWqeIboar4qGvXE+m3V5BZtfGzSBGSeWAkJbtkzBFKszDbnds4OT6pQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzuoaJcv4xs9Ys3h8l7OSwvY5GKsY92+N0wDllbcMHAIfrxzlaV4Bn0rRrLS7Lxj4ljtLFI47VR9jBiVBtA4t/nGOMPuHfqAR29FAHMW3gvT4PA9/4WE949nfRXMVxcO6mZzcFzI+du0MS7HhcD0xxWBL8IdCk8TR6493qBuo5/tCgrbkhvKMe3zDF5uzBzs37QeQBXo1cr8TTJ/wAIvHHFcXNv5+p6bbu9tO8EnlyX0COA6EMuVZhkEHBoAr6t8OtG1Xwfonhu7kvTZaSkUUEiShZXRI/KKOwGCrxllYADIY9OMZt/8I/D9/4qbXbua8kna4NyYSsG3JjMZTzPL87y9pPyeZtB5AFbX/CB6R/z+eJP/Cj1H/4/R/wgekf8/niT/wAKPUf/AI/QBX8BfDvSPBEsz6S7N5kawjfaWkbKoPALxQo79uXZumevNZp+Efh0azqeoxeZE+ofaWlRbW0LK06ssjLM0JmX77EDzMDpjHFbX/CB6R/z+eJP/Cj1H/4/R/wgekf8/niT/wAKPUf/AI/QBV1L4d6bezC4S+1K1ukhsoopoXj3RG1d3icBkZScyNncCCMcCqEfwm0GPXrrVhLKbm6aSSYvaWbM8kiFXcSmDzVJJLYVwoPQAcU5/D/h6bUL3TNM1LW7rV7REkmtD4p1FCit0JPnHHHPT09RVK48LyGQw2kWqvIDh2HjDUiI/wA3AJ9qNgO3/sC1/wCER/4R3zJ/sX2H+z9+R5nl+X5ec4xux3xjPaudsfhrp0FzDdXeqatqF7C9oY7i5aEMkdszNHEAkarsyzE8bjnrWT4k8OwaDYabe2Gp+IftSatpsW6bXLyVXV72GN1ZHlKMCrMCCMc103i7WL/w5e2urSssvhsL5WoLs+e0yeLgHugzhwegww6NlJ32G1Y5+9+D+iXthp9pd31/cR6c0v2I3MFnP9njkILRhZIGVlyoILhmGOG610+r+EdP1TwWPDMzzQ2SwxRJLbCOGSMxlSjoFUIjAqCNqgA9AK6FWDKGUgqRkEHIIpaYjhD8L9BjlvprGS+sp7iS1likgkX/AERrfPl+SGUqASzFgwYEscim3HwysJYoGTWdahv1N151/HJD51wLnb5qvmMoAdiY2KpXaNuK72uL8VfE7wp4aLx3uppPdLwba0/euD6HHCn6kVtQw1XES5KMXJ+SuTOcYK8nYS1+HGkWummxjub8xGTT5Ms6bs2YjEX8Pfyl3euTjHaPS/AEWgXdvf6TqF9dTada3NvptjeyxrbQLMysU3JFv25RRkliB68V5rf/ABw17XLlrTwT4bd5OzurXEmPXYmAv4kioR4S+Lni35tZ1d9Nt35Mb3AiGP8AciH6NXtLh6rSXNjKkaXk3d/cjl+uxlpSi5fkev6AdL8EeFrDTNY1myilgjzNNPMsQkkYlnYBjwCzMQPes7UPi34IsSVfXYpXHaCKSTP4qpH61wmlfs8WIO/Wteu7h25YW0Sx8/7zbs/lXW6d8FPBNpjzNOnu2H8U9y/8lIH6UfV8mo/HWnP/AAxS/wDSg58TLaKXq7/kZ918e/CEJPlx6rP/ANc7dR/6Ewqg/wC0L4dDnZpWrFexKxg/lvrvbT4d+D7UDyvDemNj/nrAJO3+1mtCPwn4cjQJHoGkIg6KtlGAP/HaPrGTR2ozfrJL8g5MS95L7jzD/hobw/nnSdVx9I//AIqrtv8AH7wlK2JLbV4RkcyQIR/465r0Q+FfDxBB0LSiD1H2OP8AwqjceAPCNwuJPDWkDjH7u1RP/QQKPrOTS3oTXpL/ADDkxK+0vuMSw+Mfge72j+2DA5/hmt5F/Xbj9a6nSvFGg6uVXTNZ066duiRXCM3/AHznNcrf/BvwPd5I0c27n+KC4kX9NxH6Vymq/s86LKCdL1i/tWPTz0SZR+W0/rR7HJa3w1Jw/wASTX4ahzYqO8U/TT8z26ivnc/Df4meFfn8MeIDdwp92GO5KZ/7ZyfJ+tEXxc8ceFHWHxn4dM0ecCV4mt2b6MAUb8BT/wBX3W1wVaNTyvaX3P8AzF9cUf4sXH8UfRFFfO2o/HdR4t06/wBOgujo7W4hvbKbG4NvY70IOMgEemehxwR7x4f1mw8QaTb6lpNws9pMuVYdQe4I7EdxXDjsoxWAhGdeNlL8H2fn+ZtSxNOs2oPY0aKKK8w3CimRyxy7vKdH2sVbac4YdQfeuS8b+IZLQzafYXP2V4oPtN9fBPMNpCSQoRed0zkFUXnoSQcBWANnV/Eel6Vcpa3VwXvpF3JaW8bTTMPURoC2PfGPes+TxP5kJFx4b177M4KsWtFcEHrlAxbHttrI8M+Ebh7Yy38lzpdvMwkNlazkTynn5rq5B3ySHPIVgo6fNjNa03g7QbWGSdTd2RRSxuY9QmjZB3Jbf/PigDjLa18uY3Phm7u7y3sh5Ec1ngX1jHyRbzwSgedEOq7sSKM4zy1bFp41vUlaF7vw/eSqdvlTTSaZcE/9cZVbn8RXNa14i0uz1KP7T4jtprmIEad4ggTe0RHJguxGNrxn+8MA/wCywVj6D4S13SPHXhuK9jWyu0DNFcQhknSKVThlz0IyMg9wQe9ACp4pmjVG1Dw/rECNz5sEaXafUeUzN/46Kv6T4l0bVpjBYajBJcjObdjsmH1jbDD8qqS+CvDjuHi0m3tZB0ezzbMPxjKmszWfBs8tvttrxNRiTJWz1pPtCf8AAZseah/2stj0oA6jSNMt9JtJLazDCJ7ie5O45O+aV5X/AA3O1Xa800rXL3Q5542W9e1tVD3ulXjGa6so/wDntBJybiH1BywxwcjZXo9tPFc28U9vIksEqh45EbcrqRkEEdQR3oAkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACivNfH3xb0rwxdTafaW8l/qcR2ugOyOM/7TEcn2AP1FcQLz4qeOcNapJpGnydGX/RlA9dx/eMPpkVyTxkIvlinJ+R7+F4dxNWmq9eUaVN9Zu1/Rbv9T3bUNTsNNj8zUb21tE/vTyrGPzJryP4k/FMaVeWdx4R1uxvl5juLJoi6eocOAPoRu9MDrVbTfgSbiTz/ABFr808zcuLdMk/8DfOf++am8XfBmwj0u1tfC1rLJqE04El3d3B2wxAEliBgE52jAU9TWNaeJnB8seX56/gepl2HyPDYiKq1nV7+6lH583butexFofx7tn2JrejSxHvJaSBwf+AtjH5mu48ZajFq3gvTb23juI4ptY0llWeJo3A/tG36qareA/hZonhby7mZBqOqLg/aJl+VD/sJ0H1OT7itb4l/8i5Z/wDYa0n/ANONvW+GjXUf3zPJzurlc6lstptJdbuz9E9fx+R1VcZ8UfGU3gzRYby3sVuWlk2F5ZNkcQx1J6lj0Cjk8+ldnTZY0mjaOVFeNhhlYZBHoRXUeEfN+pfHnW4bhktodII2hgWjfHJwAfnGCecDknHA71X1v4qa9ra3Hh+61bSNIW7smlnuURopYYyWR1AaTCSDaT8zLgYIBJArpP2gfhzYP4ci1TQPsmkXFvcKXSPMMc7uVjUsqDBIDMOgOGPPY+cfCnwfF4m1OTRbyJfKtLiK5vX8s7kVAeAzru3vlV3Ej5VJA7hN21Y0rm58BofEUl/KdGFzNo8BWFby4g8mKa2aVnYozASGRhsORuztGSOAPpGONIYxHEoVF4AArirTxJcxfFKbw2sCR6HHYRx2xVQAl0g8xkHsYnUgdvLPrz29YzbuawSOY+In/IBsv+wzpP8A6cLeuzljSaN45UV43BVlYZDA9QR3FcZ8RP8AkBWX/Ya0n/04W9drV09iKm5xXhBn8M61L4RumJstjXOiyuSSYARvtyT1aIkY9Y2X+6xqp8SfijpHghvsksc15qrJ5iW0Y2gA9CzngA4PTJ9q3fHej3Gq6KJdL2rrWnyC9092OB5yA/IT/ddSyN7Oar2WneHfG1vovia50yK4mEO6D7QmWizyUZehZWBHI4OcV34KeHhVUsVFyj2Ttr0+RhVU3G1N2Z4ujfEz4rcqx0nQpPQtBCy/+hyfquR2ruPCfwL8N6SEl1hpdYuhyRJ+7iB9kByfxJHtXrYGBxRXpYjP8RKPssMlSh2jp973f4GEMHBPmqe8/MrafYWenWy2+n2sFrbr0jgjCKPwHFWaKK8Ntyd3udaVtgooopAFFFFABRRRQAUUUUAFQX8Zmsp41ihmZkIWOb7jHHAbg8fgawtQ8RTS6jPpvh6zW/vLc4uZ5JPLtrU4zh3wSXwQdignBGduQTzh1m7vZJBH4i1DUXB2tH4e0xDEp9POkDrn/gY+gpp2dwPOb34Ca5qN9cXd1q2j28k0hcx2sDLGueyqAAB7V2fwz+Gev+B9REsHiOCawlYG5sjbttf3U7uG98fXNaUln4gkINtB4twec3Go2cf6KGpW/wCEuhixpcevfbhyqam1lJak/wC28ZEgH+7z7V7eI4ix2IpOhUknF9OVf5HJDBUoS5ktfVnX+JPEFroMdsJobm6u7uQxW1paR75p2AJIUZAAABJZiAO5FeZ/EqbW/iBbnwpoKa34Z1kQSXczXM6QhohgBQYnYShmIU7WwoJLfwq3beJLXVYdV0HxDaWC39zYwzW13ZQSKGKTeUWaJn2gsrQrgMVypbvgGPTE1PXfGNrrN5pU+k6fp1rNbwx3bIZ7h5WjLMQjMFRREAMnJJ6AAZ8M6y98OfDMfg/wRo+hRkM1pABK4/jlPzSN+Llj+NcvZgX/AIlt4pxu+069dXE/+0LWPZEp9gRG4Hqua9MrzPVWGi+Kby5YIkNlqVvqLEnpb3UZt5D9FkTeT2xQB6ZXm2uXZ1rXSJLQakkd01npemyttgkljGZrqfg5SM/KODgjgFmXHpNec+Csp4oto5WBZYdUjH++L8F/zDIaAOgTR/EMiBrjxMYJMf6uzsYliX2HmB2I/GvOI5dV/tgw+INHs767W5uLVdS0QNY3yPGA4yN2JC0TCQKG6BhtPQ+215v43gk0/X7q8tUBkNsmrxAE5aa0YLKB7vDKE+goA0/C3idjLa2mo3iX1rdsUsNUWPy/Odc7oJkwPLnGDxgBsHAUgrXa1wvi/QY7i3m1fSrZr21vI1bULKA4a6QAFJ4j2uEwpVhgsFA6hStjwd4oWdbXTtTu455pk3WGoAbY9SjHcdNsy4w8fByCQMZCgGp4u0ma/s47zTdqa1p5M9lIe7Y+aJj/AHHA2sPoeqgjI+HV9CWubC0G3T5IYtT0+NsZjgnyWiwOmyRXGOwZR2rsbmeK1tpbi5kSKCJDJJI5wqKBkknsAK87+H0TjV9JLRNGf7GkndWGCiz3O+JSOxADDHsaAPSKKKKACiiigAooooAKKKKACuf+IWoXWkeAfEupafL5N7Z6Zc3EEm0NskSJmU4IIOCBwQRXQVyvxY/5JZ4y/wCwLe/+iHoA4vxnrcnhbWbbSZfF3jTUNTntZb0W9nbaVlYYwSzkyQIvRW4BJ46VoaHqd3PL4H1fTfFmtappOuXbxNBf21pGDH9juZR/q4EYMHiXo2OD1BqP4oeAtX8TeKLfUrOPRtS09dLn09tO1R3jSOSQ589GWN8sMKMYGNvBBOansNDvPDWm/CzRtT1BtRu7LUnikuSCN2NPvcAZ5wBhRnsBQBp+JviJZ+G/HNroWq2xisptPe9bUTJ8sTLvOxlx3WNzuz1AGOaz/CvxUstV0a21LWreLRI3try5mhmmeSWIW9wsB4Ee05LDjcGyQArckdFr3gfRPEGstqOs27XZNvFb+Q5/d4jm85W4Gd24euCOCME1g6j8LtM/sy4Sze8mufIu0hWa5WJd890l0W3iNipWWNdp2tgDkNQBqp8RvDTfK11exzfaDafZ5dNuY5jN5XnbBE0YfJj5AxzkAZJAql4s+J+j6DpWrzLBqEuoWFrLdJZ3Fjc2v2hYyqtsd4sMAWXLLuAByeOazfBPguW28Qy3/ifWFuvEcd//AGsIIrlJWVGtTaKZCIo9wIV8FY0GVxztOctfhl4EfxFqFk/iBpdWu4bmzls/tFqLjFwpdgxWMSuwVCy+YzEKD2zQB3Enj/w9FNDFPcXsMkmzcJdOuU8je5RPOzGPJ3MOPM254I4INO8S+MbbQPEuiaTdWl3IupJM3nwW8soi8vbjIRG4O7kkgKBk8Vzuu/DXw8dSh8Qa/qzvdxiKOe91C2sH88h8R7jJbkIfmCDy9mfl6tzXV+JfDEGvXum3b3t5Z3Fj5gVrbyyJEkADxuHRgVYAdMEdiKAE8OeMNE8R3DQaRdySyCITqJLaWESxE4EkZdVEiZ/iXI5HPNYmj/EGzfxPrejazILaa31X7BZutrN5TqbeOUB5sGMOS0mAWXIUcdzoeFPBFp4cvIbiLUdTvmtrMafaLePGVtbcEHy02IpP3V+Z9zfKOaW48C6XcvdtNJdMt1qy6xIhZcGVYki2fd+4VQZHXJPNAC2Hj3w/qENxJYz31wIYhPtj025LyxFtokiXy8ypkj5oww75xVLVPiToEGivd2VzcT3TpcCG2XT7h5hJDw4khVPMQKxUMWCgZHIzXPaV8HvCY0u/sdMv5GtmYWzm3gsd8RjkVjG7rBukGVAZJi4P8QJ5q/p/wh0jTLMQ6Xqur2MhFykk1sLZDJHOUMkZQQ+Wq5RSNiqV5wRQBveHNL0vXLbR/FV/plm2tXVjBK0wTO0sgb5QScYyQD1xgZrqqqaPp8Wk6RY6dbs7QWcCW8bSEFiqKFBOABnA9Kt0lFLYudWdSynJu2iv0XZBRRRTICuV+Jf/ACLln/2GtJ/9ONvXVVx/xWuYLPwlFdXc0UFtBq2lSSyyuFSNBqFuSzE8AAAkk0AdhRXK/wDCx/BH/Q5eG/8AwaQf/FVha58TvCElwtvb+MdPiRRl5LW/tcNnoNzMf/HRnmgCz8TNHvr+CBdJkvbi9abf9nS6ESxr5bKH7YAYg8EE9jT/AIZ+DYfBmgG0DJJf3T+feSqOHkI6DgcD+pPGaoaV4v8ABlnIZ5fHukzzuuJBNrMDIT7DPboPxqxrnjvRpfDupyeGNb0rU9UWMRW0VpdxzN58rCOLIQkgb3Xn0zWMm5OyNYpJXMJ+fDlx4sVvmXxL/aSuO9usgsmbPobZWYexFeokYJrza81rwZN8PbnwppHijQ7tzpT6dbRRahE8kp8kouFDZLE4PHOa3LX4g+FlsbNtT8TaHa3ktvFNJDPfxRupdA3KlgRwQeneiWoR0JviJ/yArL/sNaT/AOnC3rta8s8Y+M/C+rafptlpfiTRb28l1nSvLgtr6KSR8X8BOFViTgAn6A16NJqtlHrEWlSXCpfywmeOFgQZEBwxU9DgkZA5GRnqKqnsTPcu1x3hof2J401zQsbbW9H9sWQ7De224QfSTbIf+u9djXH+P1+wXvhzxAgwdPv0t5z/ANO9ziFs+wdonP8A1zrQg7Ciqmrahb6Vpl1f3r+XbW0bSyNjJwBngdz6Dua8j8Xa/repXv2CV/skpQSS2UbsI7NGGVFw6ENLKwOfLVlRRyxb5dybtuRUqRpxc5uyR6vea5pNlMYrzVLG3lHVJbhEYfgTU9lqFnfoXsbu3uVHUwyK4H5Gvn1fD2nFR9qh+0sO7gIo+iIFUfln3NRnw9b27CbSJJbG6jH7tkkbGe2TncB2+Vgaj2iPOWbUea1nbufR9FcH8MPFU+swyafqbM19ApZXfG91UhXV8AAuhK5YABleNgBuKjvK0PTTTV0FFFFAwooooAKxvGWozaT4X1K9tMfao4iISwyBI3yqT7BiCa2ap6xp0Gr6Vd6fdhjBcxNE+04IBGMg9iOoPrQBx2m6BBfXUugNvPh7Rtkc8LHnULp1ErNMerKA6sR0dnO7IGD3UMUcESRQoscSAKqIMBQOgA7CvNZZda0HUJ7q9lktLx0VLi7Wze6sL/YMLKyxnfBJjAP8PAHzADD/APhOr18JFqfhp5Dxi3Fzcv8A9+lXd+GaAPSqzdX13StHA/tTULa2ZhlUkkAd/wDdXq34A1xGPE2tsRnVZIi38QGkW+Pw33B/Na0dI8DSW25ptQSz8wDzE0mAQM/c752LTN9dy0Aan/CUvLuew0DXLuBRkyi3WEEf7KysjH8BWrourWetWIurCQvHuaN1dSjxupwyOpwVYHqCM1hah4I0FbG5kgtzaXoVnTUFmc3ETgZD+YSWODzySD3yKo+EbuSfxFZ3Z2rLq+hwX14ijA85dqq+OxKsV+ka+lAHdVzHjPRZbtU1LT4I7m9gieCW0kwEvrZ/9ZA2eATjKk9GGDwzVn+MNdZNUexS+uLGytI0e6ktED3E80pKw28QIPzHDMcDONvQEkRaBD4oi1yz3pqiaYzMbgalcW037vacY8sB1k3be7Lt3d8UAL4J8RxRRWemXdxJLaTEx6ZfTZDS7cg282eVuI8FSDy23PUMBS8Q2l1pXi0TWEatPPN/aNghIUTyiPZc2uTwC8aq65/iVieFNa3izwsZ2u73S7WG5N0AL/TJW2RXwHRg3/LOdcDbIPQA9FZcCHU7e60X7Hrtzc3WheasceqSHyrzS7hSNqXPdHU4xL0PG7qGcA9D0TVrPWtOjvdPl8yF8ggjayMOGRlPKsDwVPINY3jRFgutB1J0DR218sE2enlTqYTn23vGfwrmr+3vtHv5LvU5LnT7wgBtd02DzLe7AGB9rtxna2ONwGPR1Hyi5e3ureIfD17ZJBpGtW1zG0X2rSr4Kykj5W8t8gEHB++eRQBu/D52Xwvb2cjbpNOkl09j7Qu0an8VVT+NZ/iPwkXkurjSYLS4hu38280q74guX/56owBMU3+2BgkDIzhhn+E9R1/SzqT6z4U1NHu5Y7k/ZZLeVfMMKLLjEucb0LD/AHu1bw8WqrYuNC8QQjuTYtJj/v2WoA5n7PYEiLU9G8Y3bIwZdOuXkuYCwOR8+8xuAf77kV1nhbTr2F77VNYEaanqDqzwxtuW3iUYjiDfxYyxJ6FnbHGKks/FWi3d2tot8sN4xwtvdI1vKx9AkgVj+ArboAKKKKACiiigAooooAKKKKACoru2gvLSa1vIYp7aZGjlilQMkiEYKsDwQQSCDUtFAHK/8K48D/8AQm+G/wDwVwf/ABNWtL8FeFdIv4r7SvDWiWN7Fny7i2sIopEyCDhlUEZBI+hNdBRQB5L8YvEPi7S9Uih8I2utM8dss4Nva+dbzt5hBjIW1lO7aOQZIRhhgk0Xd949ttQmvbSW/u1k1W/tItOmsY1gWBIJmt5C4QOAZEjXeX2kMB15PrVFAHlHwuGqXXjjUdS1OTXbnzdEsonuNV037HtmEs7SRRgRRgqu4H+I/N94jFY+neGNdTxPZzi51dTJ4l1SQSy2ke21VrS4SO4GIxkMWQAuSpwoA559vqlq2q2GkWpudUvILSAfxzOFB9hnqfYUm0tWVCEpyUYq7Z594MudW8Z6Pf33iRVWGweOC3gWPejXtqT5tyAnzOvnDCrnH7rOMnNX/hLqWvahbakniJtVmlhaMJc3lt9njlJB3eUjW0DgDjIYPjIAdsGsmx+J+jSavp3hvwRpgmEsoiRljEFvEucsyoBkgDJxgV6rUU6sKl+R3sdWLwGIwXKsRHlcldJ729N18zwG38V+Or3Q7+80O71rUboWWotIr6QqwwTRybbcW7eSPOY4IKgyDrnFdJ4svfGmk6xc29nqGtXbLBDLpwt9LjlgvJ2kbzY53WI+TGo2AZZDtJJdyK9Us7S3srdYLKCK3gUkiOJAigkkk4HHJJP1NTVocZ4dYXHi7SvEGrQ+HotXmnm1fUZnsbvTTHY+SUkaOUXDRglmkEYAWQggn5RjNP8A7c8anS7prXUPEDRrHaO1xe6E0U4nbf50ESx2rnYAEPmGGQDpubOR7dRQB5DYax4lur23j1mbxTp9u9lA1rCmkx3Au5GLeYt1ItuRHyFGMQ4U5ODnEHhHUfFdvqnhCyul1VLJ9OskuLK20v7LFav9nBk8wta+XtDfwpNGV4UJxXstFABRRRQBna/rNloGlyahqckkdqjxxkxQvM5aR1jRVRAWYlmUAAHrWF/wsHRP+ffxF/4Tuof/ABil+KX/ACK1v/2GNK/9OFvWnWNWq4M1p01NGX/wsHRP+ffxF/4Tuof/ABij/hYOif8APv4i/wDCd1D/AOMVhax4pu59TOleF7dbq7Q4lnbmOP1xyM49ScZ45pv9j+LGQyHXIxMTnYfufTAWo9u+pXsl0N//AIWFon/Pv4i/8J3UP/jFc/rHiaw1bxdp9zLHqUmhaKfNPkaZcztJfPH8iNGkZZfKjdiwYDDyIOGUijS/Fd3Yakul+LbcWly/+quVwYpfxH8+3cCuxhijhUrDGkalmchFABZjknjuSSSaHXa3Q1RT2Zjal490aXS78JDrSlbaV90+i3sCAKjMcu8QVRgdSRVbw14t0zRPDOjaXewa2bq0sYIZDDod7Mm5Y1Bw6QlWHuCa6KaKOeF4pkWSKRSjo4yGUjBBHcEU+l9YfYfsF3MxPiDoLT28TjWYDPNHbxvcaJewx+ZI4RAXeEKuWZRkkDJrW8TaBa+ILBYLlpIZ4nE1tdQnbLbSjpIh7EZIx0IJBBBIrmPH3/IGsP8AsNaV/wCnC3rvq2pz51cxqQ5HY5rwbrd1ei70nXFSLxBppVLoIMJOjZ2XEY/uOAeP4WDLzjJu+MtKbXPCWsaYh2y3dpLFG391yp2sPcNg/hWP8QbaawS28VabG732jhmnijHNzZnHnRe5AAkUf3kA7murtLmG8tYbm1kWW3mRZI5FOQ6kZBHsQa0IOH1XWotZ8E+FNQnaOO01OeyuJ2fgKmBMQc9BlADnoM56V5Vp2vaV9t1G3fVLSa9N1LPJIjhjcB3JWUY6grtGO2NvYVmeLb6/spdC0zWGto/C9rc6jZQRecEM0sVxIoDZHQxBFVRydzLnkis6X4haZdXsMzafqtlPG2YdSi2I0bDP3Xzz7qcqRwRXBisRUpzUY03JdWv61HUwFHGUmqlVRa2R3tpcRXdstxauJYW6OvT0I9jnjHapa2fBOlaL8QvD02qXUNvHqyXDR/2ppy/Z5JDtV1lI6FirjIYEE5GMcVWuPBOq6Vb6jfeI/EDiyiMaW0ek2qGWZi23BWRGwzsUAUEgEnnHTeMedKUdmeBWyerCfLForfDhJJviGl5ao6WzJPE5Ybd7RBUkbHXALQLk4zt4yADXttcb8OPCn/CPWc1zdx7L+7xujMnmmFASQhf+JySWZuhY4HyqoHZVulZWPZo0/ZU1DsFFFFM1CiiigChrupxaPpU99NHLKI9qrFEMvI7MFRFzxlmZQM8c84rh7jUdZ1C9ltZr3UJb2PHnafoCRiO1J5Cy3M3BfBHClT324wT2niXSzrOiXVkkxgmcB4ZgM+XKjB0bHfDKpx3xXBWutXvh26uPPNtpj3EzTT2GqFo7cyty7292qlSrE7trgkE/w9KAJpNQ8R6Gnmv/AGulqASw1O3ivYxjn/WWzeYg92VgK0oviLp1qLNddjFq16WWzmtH+2Q3jDqsTRjcW9mVT9aoT+PZ7pVjtbvQLF2O3ct2dRl/4BDCMt+LD6VX0Xw1dT3t1faTay6dfXgIudf1KCP7Y4I5EEAG2MHjlgOxKv1oAuX3inXL6+Nlptm9lNgN9mSFbm7VTyGly6wwZHIDOzH061Vm8a3vhppZPEV2vkW+GuYNQiS2uFjJA82F0YxzqO6rhh9SFL7D4b3mlwGPT9XiLud80zi5imuXxzJM8Vwodz3Yrn8KwfEOjPo+p2aPqeh2l4qyXl1fDTmurm0tkUkyB55ZNpZtijjknocYoA3/ABb4rg1mzj07T0um0u9zHJcRxkS3y/xQWqHBcsOGl4RFJO7PI6jwlpNzaLc6hqqxJqd7tDQwnMdrCgIjgQ9woJJPGWZjwMAV/h/oY0/RLO+1CKSTXrq2jN7dXJ3zu2AdrMegH90YUHoBXU0AebxfJ48ElzjZ/b0ifMRw505PLP8A3yHA92969IrgfGmneTrEjtL9mtdY8mNLsDP2S/ibNvIf9l+EPqVVf466XwxrX9sWci3MP2XVLVvJvbQnJhkxng90I+ZW7gjvkAA2a5rxJ4ca7nfUtHaG31fy/KkEq5gvY+f3M6915IDdVzxkEqelooA848Ka6NDY2dwk8GjJMtq0Nw2ZdHnONsMh/igbI8uToMgZwRt63VPDOg37ST6hpFhNKfmaZoF3/wDfWM/rWV4xsbaPVtNvpolkt74/2PqERHyzwSghA3rtkIA9BI/rVnwlLc3ngWFLiRpLuKKW0aQnJdomaLcfc7M/jQBw/wANPCmj33mG7t5rgf2dYzMst1M6+bIskjkAsQMhkGBx8orux4H8Lhcf2Bpp9zApP5nmsL4V4XzhjG/TNMlX/dMBUfqjV6BQBx+q+BbOSxaHSJWtB1FtPm5s5D6PA5Ix7ptb0NY3hnV7nQ7hbe781NOS4Wxu7SaUytps7Y8tkkPL20mVCk8qWA4G5U9Jrh/GdhFca9JBjA1TRbu3m9P3RQxt9VMsmP8AeoA7iis7w5eSah4e0u9m/wBbc2sUz/VkBP8AOtGgAooooAKKKKACiiigAooooAKKKKACiiigAr5n+N0Gl3/jWOx8Pi+vdad9lwPOaVA56RoDkgjuAQB0x6er/GPxwPCOhCCycf2vegrB/wBMl7yH6dB7/Q1k/BHwGdGshr+sxltYvFLRrJy0CH1z/E3f2OPWvPxX+0S9hH1b7f8ABPrsi/4SaDzas2r3jCP8z7v+6vz/AB5j9m3w4Wv9R165jI+z/wCiQBh0c4Ln6gYH/AjXv1ZgXS/DemzyEw2VmJHnkZjgb3YsfqSTwB7Adq898RfGnRdLnkitolnaPhhLL5Zzn0Ctt/4Fg+1dOGoqhTUDxs6zOWaYuWJasnol2S/q56rRXhkPx/Q5d/DUksIPzNaXolI/AoufzrvPD3xN8P6yVV3udOlITKX0Xl7SwyoLcgEj1Irc8o7eigHIyKKACiiigAooooA5L4pf8itb/wDYY0r/ANOFvVbxpqh0nQZ5lJEj/u1K9cn098A498VZ+KX/ACK1v/2GNK/9OFvXP/EaNHl0Jpj+6W8G4Z4ORjP4ZP61zV/iR0UvhZq+DNHXR9EhR0UXc4824I/vH+H6Acf/AK63qOhxRXNe5uilrGl2er2TWuoQrLEeRkco395T2Nc54evLvQ9Sh8P6uzTRuMWVzj74A+63vj/PSuwpCASCQMjpRfoDQtFFFAzm/H3/ACBrD/sNaV/6cLeu+rgfH3/IGsP+w1pX/pwt676uvD/Cctf4gIyMHkVxnw8zpU+teFnG1dJnElmP+nObLxAeysJYx7RiuzrkPEWdM8eeGtTU7Yb4TaRcehLL50LH6NE6j3lrcxOH1rQLXW7rULXU7O+utMsfE8st0tn5hkVZLNWGUT5ipaUcgEgEepNd0t/4W8S6dP4bjmtzHLbtEbJojE6IBg4RgCpXI7ZHBp/g3/kY/Hf/AGGo/wD03WdVfi3amXwhNcQSrDfWzj7MzHG5pAYSnqdyyMAB3I9KBWOJ/ZkjNlpWv6a80UrW1ypHlHKsp3BXHsyqCPavRfGmGn8NpIcRNq0W/wBDhJGX/wAfVPxr55+G/i5/h/8AEfUIdcRo9N1QhJW2ktC0XykHH/PI7lK/3CrDgc/SXiKwGveHpI7G4jWZglxZ3AO5VlQh43yOq7gM46jPrWGHlzU0+ppUspuK6fl0fzWps0VleGtZj1vTvO8s293Exhu7Vzl7eYfeRv5g9CCCOCK1a3ICiiigAooooAKCMjBoooAwvEmsLodtBHaW8Ml5dOyQxySCGJdqlnkkfB2oqqSTgnoAMmuTtdQ8WavEl1ZtqD20oBje3gt7OJl/vL5/mSEehKrnritL4oaVd39jBNaQzTIsVxbTLDH5jqkseN4TI3AMFBUHJUnFdbpU1xcaXZzXtuLa6khR5YA27ynKgsue+DkZoA4dtM8Z3K7Jbq5VD1DapDGcfWOz3D8DVvw/4GS3nW41c28m2QTraW6t5ZlByskruTJO47FzgdQoIBrt6KACiiigCtqVja6nYT2V/Ak9rOhjkjccMprzvVba+0HUrZ7y/MN1EBBYa5OMxzxk8Wl9j3PyycZJyCGJV/TajuIYrmCSG4jSWGRSjxuoZWU9QQeooA5+x8WWolS01+I6JqRO0Q3TDy5T/wBMpeFkHtw3qorpAQQCDkHvXKTeDIo7aS20vU72zs2G37FIEubYD0CSq2B7KQKxT8OH2lUuNHjU9RFpskYP/AEnCf8AjtAF/wAa6zZyXlvZpMHh0yUanqckZBFtFCC6Kx7O7hcL1IDHtW14IsprDwppsN2pW6aLzp1PVZZCXcfgzEVnaT4F0+1WAX0r3qQOJIrby0htY3ByGEMYClh2LbiOxrraAPMvDEg0HX7aCdmWKGSTQpix+7hzNZsfZo5GTP8AeYCvTa47xroTTSyalbWbX0U0H2XUbBG2vcwglkeM5GJo2JKnIzkjIO0ip4c8T3iWzRbJfENrD8ourTat3HjjZc27lWVx3I69dq9KAO8rznxNfve32t3VmdxhgOg2AyMSXc7DzCPUJiLJ7bJP7pqz4k8T3j26wbJfD1tP8pubrY93IDxttrdCzM57FunXa1W/CGgv5tnf3lmbC0so2i0vTWbc8CsMNNKcnMz5OeTtBPJLNQB1dhax2NhbWkP+qgjWJM+igAfyqeiigAooooAKKKKACiiigAooooAKKKKACq9/dwafZT3l3IsVvAjSSO3RVAyTVivHv2i/EL2ui2fh+0JNxqD75QvXy1PA/Fsf98msq9VUqbm+h6GV4CWYYuGGj9p6+S3b+45rwJYz/E74kXniPV4ydKsnDJE/K8H93F6YH3m9T/vV9BXU8VrbS3FxIscMSl3djgKoGSTXPfDrw4nhbwlY6aAPPC+bcMP4pW5b8uAPYCvLfjV42OtXEfhPwuwvHM8S3bQkMHYtxEB3HykknjO1eSSKzwtJ04Xl8T1Z1Z7mEcbieWjpSh7sF5Lr89zI13Wtb+KvjJ9I8OsYLC2PzTN923j/AL7cYDk5AHJOCBgK5Pong/4NeFfD8Fv9qtjrF5FyJ70BgG7kRj5R9SC3qTW98M/B8HgzwxDYJiS9lPn3k/UyzN1Oe4HQewrrK6TxTAn8GeGZ02S+HtJIxji0jBH0IGRXPeIPhtZXdqE0txCY1KxwzfMqr/dWTBdQT7svfbXoFFAHlvw2/wCEq0bX/wCwtT0+7l0gROy3b42REY2r1xk9MISp4OEIYH1KiigAooooAKKKKAOS+KX/ACK1v/2GNK/9OFvWX8RbF7zwxM8OfNtmE64GTgdfyBJ/CtT4pf8AIrW//YY0r/04W9aTAMpDAEEYIPeuWu7SR0UVdMo6DqMer6PaX0eMTICwBztbow/A5FX689t5n8Ca3LbXCu2gXr74pBk+Q3v9OAe+AD6138UiTRJLC6vG4DKynIYeoNc8kbJj6KKyNf1yDSRFEAJr+4Oy3tlPzOx6cenvS3Kbsa9Feb/Gi3cfCO9gvmFxI1xZCUuAQxN5DkY6Y5xj0rxjQ/Bmm6rHqLx6VbEWdq9y3l2sR4X+9uZcD3G4+xranS51e55GYZssFUjT5HJtX0Povx9/yBrD/sNaV/6cLeu+r448E2NpZeM7H7HawW+9rPd5UYTdjVtOxnHXqa+x66acORWHh8WsZSjXirX/AEbQVyPxXUx+Bb/UEH7zSmi1RT6fZ5FmP5qjD6E1r+KNVl0rTkaziSa/uZktbSOQkK0rngtjnaoyxxzhTjmuE8T6FI2o2eiyadZeJ9Z1Swu5pbzWLtoI4VjMKMIo1ikVMm4GAAOF5ZjzWhsJ4O8R3Gq33iseErdb2S51mQ/2hMD9kiVIYY9xYf60/u+FQ8jGSo5rsdO8LWlvcQ3+qzz6tqcWXF1eNkRt3McY+SP/AICM46k1wv7Ompao/hn+ytcsUt7tLdNU84TFmlW5nucB0KLsZfJxwWBBByDkU3x9rw8RarLo8UoTQ7WQwz/Nj7dcD70XvGnQj+JgQeFOefFYmGGpupPY3w9CWIqKnAz/AIx+HPD/AInsJ9Y0i+s55o5oob5rSdXMbMRHFONp+WRCV5/iTIOcLi18EfGOkaX8ONMt9d1W0s5TPcJFFLJt2IsrDn+6obIBOAMY7VyuuxRwXEPkosYe2aNtgxlRNbsoOOwIyPSub+DChtM8QFvmLarMhzz8oC4X6ZJOPc+teR/aajSeKjHfpfztc9L+zOasqDltfXysmfSereHrfUbj+09Mu5dO1RowFvbVgRIo5USIflkXnuMgE4IzmqkHiiTTGFt4wgXTpgQq3yAmyn9CHP8Aqz/svjHYsOa4zwDrTeG9Wt9Hnc/2HfPstc9LOc9Ix6Rv2H8LcDhgB64QGUggEHgg969fC4mGKpqrDZnm4nDzw9R05kdtcQ3UCTWs0c0LjKyRsGVvoRUtc1f+ELLzGu9Cb+xdT6rcWahUc+ksQwsi+uRn0IPNXvC2qyavpXmXUSQ30Er211EhyqSocNtPdTww/wBlhXQYGvRRRQAVymreINaXxRd6Roek6ZdLaWUF5NPfak9qAJXnUKAsEmceQSSSOorq640OkfxD8VvLbvcxroOnloETe0o86/yoXuT0x3zQBR0XxlreuTTRaJB4I1GWHmVLTxQ8xj7fMFtDj8a6bwdrM+vaH9svLSKzuUurm0lhimMyK8E8kJKuVUkExkjKjrXkHwrfU/EnxVl8UeItG1Pw95Fk2maVpTaTcxLHADuLSzGMR9jhd3U4AGBn0z4clx4YvzEFaT+2NX2hjgE/2hc4ycHA/CgDW0vxJpGqa3qmkWF4s2o6YUF3CFYeXvBK8kYboc7ScHg4PFSWOs295rup6TEkouNPSF5WYDYwlDFdpzk/dOcgfjXlX/Cp/EFvpnmWXiVv7Xv7O7t9SMm1Yle4DSM0TJGJGxNtxvYkIWwV6U+x+G2s2V2+o6bpXhnS5Yr+xvbfTbK4kW3byY5Y3DSCAEFhLuB2HkYPrQB6Jr3i/S9B1QWWqPND/oMuoNOI90axxyRxkHGW3ZmXAAPGea6GvErr4Ua1qOj3EGpPor3E1nqaFNzvEJri/juo+qZ2gIQTjIOMA1raP8Pr6y8f2Ou22i+HNLtk2iaOGVbny1ERTbbqbSNouccrKF+8ShLGgD1BbmNr17ULN5qRrKWMLiPBJAAfG0n5TlQcgYJABGZ6828d+ALvxN4nlvC1i+nTJpccsM7Nl1trySaUEBSMMjgDnk5zgc1u+EfC7eH9E1rTY47ZLS4vLmazt7dzHHDFJ91Bhf3fOfuggZ4zQB1lZi61bt4lfQwkv2tLRb0vgbNhcoBnOc5U9unevJ/Dnw08RaDd6bf2Ft4ejl0298+C084L5qNbywsZbiO1jLsPMUjdGx4OWJbIq3/wl1y50u2tpbXw5eXH9kvp/wBquJ5AbGZp5JPtEC+UdzKJBjlDkdcUAe61S1LVbLTZtPivZvKkv7j7LbDazeZLsd9vA4+WNzk4HH0ryvVvhjqV3B4kt2s9CvLzUXklt9eupW+2x52lIWXyjhAV25WQfKc7c5ymtfDnWtc1K51fWNL8MXl0+sQagNPnneWB4UtDA0bSNATkna/3CDsHA4wAexVlat4d0fV5RLqemWdzMowJZIgXA9A3X9a8f1D4U+Jb3W9evfM0G3/tCx1O032wWETfaEZYjIqWyv8AKdpYvLKc5Ix0N3XvhFeyR3kGgtptlp8stjObCMKkVw8UcyS+YGhkT5jJG2TG+TGMjOCAD1TSfD+j6RI0mmaZaWsrDDSRxAOw9C3U/nWpXh118JdYbSLazjj0m4ZdOayhkv7tpH0mQzySefbMlugLYkUABItvlIuSorVn8AeIW1MQf8SqbR49XvtVEhvJYriX7RbzJ5ZAiITDSn5gzcc4yMEA9crM0vXbDVbWxudPkmnt71GeGVbeTYQvXcSuE9g2M9s1y3wr8H3XhbSdRstRtdJignkHlw2iRsSm3B82RIIRIT7pnHVmzXJaT8Kr6y0ez0/+zdBhjtra+tZWsruSB77zkVUd2WDKNgYP38DGM9KAPaaK8LufhRrcvh20sxp/hk3NtczzQKTCIIw6RKDLELHy52yhywjiYLhQ3Jatm58AeJXvzbwXOlw6cdbfWPtkcsi3CF7YxFVi2bRtZiQd/Ix0xyAet0V5f8H/AIfaj4MvLubUWt90ttHAzW1zGUnZST5jxpawnfyfmZ5G5wSeteoUAFFFFABRRRQAU2WRIo3kldUjQFmZjgKB1JPpTq8D+LWqX/i/xxH4Os3P9lxBfNgViBdSlsYkI/gXB+XpwzHOAKAOt1v40+GrS4Nvo5l1qYHBNpgxgdzu5498YPY1x+s/FDWtYeI2Xg3T5hG4kglv2LlCDkMFA3E8ZG3Nek+GPhtoGjWapc2kN/cnBkedAUJ/2U+6BxxwT71e8XzyeHfDwn8PQafbXc15Z2iNJb7o18+6ihLFEZC2BITjcOQOaTV9yoycXeLszyeaX4qeLAyXsEtlYSceVbQC3Vvr5hLsvsSAe4rvvAHgSfSbqLUNauGmnhRltLUY2W+9izsxH3nJOBnIReAepOf4q8W614VE7694l0y2t4ArS3I8G6jLAgbAGZUuCnUgfe6nFbmg6vrv/CUaVZanqGk6hp+p6XcX8Mlppsto6GN7YLnfNJkEXB4wCMCmSdtRWZY61b3utarpkMcwuNN8rzWYAK3mKWXac56DnIFUNB8Urqmt3OkXWk6lpWowW6XXlXhhbfEzMoYNDI46qeCQfagDoqK5KDx3o8U2trrt7YaNFp2pHTklvLxI1nYQRS5G7bg/vcbefu5zzxqXXinw/ZvGt3rulQNIFKCW8jUsGUsuMnnIBI9QM0AbNFY2reKfD+js66vrulWDRuI3F1eRxFWK7gp3EYJHOPTmny+JdCiv7Oxl1rTEvbxVe2t2uoxJOrfdKLnLA9iM0Aa1FFFABRRRQByXxS/5Fa3/AOwxpX/pwt606v6rptjq9jLZarZ219ZS48y3uYlljfBBGVYEHBAP1ArA/wCFceB/+hN8N/8Agrg/+JrKpS53uawqcnQs31pb31rJbXkKTQSDDIw4P+B9649fCur6NKx8M6sUtTyLa5+YA+3BH6A+5rp/+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDiahUGupTrX6HOyW/ja6QRC906yBGGmWPe/wCAOR+la/h/w9DpKmWWeW9v35kup8bmPfHpVv8A4Vx4H/6E3w3/AOCuD/4mj/hXHgf/AKE3w3/4K4P/AImj2HmHtvI5f402tzefDnUIrK1uLqf7RaOIreJpZCFuomYhVBJwATwOgryXw1qGqaJDq6f8Ix4in/tCyks8/wBlXS+Xux83+qOcY6cfWvoL/hXHgf8A6E3w3/4K4P8A4mj/AIVx4H/6E3w3/wCCuD/4mtKcHBWuebjcFTxlSNWTaaVtLfqmfOXhaw1CPxVY3NzpWq2luktlGZbuwmgTc2q6eQoLqASQrHA9DX1vXNWngHwdZ3UN1Z+E/D8FzC6yRSxadCrxupyGUhcgggEEV0tWkaYbDww1KNGF7Lv63Ob1oG58a+HLYH5YEub5h7qqxL/6OarWv+GNN167tLq/+3Jc2qSRxS2d/PaOqSFC6kwupIJjQ4Ofuiqd/i2+IWkzSZ23dhcWyH0dXjkA/FQ5/wCA101M3OC8QWNl4G8P6vqeim8bVr5IbKOa9v57ty+9liAMzsQqtK7YGO9eNeI7zwpb6DNoOqanYxGGLy1WeQGZJMcSAfe35O7cBnJzXrnxamLXvhuz3YQzTXRHqY49g/WXP4V5xd+JvDENyVutY0YXEWQQ9xEWT1HXIr5jOaspYiNNJtRV9O7+TPocppJUJTbScnbXscqnii3bw54fuNSn3XhtCl2g+aRGRomkdlHPSJ29+PUVmeBNVl8P+G9a1CSLdZxa4zXOOT9nkRNsi+oyyN7jOKvWl/oU3jvdBZ3f9mQRu8y2kEjLJLjKb0HCguFIyOQjHowNc1FoGqQ6HJFqcccFlclVCvJ/x7KNpAk2/Lt3bjzuC7s/LyapYdSw6urJvbra9/1/rYqLq+3bhFuy+LpfRf18z2vULRL2zntZWZFkUrvXhkPZh6EHBB9QK9W8B6zJr3hSwvboAXm0w3IGMCaNij/huUkexFfMXgzXtV0jV9Q0XV7DUJIYtsqqP38lsG4yNvLwkgkFQSpyCO9e8/CGch/EdmPux3iTr7CSFM/+PKx/Glkynh68qDd01df18yM2ca9KNZKzTs/6+R6JXN6Dut/F3ia1PCSm3vlH+/H5Z/WCukrm9NP2nx7rc6BvLtrS2tGPYyZkkI/BZE/Ovpj586SiiigArmtW8LS3mvzavYeINX0m5ntYrSVbNbZkkSJ5WQkTQyEEGZ+hHb0rpaKAOV/4RfV/+h78Sf8AfjTv/kWtXwxosfh/SFsIrq5u/wB9PcPPc7PMkkmleVydiqo+aRuAoAGK1aKACiiigAooooAKKKKACiiigAooooAKzPEWvaZ4c01r/W7yO0tQwTe+TuY5IUAck8HgehrTrlfif4fHibwNqunBN1wYjLb+vmp8y4+pGPoTW+FhTnWhGs7RbV2uxFRyUW47m/pOoW2raZa39jJ5trcxrLE+MZUjI47Vbrxv9mPXzqHhC70iViZdNmymT/yzkyQPwYP+Yr2StsywbwWKnh39l/h0/AmhU9rTU+4UUUVxGoUUUUAFFFFABRRRQAUUUUAFeC/CqNtX+N/ibVJIpDHBCzxSMOMSSuEA/wDI3ufyr1Pxhr1vbWlxYW13HHduhE0oORZRH70rnsQPug8s2AOMkY/gTwxd6Roms3lmEtNV1eZpYROrMLaEZWBGXrlU+Yr/AHmYUm7DiuZpXsc18dfiD/Zds/h3R5cX06f6VKh5hQ/wj/aI/IfXjoNWuvt3ws8MXR6y3mhs31+3Wuf1zXhfinwbfp8Q38P299/aurT4keV18vdIyGQg5J7c5PrXvHgHRE1f4Wado3iK1uY2hfZLEJJLeSN4Z98ZDoVZSCiMCD2rzsLVqVK8udW/4B9rn2X4TB5VQWHkpNtNvZtST1s9baWX+ZT+JvhnWPGvizw3o8tps8G2sv8AaGpTtImLmRD+7g2bt+OpJxjn1FdFqX/JU/D3/YF1P/0fYUf8IHpH/P54k/8ACj1H/wCP1a0bwjpWkaqupWx1Ka9WF7dZL3VLq72RuyMwUTSMFyY0JIGflFekfEmfN4a1yDxTq2q6Nren2sGpCETQ3GmvPInlrtyjiZQCQSeUOD69Kb4Q8IXmi+IL/WNQ1Ozubm7gSGVbHTxZpOysT58w3v5kpzjd8oAyAK7KigDzbX/hxqGoS6o1h4lmsYtR1CW9nhWOZVdXt4YQhMU0bkr5JYHdtO8gqcVZ8L/DOz0nR77TdRul1G3vNJtdJlJgEZ2QxNGSOW+9uzjtjvXoFFAHlsvwu1M+Hrewi8WXIu3mlm1K6aKWP7ezqqKWEM0bDYqKoG8g45Bqpp3wa+w3Gmlda+0W8ENjHcwzLdKsrWqqquqxXKIp+QEb1kweeeleu0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHOa3um8Z+GoF6RC6vG+ixiL+c1dHXO3P/JQ9P8A+wXc/wDo6Ct+aRIYnllYLGilmY9AB1NAHhI1e513w/4Nv9QkaWc/2lYzPIOWdJQBn3KxE1y+r+Ev7Y1BLFre0sPDkCqTFbRIsl2/XaSB8iDjpyT+FdL9mXTfAbCaaCCSyjtvElubglVkWWLy5o8gEg7i/QHmRPWvM7zVPEeuqHu7uLTbViGFnAhbI9JGOCfcdPavn8wwlWWJ9rGSimt338kutj3svr0/q/JNXaf9anRw28Wj3upvZWh/sRXRpLu3jzDaybQhjkYdPuhs9t3zYyM6brHPAyOFkikUgg8hgR/KszS/iB420aCO1tJ9Fu7BBtW2lslgRV5+UCMYx/8AXrmtT1W7u9auH0i2i0YmON5bWykVoFYlssquCFzgcAADHfNdMaNNU0oVLtd9PzO6nnbwkX9Yh7nk1pf1smdNY6ffXWh+H9X00p/bFjAYSkzYW5iyFeJmHT7gYNzhh7muvt9UutG8M+KdSsZnguJ9S0/ToWBBKszRB8duBK361534R1LU7TSvs8l40cNmwt2luIEmjDsAwLlGV1VifvHd+JFehmGG8+HOm29s3mypa3HiLUHx/wAtl3ALxxjzC23n7sNTgctrYev7Wpbls7Nebv8Ah+p5mOxdOrQiqfWz8tEe7VzmgFovFvii2Yffkt7xT7PCI/5wGuiRldQykFWGQR3FYFnj/hPdXx202zz9fNua9k8Y6CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPnXwMP+EP8A2iNV0f7lrfmVEH8IDgTR4+n3fxr6Kr54+Po/sD4n+FfESAquEZyB94wyAn/x1wK+hwcjivoc9/f08Pi/54WfrHRnFhPdc6fZ/mFFFFfPHaFFFFABRRRQAUUUUAFYXiLw1Frc8Usmo6nalF2GO2uWWKQf7cf3W+uM1u0UAc9pfhLTrB4mYSXBhcSRJIFWON/7yxoqpu/2iC3vXQ0UUAeC+AR/bP7QGv3zfMtobgq2P7pEI/Q171Xg/wCzuPtfirxTfnDMQPmHI+eRm6/8Br3iuPA60ubu2z6Xiv3ccqP8kIR/C/6hRRRXYfNBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRVXVb+30rTbq/vpPLtbaNpZG64VRk8d/pQBjTOJPiLZonJt9KmaT/Z8yaLZn6+U/wD3yaPiC7nwrdWkTBZdQaPT0P8A12dYyR9FYn8Kf4QsLmOC61TVIzHqmpuJpoyc+QgGI4f+AL19WLnvUPjI+de+G7SPBuZNTSZV9EjVmdj7AcfVloA8v/agmtrPTfCFqh8qSe/+ziNTgPAACyH23LEceqivHtY1yysvNtmu/Lu9vASIysmRxkDv35r3r4ueEm8b+JrLTxGZDYx286hZfLZA8koeQN/smOMnHJ6VJe/AXwfdaTbWqpeW13FktewS/vJSTk79wYNySeRketcuIw3tmpX2O7C14U1y1Nm+m/6HzxpsMlzaw3UEeo2NvO7x297LJv8AtDIPnUhsjcM5A64GRgZFXtG05NMt5nkZTPKd80uThsDAJJOenJ989sAfUug/D/QNJ8GReGHtBfaarF3+1gO0khOS5OBhs9CMYwMVlah8HfBd7p11aNpbx+cu0TC4keSLnIKF2YKQR6fpWU8G2rRdkeLicLKq3CNR8l9nq/z/AF3Pmex1Y33i7TLLRJGEl1KLa4uEQOrwNy67TlXAGWyQQMcd69++BNtE2n+KNLut8wtLr+z4zNjLWiIRGDgAY3Gbt1zUmkfBnSfC+b7w9JcXGqKpXffurB1OMqCqgIeOoHsc9tPwDZ3Gl+IYobqEwT3mnSXM8LY3IwunZd2CRnExHU9K76MFSw6he7v9x6jhh6OHVKhd2e736/JeiOk8ASyN4TsYJzmey32Mh7loXaLJ+uzP40lo6x/ELUo34afTLZ4/9oJLOHx9N6f99Co/BTeXLr9pJxcQ6pM7rn+GTEiEexVh+INSeMLK5MVprGlxtLqWls0qRL1uIiMSw/VlAI/21Sg5zoqKr6de2+pafbXtlIJba4jWWJx/ErDIP5GrFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeKftT2Xm+E9IvQMtBemLPoHQn+aCvUfBV6dR8H6HeMctPZQyMfcoM/rmuK/aNgEvwwunOMw3ELjI/2tv/s1bfwYmaf4X+HnbORblOTnhWZR/KvoK/7zJaUv5ZyX3q5xw0xUl3SZ2lFFFfPnYFFFFABRRRQAUUUUAFFFFABRRRQB4R+y7/zM3/br/wC1a93rxz9nrw/q+gnXv7Y064s/P8jyzKuN23zM4/76Fex1yYFONCKfn+Z9DxXUhVzWrOm00+XVar4UFFFFdZ88FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcz4pQ6lrmhaMwzaySPf3I/vJAUKqfYyvEfcKR3rpq5myxe/EHUbhCTHp9lHZ5xx5kjGRx+CiE/8CoA6auZsv+Jh4+1C4OTFpdqlmnHAllIkk/HasH51p+ItYh0PS5LuZGlkJEcFvH9+eVuEjX3J/LknABNQ+E9Lm0rSAt66S6jcyNdXkifdaZzlgP8AZXhV/wBlRQBzOi6z9q1vxH4guImMNpfR6LbDdhRCHQPL7kyO3/AUXpzSeOPHP9jQXNzp7q62rS2hRlyJrnarKi98j5h/9YVzWk21/aeHNAz5h0bVr6GW4eNd3+tZcpIOqgsEIkBxhmUgZBOb4pmSz/tGSHfOE1qe8tk2gme4kikiCrk42qsc7Enjp70Ae22N9BfG4+zlmEEnlMxUgbsAnB74zj65HaqPijW4tE0i+uPle6hs57qGA9ZfLXJA/MfnSeDtMXSPDdhaieW5cRB5LiUYeVyMsxHbJ7dulZ3xL06e98KXk9jcfZr2yjkuInK7gwCMGQjI4ZSR7cHtQAnhrxZbakF86eMi6Mkto6Y2PGoUkA9yAc/Ssm91WaLxb4W1pEEVtqlktvcxH5jh3TyyD6q8ij3Dn0Fct4QW0n1Hw++PKshqWoSIrLt2GYypLbuvVWWUp9d6ipzFf3ngu81CaSZ7PSlnFpNMu15BHKnl7V7Iqwqd38bEkYGMgHe3H/Ev+INpLnEWrWbW7DHBmhO9PxKPL/3xXTVi+LdMn1LSlOnsialaSrd2bOcL5qdFY/3WBZD7OaseH9Xg1vS4r23V4ySUlhkGJIJFOHjcdmUgg/pxg0AZXhJDp2q65oqgi2tplu7Udlin3MVHsJFlx6Agdq6euZuW+xfEOzkdsRalYNbLxwZIX3qPqVkkP/ATXTUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB578fgD8JddyOnkY/7/wAdL8Av+SS6F/23/wDR8lec/tCeLNYsLjVPC13FFLpeoRw3NrMBteMBgWUkcMNyH3GRya1v2e/Ft7qVhY+G7HS0jsNMhd7u9eQtuLuzKqqAMElj1J4U19dPLq0ciT0tz897/Z5bfffS3c85VovF/K3zue40UUV8ieiFFFFABRRRQAUUUUAFFFFAHj2q/HDT0W9l0ax+22lvcG289pHXc44PyiM4Gc8kjjnArH/4Xdfy4aOxgjB/gigNwfrkyxivRPEfwx8L69fm+uLBYLwkl5YAo3k92UgqT7kZrMk+EmkGPZDfXUAHKPFb2yPGf7yssQ2nIzkUAclH8ZNQuZPLtJtI89QC1vc27RTEf7CLO5Y/kPerTfE7xSE3nT9Lhj7G6hniJ/75Lj9a3pvhPDJAsDa5fTQg52XKiQE9yRkDJ7mqo+CukK2+G7NvIRhmt7WNNw9DxzQBizfF/U7YAXsdjFK5CxCKzeUSseiqTMvJ9MVbi+LGsaZeeT4q0uw0xcBlN3K9q0gYkDhgwU8EDJKkjBZcitMfBXQCHDGIb1KMUsLdWKnggnYTg03Qfgzp+j62L6HWdR8vyRAyI213QEnYZMlgvPRdpGBgjnIB3Oh+JrHVrySxCXNpqcSGSSzuoikirkDcDyrLyOVJHNblZukaDpWj7jpen21s7Da0kcYDuP8AabqfxNaVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVBfXltYWkt1fXEVtbRDc8srhFUepJ4FAEesahBpOlXmoXZIt7WJpnx1wozx71meDbCbTdAjfUdq6hdM15en0lkO5hn0XhB7KKzLq4l8YzWdvZ2dxHoCTpcXF1cx+WLoIQyRxo3zFS4UliACFIG7dkWfGDPqlzaeGbdmX7erSXrqcGO0UgOPq5IjHszEfdoAi8ORnxFqa+JrrJs0DR6RCRwsR4a4P+1IOnomOm5q1vGNxJaeEdcuYGKyw2M8iMOzCNiDWrGixxqkaqiKAqqowAB2Apl3bx3drNbzqHhmRo3U91IwR+VAHNeI9LI+G1zp2nSpA0NgEglZtoQoo2nPbG0c15z9otb7UtG1Gaxkaxs7FRPa20H2iPEbtsGei5757ZBzXofh9J9T+GiWjljdiylsWJ6mSMNET9dymuV0fVYYdcXyYRb6fOlheSImERkkheJxgfwqzwkg+57GgD0/T7pb6xt7pI5I1mQSBJFwygjOCPWk1O4gtdOuZ7xS1tHGzSKE35XHI29/pXHaVqV94bvZ9H1GRLmyt1YWkhTa6xhGeJWbOGBWORc4BzFzncMR3viW/wBc0fSLTSIYYbnV7W3kmlclvs6zoWIQDqwRJWycAbV4O4CgDhraewsrzxBPYx+dY3Nofs8MiNCF3SAlizDBdSFAIOTsXHIr0F7KUfBya1nkSa4/sZwzochn8onIPfmsrVLy1/4SOzsLmJbnTILqfasihlijhssMDn+Hfkf7yn0rZvJWsfhFI7grKujYAPXeYcAf99ECgDq7C4F3Y29wv3Zo1kH4jNcz4gQ+G9VbxHbcWExWPV4gONo+VbkejJwG9U6/cWul063+yafbWwORDEsefoAKlmijnhkimRZIpFKujDIYHggj0oAxPGtlPeaE0+nrv1Gxdb20A/ikj52f8DXch9nNaumX0Gp6ba31o263uYlmjbGMqwBH86wfBskmnS3fhu6dnk00K1rIxyZbRs+WSe5Xa0Z9dgJ+9VSyuZPBz3NnfWlw+gmZ5rW8t0Mi2yuSzRyqvzKFYthgCu0gEjHIB2VFQ2d1b31rHc2c8VxbyDcksThlYeoI4NTUAFFFFABRWV4s1f8A4R/wrrOs+R9o/s6ymvPJ37PM8tC+3dg4zjGcHHpXLa54u17QI4n1208FaYkxIja98TyQhyOoBa0GevagDvqK4mx8Va2dS0BL/S9DOm6xcPbQ3enaw91giCWYMAbdAykQkZDdx1roPFHiLSvC2jy6rr12LSxjZVaQoznLHAAVQSfwHAyTwDQBrUVl+ItctdB8P3WsXSyS2lugkYQAMzAkAYyQD19a0LmZbe3lmcErGhcgdcAZoAkorC8K+KdM8T2cM+mvKHe0tr1oZUKvHHOm+Pd1XOM5wTjFbtABRRRQAUVlxa3bSeKLnQlSb7Xb2cV6zkDyykjyIoBznOYmzxjBHPpqUAeK/tP6C194a07V4ELS2U/kvgclJMD/ANCVQP8Aers/g/4RHg/wZbW0ybdQuf8ASLs9w5H3f+AjA+uT3rsbq2gu4fKuYkli3K+1xkZVgyn8CAfwqavUqZrVngIYH7MW369l8nd/cc8cPFVnW6sKKy/C2t23iTw5p2tWKTR2t/AlxEkwAcKwyAwBIz9Ca1K8s6Aorn9Z8W6XpVvqkkjyzPpkkEV1FFH8yNMVCY3YB++DweB78V0FABRWX4l1u28PaUdQvUmeETwW+2IAtulmSJTyRwGcE+2evStSgAooooAKKKKAPNPEml+Hbrx54o1HxRo2n6pb6Z4fsbgfa7SOcxqJb9n2BgcEhR064FcX8LP+EQ8W31oNV8M+CrGa/tmu7XSR4aaOYxZ+VhcyYjmwM5CJ+PBrvtbu7TT/AB5rw1rT9WuNN1LRbK2DWml3V3HJtlvPMQtDG20hZU4ODhhXM+E9L8IeG9W06/iPji+bS7eS106K80C9ZLONySypttVJ4OMuWOOM0AdJ4RI0X4W64dKSK0Fjd619mSKNQkWy9udgVcYAGBgYxxR421zXbT4KTa9pN/DbatFpS3jzy2wl3HytzbVyFDE9CQwH901q/DuITeD7j7baTRQXWo6nN5N7btEzQy3s7qXjkAYBkYHDAcGsbwHpngHxX4dln03wp4fiheXbc2v9nw4DpnaWG3B4YkH/AGj71Lkk1F7s1jQqSpyqxXuxsm+172/Jmx8X7u5sPhd4pu7G4mtrqHT5nimhco6MFOCrDkH3FYOpfFP7D4vOkDTIrm0aS5gS8gmnwJYYXkZHLQLGD8hUhZHI4yPTvxo+mjSP7JGnWY0ry/J+xiBfJ2f3NmNu32xiqbeE/DrarJqbaBpJ1KQkvdmzj81iVKnL4ycqSOvQkVRkcZd/E2503TdP1DWdBjt4tUsDc6YIr4SPPNtjKWzAooV338YLDCk+wgv/AIsjS/Ef9n3mkxyWgNzG9zZSzy7JoIHlkjO63SMt+7ZcLIxzjIHOPSJNK0+WCzgksLR4bN0kto2hUrAyDCsgx8pA4BGMVTXwv4fXWG1ZdC0oaqzFzeizj84sQVJL43ZwSOvQ0AYPw68bXni1rj7ZoF1pkawxXEM7R3HlTK+flDSwxZYYBO0MuGGGNdtWVovhzRNCkuH0PRtN017jHnNZ2qQmTGcbioGcZPX1NatABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXjmv+I7jXL6/wBT0xLa6j0ZZpoIrhS8FqIgwM0qgjM7spWNCQUQFzgnB9jrhPizq9tpWhrHcqPsp33t4oGN8EGHZfq8hhj9/MNAHd1zWhIZvGPia6cZMRtrNCeyrF5uB+MxNeO6X4w8UWlxbxXWpl9Qt4kt5hcbvJ+3XbfaZiwz/qrS1UnHGCcV7L4HhlOkzajco8dxqtw9+0b8MitgRqR2IjWMEeoNAHRUUUUAcr4cuV0yLxTHcsTFYahNOQvJCSIs5/WRvyrhtF0yC+0mz025IHiXQw0c8Lv5Yu7OVcsuc4ZfLlGD/C6joDz1euSx6br3ibzsrDfaMLgH1eLej498PEKpa1YK+oWHnxxi5sLWyjUgAFXmnEbAkdQUVlx6M3rQBz1xPqN9omrxandCa6XQYLq3vfL2MXRWkZXUHG4+YoyMAgngY5f4WN5puheDXtfIk1C7RIgZQxSFVtI4Sz45JEiABR1L9Rya6TxFYXGleC9fs5VEkWyKC3ujjzJYmKoEfHVkyRnuMd8mptMhz4anWzso7i+tNVuYrXeCRETdvtZsc7VBDEdwtAHJLaLB4YudT1GUyatq1kml6VGRkvJMp3zBRnBaadyT/CgHTJz1upT/AG7wf4esWjJe7vbW0lQ9jE+6UflC4qhY6bbaX4ptfPY3E1ncx2QklUY8qSEyAgdFJnUnI9QOgFWdGAn8S6RpoYg6XLqF1KhHKsZNkX5pMxHtQB39FFFAHNayPI8b+HLhQAZ47q0c+oKrIB+cR/X1ro5CVjYqMkAkD1rnvHKSRaZb6rbq7y6TcrelEGWaMArKAO58p5MDuQK8Z1Pxh4quJrpYNR26lLEyxR27P5Iv7FhPsQf88rq1YOASc0AdP4b8R3GiX+m3upx29rHrSwzTw26lILjzgu2eFSTiVXbZKgJLKVk7Yr2KuG+FGq2upaCYLQA2kJS5swecW0w3xj/gBMkX/bKu5oAKKKKAOV+LH/JLPGX/AGBb3/0Q9U/iXcW62ZtZYdehuJraVYr/AEjSvtroDgND/q5Nu/jqADt+8CK6bxDpUGvaBqekXbypbahay2krREB1SRCpKkgjOCcZBrF/4RfV/wDoe/En/fjTv/kWgDhPh/pmoaN4K+EWn6xpyabfQalMJLZSTtzZXxBbJOGYEMRngsRgdB2Pjzwhd+LtV0eOTUXsdIshNO/kCN5pJ2Xy0G2SN02BHlySCckYxjNWrfwjcf2vpl/qXifW9T/s6ZriCC5S0SPzGikiyfKgRjhZX43YzTPGvijUND1HS7DSdJt9Rub6O5l/f3htkjWFVY8iNySd2Bx19uQAecap8KPEN5p/2S8XQNXkSxi0+0vNQmk82xWGVyskY8phveMxhyCpDL1YYFbx8CeIRr0So2k/2PFrV7q6zG4k89vtEEqBDH5e0bWlPO85A7dDGPidf3WjQ3FzpB043VtpmoWrWt8srNBdXSRYffDhWAbkANkEgMp5Gm3xD1L/AIRq58RR6BayaR9qjtLYLqJ+0ys12lv88flbI/vM2N5PABxkkAHKwfCG8t9NktpdJ8P380+j6fZSXX2o280c1uio+1jbSbo32rncPmC7WUg8dNc+G9T0r4GeI9EltbN79tMv0httLgUK29JNiBY44w7nIyVjTcx4UVJd/EPU7TU7m1uNCsfLsr61026ddTJYT3AQp5aGEF0HmpljtP38KQuT53a+Jtei8FTyXl1fQ6hqWk3WqCeLVZJ1yl1AgIVo1MJAlZQsbBAo5DE5UA6XRvhfeSPDPc2OjaZYy3llcTaVaSu0RSGKVZHYmNMySeaoYFQCF5LVLP8AC7UhrVw+m/2TpyG5uJYdXt2db1IXgaOO1CBAojQsuPnIwi4UHmr+pfFj7D4ju9OXS4rq0jS98q7t5p9ryW0TSNGzPbrHn5GU7JJCpHIqa6+IF7ZXC3GpWcFkkulfbre3kvS8b7pYkQPst2kEpMmNqbx0GCTkAHN2fwq1m3kN1aaf4a0y4t10t4reznk8u6mtLhpXeZ/JBBcMBuw545zjNaL/AA91y4nivdV0/wAOauTf3t3NpF3cSG0PniPY4Ywtl08tgMx4w5I2mmr8ZriW2git/DFxJq73V3bNagXZUeQsTMfltTLkiZMBolxzkjjPR+N/E2s2/gvw9q2iWv2O9v8AUNOjltb8mFo0mlRWifMbFT82wnblQSRyACAYGh/DTVLH4kLr9xJbG3F29ykkFzGkkUbRlRb7fsm941ztC+eq4AO0EYrX8ReC9Qv/AIl6d4hs7XSvJhaETT3brNIEQkkRRtbkxtzgMky+pU4ArK0LxlrOleIdcTWbOGXTJfEKWDTnUWc2bvZwNsjRowGiDZOcp98nb1rL1j4t6ve6ddw6Pp9ra3qGwuYLoTTmCeCa8SE7TNapkMGA3KrLtcsrErggBZfB3ULDwxDp+m3Gm6ddyaANOvZ7XI+03IlicMx2fMpVJE3MCQHxtI4qjefCHxBL4f8A7Mhh0JbeWeaaSCeS3lWJmjRFeE/2eEi+625UiUk4IcEmvV/FXiO48O+HLa9ubazOpTyRwLaefMyPKwJKRtHA8jnhsYiycdBXLaB8U7jW7W0mttA2FrO5vLpZbplMKwXBhkCgxbmbglQVUk4B28kAGB/wqXUTZ6jbzWXh64udQs7CKXUXkdbhJIViEyj90Syv5ZO7cCSRkd6n8RfCa/nju7fRTpkGk/2ub+30kbEtzE1tHGQVe3ljVhIruB5TD5s5B6dZ8N/Hd54wkk+0eH7vTrZraO6guWSfypFYn5C0sMY3gbT8hdSDwxxXd0AeGn4S6uqW0Rg0e9aNtOaG91C7aa509LeVGeKFhbgFWCnkCP7xBBGMe5UUUAFFFFABRRRQAUUUUAc58RdS/sjwNrd4G2ulq6IfR2+Vf1YV80fCnxi/g/xKk0rMdNucRXaDsueHA9V6/TI719Q+K/D9r4n0oadqDyizaVJJUjO0yBTkKT2GcdOeK8J8QaZp3gb4y2v2iytz4fvFX9zLGGjWNxsbIOR8rDd9MV5eOjNVI1U7Jaff+h93wtXws8HXwU4uU5pu3dJKyT/m3aPoyKRJoklidXjdQyspyGB6EH0p9Q2VtBZ2sVvaRJDbxKFjjQYVR2AHYVNXprzPhZWu+XYKKKKYgooooAKKKKACiiigAooooAKKKKAMrXfEeh+H/I/t7WdN0zz93lfbbpIfM243bdxGcZGcdMinaFr2ma9HcyaNeRXkVvKIZJIslNxjSQbW6MCkiEMuQd3WuY8aeG9V1nx74VvtOvLzTrSxtb9Li8tPILo0nkbF2yo4IbY3RTjHUZ55HxDZeJPCx1bVNNmcajeeIfLsbeWYbNQWe0ggVmVOMpJGZOQCFjfAAagD2K8u7axg8+9uIbeHcqeZK4RdzMFUZPcsQAO5IFTVwHj/AMKXl98MYdEsnv8AVLy0kspNxvGjnufJnjaQmQuvzlVcjLABsEEEAjmW0vxs3j3SLqw0/VrDRoLm3Egm1V7gPaiEBxLuvGUyBjghYWJK7hKxPIB6xomq2euaRZ6ppc3n2N3Es0Mu1l3oRkHDAEfiKxPHfhG18U2C744ft8H/AB7yTbzGPmVmVlUjcDtA9R1GDXlGieFPiNpvgO30ordR30NtZpGbW9CxpboV822CLNHibIJ80SDcuQHT7tXn0HxzHpmkbV8RX1zFLKWtp7wW0SK0gKiSSPUDKdozglp/l4K5oA6HQPhLaw3ktz4hvDqMy3st3E0YMYkMrbpfNXJDbyEUr02xIPXPqFef/F2y8R6hY2Fv4ZtLqXLSGaa1vJIJITtGw7VubfeCc5y5xgHa1dL4Ij1SHwbocXiHcdZSyhW8LuHYzBAHywJBOc8g0AbdFFFAHB/FcNZW+i6ykbyR2d9FFcoozut5JE3DHf50iOPaui0q2b+29Wuiga1uhbyQy5BD4Xt9MA/jUPj+B5/BmrmHPnQwG5ix13xYkX/x5BW3aTx3VrDcQndFKiyIfUEZFAHP/EX/AJFK5z0M1uD9PPjz+lHgbPk611x/a11j/vuj4kf8iXqPr+72/XzFx+uKk8EKo0y+YfebVL4t9ftMg/kBQBY8UWTXGlS/ZYA9y01u2UA3HZKrZz7AE1l+HIorjx14s1GKNBt+y6eZFOd7RoZG/LzlH/Afautrmvh9tm8PvfgEHULu4vMnuryts/8AHAlAHS0UUUAFeX6z8Jrc39rdeHL06fIt7HeyGUGXY0XMPljIACgtHt6bJCOy16hRQBzHgPwla+FdMMcSRC9nC/aZItwRiCxUKrE7QNx6dcknkmunoooAKKKKACiiigArnvE2p2FhqujwTaTLqepXbSxWyQxxF402gysWkZQqY25wcngAGuhri/GvgmPxN4k0TUZI7LFhBdIJpYg8sUjqvlSR5HVGUsDkYOCKAOiOgaOYoojpOn+XFFFDGn2ZMJHGwaNAMcKrAFR0BAIxVceE/Dovrm9GgaSLy5YNPP8AY4/MlIdXBZsZYh1Vue6g9QK8rsfhXrVta272tt4e065sjp8iQWk8vlahNbTiRpp28oFWYAjIVzycs3Fatv8ADS71PULe58V2ui3cJvdQvJrTc08YNwsYjA3oNxUockgdiOegB2Xi2Pw9o7ReJtV0a1ub6Ga3to7tbWN7hDLMsSbXbBADSAnB6ZxnpV2bSNCWS1spNGtGV4JIIlFiGjSLKs0ZYLtRSwU7SRuKjGSOPJx8KNea206O9TQdRu4Y9KH9o3U8jT2X2VozKkGYjlX2Mc7kJLkEHt3HxO8IX/iqMLp81rGRpepWP79mHz3EIRDwp+UEc98dAaAN/wD4RHw3/aM9/wD8I/o/2+43+dc/Yo/Mk3gq+5tuTuDMDnqCfWrN7oOj38JhvtKsLmIwi3KTW6OpiBDCPBH3cqp29Mgelc94G8HL4V1rWJbOGytdNvILRY7e1G0CaNXEsjLgDLbk+bknHNebeJfh1rNjpXiGS20fS7iC/urQpbRMLi4nJ1CGRvMmW2SQRhQxIYy4HOcLggHq83hTwmttb6NJ4Z0prKR2nS2Glo1urhQCxwmxWxgAnBOMDOK17rR9MutJGlXWnWc2lhFjFnJArQhFxtXYRtwMDAxxgV5JL8K9XfSdRgt/7H09buHVUisLaR/s1mbq3jijSM+WMruQux2ryxwpqXWPhbqEcOo2vh618PRabeNZM9nNEmxmiSUSuA8EsayMzR/OY3JCnODg0Ad/bReH4NePhy30a1iligj1MBLWNYgQfJRhj+MCMAHHCgAHjFctFceCbTXZ9EtPBVslve339jz3UWnWq200/lGcxuNwdgAnJKEbscntL8LPA2reFJbFtUubSYW+lmw/cyMxB+1Syrj5FG0I6rwByMAAYqnN8Lc6lLd28OlW00/iCbU5Z4o9srWz2ssQQkLyweUttJxyTnJoA7zV9I0M+H00/UdHtLnSIdiJZfYRPGgBCqFiCngZHQcDngCqipoPhvWNF02x0i2tJ77zoLZrS2jjWNVBmdTjBAJGcAHLcn1rz21+HPiiXSLaxv30WIWWj2ekwNDcyv5vkTxyGRsxDblUPyjOD3PUWNM8Aazo/iqLXE07RLu4s7jULo3yTN9u1Dzlk8qJ90YVdu5V/wBYVwBjbjFAHpGj+G9D0S4nn0bRtN0+ef8A10lpapE0nOfmKgE8+ta1ch4q0PWPEnw6Om3UljHrkkdvM5UMlv58ciSFR95ghZMZ5ODnnpXLwfD3VdU8QjUfE0OjtbTa3JqVxZRTSTIYTp/2YR5aNd53AEggKVz67aAPUbS5jukdolmUJI8R82F4zlWIJAYAkZHDDgjkEg5qavHH+Eb3d1ef2nBo9zaGHWBaxSAsIpLq6WWBgCmBsUEEjlTjbnrUenfC7XLfxxZa3fXsN4IpLaU3C3SJPH5cSo0QLWryPGSrHAmjDBjkA5JAPZ6KzPDUmqzaHay+IIYLfU5FLywwfdiySQmdzZIGASCQSCRxitOgAoorlfix/wAks8Zf9gW9/wDRD0AdVRXiPxV0LS/Dep+Ho9C8A+GG0y7ac6lft4Xa/FkiKhVikO04OW6+nsav6HpPhkTfDjXPD1l4caa71SdTqOj6WtksyfYb35QuWYAFQCCx5Xt0AB6/XBfGLwafF3hrNmgOqWRMtt/tj+KP8QBj3A96xPiJ451nwp8RLdYEe80JNLElxZRxAuZ5JWjiZWxu5kEceM4/eZ7Vi+GPiVrOmaDbT+J5JdT1CK11F5vKMUEUkkWoR2yAgR5UDzB827AXcSrHBEVKaqRcJbM6cHi6mCrxxFF2lF3/AK9dmb/wM8ZXOt6bLoeqwz/2jpiBTKynDIDtAY9nHTnkgZ6g16nXn39vanpPiNNPfwvpUWqX9rNqVzLa6gzJ5cLxISzGBWZsSHA29QB0YsvJeK/iNrOqeEUjstNg0+fVbazvLSWDVWLi1muoYSHZYgYpD5qj5d2MsQxKYM0YShBRk72NcyxNHFYmVahDkUtbefX5XPbqK8Yi8V3OlazZi8u5ba10ttThnju9SeWEmKC3ZQ0vlh2UM5wzq78k8k7Rpab8Vb2+nWyXw4F1RtUi00RSXE0KfvLaSdZCZrdJAB5ZBBj6HI3cA6nCeq0V5JqnxRutF02+lawjv763ur7zbNrmV5EigYAtH5Nq37sE43ShAPl3Oc8XtM+Kcuq+KItO07w5fz2HnQQTXSRzs0TSxLJuO2ExBFDrktKp6nbjGQD02iuO8Z+L73w7q9jbrpMb6dOqmXUbiWaOGFi+3aTHDIAeQcuUXkDOa4bw/wDEfUfDvh2SfX9PkvbEzaxLBeLetLPJ9nuZTsaNk+VQvyqQ7YCjgCgD2qivL9O+Juq3ptLQeFZINUvbpba1F1LcW1rKDE8pbzZrZHyojYYWNuSMEg5HQfCO9u9R+H+m3WoTNPdSSXG92lMvSeQABzyQAAAcDgDgUAdhWL431WfQfBev6vZpE9zp+n3F3EsoJQvHGzAMAQcZAzgitquV+LH/ACSzxl/2Bb3/ANEPQBkeKdV8Q+FNFn1bxB4u8L2WnwkB5W0C4bknAAVbsknPYA07T9c8QLe+EbmbV9E1PRten8tDbaTNaybDaTXCOC9w+P8AVKMFc4Y9DWP8cfAOueMLC6n0q9tbgQafLDa6VPa7t075BlWXzUVXKnaCysFBY96taVp2oaRoXwi03WfKGoWl0sEyxrgIV0u7G37zAkAAFgcEgkAA4ABe8X+Mbzw340WJrO/v9Jj0aa+nhs0hLR7JVBlJdlJAXI2qSTnhTVHRPiGzahrMJgvtall1V4tMtbKOJX+zJZ20zHLsi4BlJyzbiXAGeAOr8SeDND8SXa3Or29zJKIGtj5V7PAskTHLRusbqHUkDIYEVl634b8HxX1vaXsElreahcS3cRtbi4hk3rCkcjB4mBjTy0jUjKp93PJ5AIV+KGkSpHPZ2Oq3VgIbea6vI4kEdmJjhBIGcOT3OxWwOtV7Lxxca1440C10y1v7fQ7lb4G5nSER3hi2gNHhjIADu+8qZz3rUg8C+EL+HTryysontFgtxB9kupFt54o/mhLIjhJQM5UsGq3pXgfQNK1hNTsbOaO7jMrRA3czxReacybImcom48kKooAzfE/xFs9A1S9spNG1m8FkbZbi4tUhMaNcNsiX5pFYlmwOAcd8Dms3VvjDoOk2kbalaX1retcT2zWNxLaxSI0IQvl3mER4kTGHJO7gHBx19/4X0fUJb2S8s/Me9e2knPmuN7W7h4TweNrAHjGe+azp/CfhnUr66CK638Vy9zM9nqE0E8UkqJuy0bh0DKiHbkA7QcUAZTfFfw+NX0KxCzMutC3NpMs9tz56gx7ovN84DkAny8A9+9bXw01S81rwLpGoalN515cRFpJNoXcdxHQAAdOwqJ/h94cfVY9Re1u2ukmguMtqFyVeWEKI5HTzNruAijcwJOOSea3tG0uz0XTLfTtNh8mzgXbHHuLbRnPUkk9e5oAu0UUUAR3EQnt5Ym+7IpU/QjFefeDPHuiR+GdNswNWubmytYLe5+x6PeXSRyiFGKF4omXOGU4z3FeikgAknAHevmDSP+Er0iKK20L+zptPbWtL1i5lN5JGWFz9nghtHxEQDwHYgt8pU46KwB7VrGs2fiXStDj0pnlg1DVViImheFwLaVnlDI6hlIaBlIIHJq/4Rxbar4l04t80V+blB/sTIr5/778wfhWF4Z0q+0zXdBttUW1F6TrOoSpbStLHH592sigMyqTgTBclRk54rejOz4j3AzjzdJjP+9smf+W/9aANrV5zbaTezg4MUDvn0wpNUfBcXkeD9CiAxssIF/KNad4wDHwlrYjBLmxnAHqfLarOglG0PTmiOYzbxlSO42jFAF6iiigAooooAKKKKACiiigAooooAK5H4g+K77wtFZy2ukC9tpBI1zdSyTJBaKgBzIYoZWAOSclQoCklhxnrqy9a8O6LrrQNrmj6dqTW5JhN5bJMYycZ27gcZwOnoKAOHn+Jl1DfSFtEt5NLGpPpcdxFqBaWSUQ+aGEXlY2EcZ3ZHXBFZXij4n6lN4Z0qfw/aW9vfX1jpmqM0t0CIluLqGNoT+7bOQ5UtgYBJAyAD32jeC9C0nW7/WbfT7eTVry4e4a8lhjMyblClEcKGCYXpnuaoSaR4P03XLbw+nhjS45NatriVxFp8IikjiaLesnHOTIhAwRwc4wKAKLfEKW3u7qzv9LhivLbWLHR3SO8LKz3EcTl1JjUkL5hwMDcFz8ucDCh+KuvT2kdzF4TsfLl0u51eMNrDA+RAwVw3+j8OSy7QMg55K13dv4Z8LvqiyReHNNW904RRxTtpqoYlUAxiKQoAQuBjYcKRjgiptTs/D+i6NdX17YWFvp9hYzLKwtVIjtcb5UCqpOw7clQOcDg0AXNJ1ez1SNPs08RuPIiuJLcSKZIlkGU3qDkZwceuDiuCvvihPp15PJf6Gi6Sl/eack0F4ZLh3t4pJC3k+WBsIiIzvJBIyMc11Hh250YeJdasNJtXiu1gtLy4lxhJEkRo4gnOQAsBG3AAzkZJNLofgrQdG1S/wBTttPtn1S9uJriW9lgjM/7w5ZA4UNs7AEn8aAON0r4q6nfR2mfCVzE97Pbw2ryPPFDJ5yyN/rJrePldgyFDDDZDNjFWIPHmsrqL6bBpNtdag97dwsLrUxFBAIIoXYLItvkr+8IG5c8ZJwfl39C03wnbeJ9U0nSfDmm2V9YpbXs0sNjFGrGQzCNgVGSy7JOSBjdweTVjXfAnh3XdSsrvVNLs7kWzzS/Z5beN4ZpJQoZ5FZTubCLg9frQB57o/xI1CTUNQ8QQ6dJPoNxbaRK8M96yPafaCU/dx7CrnLAnlMhQcmtE/F2dhrlxD4YvpNN06K/dLnbcKrNaq5IkcwCJA5jYArI5BwCoPA9JfRdLdJUfTbJklEYkUwIQ4jOY88c7Tyvp2xVOTwl4clv7q+k8P6Q97dI8dxcNZRmSZXXayu23LAjgg9RxQBxHiL4pXegywfbNFtJFKwS3EVtdzzTW0c0m1Gk22xiQnk4aRQSpCluCbGl6lfP8M/HF095ctc295rSwzGVi8QjmmCBWzkBQABjpgYrsdS8LeH9Uu4brUtC0q8uoFCRTXFnHI8ajoFYgkD2FXk02xS0uLVLO2W2uGkaaERKElMhJcsuMEsSSc9cnNAHkj+NNWnXQdIv4Gsb+G50i4ea0vXnE8E7su2Q7FIc+Wcp8wIPU1eT4uTDTra9uNChWLUbNb3TRHqIdnVriKBRP8gEJ3ToSQXAAfklcV3+m+FvD+lweTpmhaVZw+ctxst7OONfNX7r4UD5h2PUUQ+FfD0Bv/I0HSYzfgi82WcY+0gnJEmB8+cnrmgDh7r4jalNNdaLBo1lHr0T3cU2dUIto1gihkZkmEW5mxcJ8uwEENnG2ul+GOqpe+BfCsd3frcatJolndzLJNvncPEv7xgTuOWDfMepBq+/g7wy+nW+nv4d0ZrC3kMsNsbGIxRuerKu3APuKuaZomm6XcSzadZxWzyRRW58sYURRAiNFXoqqCcKAByaANGiiigArmvibbT3nw28WWtnDLPcz6TdxxRRIWeR2hcBVA5JJIAArpaKAPOPEmu6drLwvb6n490hkjeJvsHh+8xIrY+8slo4yMcMACMnms7QINGsZfAPh/wlpmuxWGlajLM7XekXkCohs7tS7ySxKuTJKvfq3Ar1iigCD7Hbfbvtv2eH7YY/J8/YPM8vOdm7rtzzjpmsDw1D4e1/RU1Cx0W0jtpxc25SW1jDFWmImUgZG13TcR/EcE81z/jrwTf65430jWrC10pzaCFGmv3WUIqyl22QNbvhsE4dJY2ztzkKAecm+EN+ulRR6Xc2Gm6lLaajb315blg9wZ5VeEMduWUAFTu+7ngGgD1TSPDmiaKUOj6NptgUV0U2tqkW1WKlgNoGASikjvtHoK5nV5vBPhiy8TSromnh9Ot4tT1K3tdPjV5Bud4nOQFdt0TEZOQVzxwa4VfhPrieH206O30TyZr0XM1rNJbSxjEWwPCP7OEcTZ6/uSWH8QJNRQ/B3WYtDvbWW38O3mpXvh6LSjqM0jiW1njjlTch8klldXjUnKkKg4bAFAHtE2haRM0jTaVYSNKZC5e3QlzIAHzxzuCqD6gDPSoNN8K+HtLWMaZoOlWYjlE6C3s449sgVlDjaBhtrsM9cMR3NeceJfhS8p1SHQ9O0hdPnu4Lq2tGnEMUTpC0bu8TW00TliRwUP8AeyGArvPCEGuWaiw1WDTorCys7a3gazi8sSyhP3rKobCRg7VVdoPB7YoAtaj4T8OamF/tLQNIu9sjzD7RZRyYkY5Z+VPzEgZPU0reFvD76lb6i2haU2oWyqsF0bOPzYgowoV8ZUAdMHivKD8P9X1zxPrt1b2lnorjWbiaPW8uL542ttgSNfLA8os2c+YQcH5c803w98HtQtbMWupJp7QNd2MtxCtxG8NykLsXJjjtIQHIbGWLls4ZuASAevaj4d0XU9Rt7/UtH068vrbHkXNxbJJJFg5G1iCV55471W0uLw9qD3dvYWdk50y5ltpUFqFEMsirJKBlQPnEoLEcHccknNeVa/8ACDVrq3tra0l099Ntru/eHTjIkcMMU8oeIp5ltMqMi5XCoMZ+Vhzmza/Ca7glvIhZ6KyXWp2N++pNO32xo4mtjNCzLCu7cYZH3Bhl2yVXJIAPSI/BHhSPT5rCPwxoa2MzrJJbLYRCN3XOGZduCRk4J9at+FJ9IuvDmn3PhuOCPR54hNaiCHyU2N82QmBtznOMDrXmOo/C7UZ/iBZanaWvh210W1u42SO3gihc2oi2NCyrbl2zlhzNsIwNgxmufb4Kax/YWj6eLbQkjsbaS1lit50jFw5CD7WWks5dkxC7ThdwwpEnagD6Eqpq2n2ur6Ve6bqEXnWV5C9vPHuK743UqwyCCMgnkEGn6dC9tp9rBI7ySRRKjO772YgAElsDJ98DPoKsUAcr/wAIHpH/AD+eJP8Awo9R/wDj9S2PgnR7PU7O/V9XnubN2kg+2axeXKRuyNGWCSysudruM4/iNdLWP4u8QW/hjQptVu7e5uYo5IYRDbKrSO0sqRKAGZR95x1I4oA2K4bWy1r8S4ZJDsOoaLLZ2Mmcfv1k3sgPZmUqR6+WfSobX4mWs94trPoet6ezXUunma5jgaOO6SJ5TEdkzEkohIIyvIG4HOJPDnxBj1i0szaaXqWoH7DbXd7dwRQwxW/nQiUBkebdnaQ21DJgEDJoA5S08L+NzpMNzc3WsjWLWz0ZYEGrHY0qbReF1EmxyRuyXyG6jJrm7S98R6h4mvNG0XVr6TxRHbaqLuf+2VubUS7wsGIElYQbc7QHjjIP97BNel2/xOtLqz0+4s/D2v3H26y/tKGJI4A5tQqFpSGlGADIq4+8xztDDmsHTPH99qPjK8njk1CLQReWNjaL9mt3t5RcRRSBm+cTB2EuQc7VXqpbigDGg8O+OV8OTxyv4oaf7VFJHarOo4Ebq4aQ6mZShJU4Ey4ZR8pBIqVvCHiOKbXLgaf4jt7+/trGSObTtZM0aukcaywuJbqJnOVI35Dbc7ZATzsaV8WLTSPDPhuTxSZZ7vUYlZ7iOa1Q5aUxj9yZFkbHBOyNgBz2OOhHj6G6vLaO0sr+C2OsSaQ9zPBG0byxtIjquJQw5jyH2sMcYzkKAa/w/g1K28JWMOt20ltfpvDxyXT3Dgb22lneSQ5IwceY4XOAxAFdDXmP/C6vDKR6obpZ4JdPWNnj+02ku/fJ5aqHinZFO7qHZcDk4HNTr4/i1nStH17w/OwsF1mLSr+1YwyhjK6xAh42Zcq0kbAo5BBIOewB6PRRWF4p8SW+gxQxLFJe6rdkpZafBzLcP/JUH8Tn5VHXsCAYnxe8STaH4Wa00l0bxBqjrZafAc5Z3YKzcdAobO7oDtHJIBzL3wzbeFfBPh3QLSRppZdZ09pp3+/PKlxHM79eOIeBzhQAOgqSTw5NBq2g6lr06XevX+pILiVMiKGOOKaVIIQekasoOTyzfMewGz4iJvvH/hTT1G5LQXOqy+g2x+QgP1NwxH+5ntQBZsF3fEPV2nwZI9PtRBz92Nnm3YHuyjP0WjXgIfGXhieJsTytcWsi4+9CYjIfyeKP8z6065UQ/ELT5ASDc6ZcRsPUxyxFf/RjUl2RP8Q9OjIyLXTbiX6M8kSj9Ef86AOikRZI2RwGRgQQe4rnvh9I3/CK2lnKQZtOZ9Pkx6wsYwfxVVP410dc14bPk+KfFVsoxGZ4LkD0Lwqp/WPP40AdLRRRQAUUUUAFFFFABRRRQAUUUUAFec/GPwZq3jO1sLXTU0eS2jWYTC+SPzFZlARo3eCYDHzZAVWPGHGK9Gqnq+pWmj6Zc6hqMywWdshklkIJwB7Dkn0A5J4FAHldr8K74CO9u20yXXYpdIeK+LOZI1tlhW4CuU3DeEccfeBG7Haz4F+HmpaD4u03U7u20RfslteQXGoW8jtd6i00kbJJNmMcgI3BdsbuOOBheIfG/iTXdk+nXEui6I0ka/6IYZLmZJVYxEMdw+YqwIQF0K42v1C+Do/GS+I4bS28Q3xuGhE88OrBpVjVYlBBjkSN/nlJ+ePKgD+EkKQDqfEXw7m1zxU97fJp11pUmsW1/JbXGX3xR2UsBUqVKk73U4PBAOT2q5beB7j/AIVBqPg+5e0M09teW8LAF4ohI8hhwCAQEDJwBxt46Cun8Naz/a9pKLiA2mo2snkXlqW3GGQAHg/xKQQyt3DDgHIGvQB4uvwlmnh1Gd9J8N6dfm0sYdOWzZmSzlhmleSRG8pChcOpyq5zuB45N/w78N9U034nS+Iru5iuYWvLm5W4W4jSYxyhtsLp9l3uq7gADPtG0EKMBaz/ANofxf4h8MX/AIah8OarJpyXcd285SCGQuUMAX/WI2MeY3THWvP/AAx4w+JXiN9RWx8YPGbGzkvZPOtLUZRMZC4gPPPfA960jTclc1jSlKPMtj2HxZ4J1fUPFN9renSWDP5ul3FtBPK8YdrWSdnV2CNtBEwwQG5ByPXAj+E99qVxeXHiSDQ7pp4NVKRbnlSK4up45ImXcg+6FYbsZBxgHtrfs+eJdZ8T+FdWufEOoPf3NvqbW8crRRxkR+RC4GI1UdXbnGea9RqGrOxm1Z2Z4BN4U1O28d6VBPpUOragupWF0+svbXJktoYoUDxLM0PlbNyM3EoJL4KE5Ndz8KPBN/4Ru9TNzbaVbWlwsYjW3dbi4ZgWJMk4t4WccjG8O2dxL84r0aikIKKKKACiiigAooooAKKKKACiiigAooooA8S+Nmpa9Fq2urp881tZ6b4bmvY5LfU5rZ0lYuvmeWi4kYbQAGbAyWHOBXap42nuvFMvhiDTxDrC3EyOWl3LFarErpd42jcGaSNNnHzFhu+XNdXe6Tp18ZzfWFpcmeH7NN50Kv5kWSfLbI5XJJ2njmqC6XY6d4nudaf7XNqGprFZBvKMiwpGHYKCq/IhJdiznG4gZ+6KAOa8La/faX4gs/CGo20uyCPyIdS1C4nafUGSMM0iZiMbZ+YkeduAB+XGKj8XfEDU9E1fVLax0C2vbXTmso5ppNQMLs91II4wqeUwIDEZJYcdM9K7G38O6JbazLq9to+mxatLkSXsdqizvnrmQDcc4Hep7jSdOuWna4sLSVp2jaUvCrGQxndGWyOSp5XPQ8igDzbUPifNp2+fVdNlt5NPOopd21pdLNE7W8cbghmiViCJBg/JjnIYVWs/GuvWPi/V7e/sLWXUb240+zs7FNVd7WFnhnkLNKYhtysZyFQknaBnrXoWjQ+Hte0231jTbKxuLW/ja4jnNqFMqyqAzEMoPzKFBzyQAD0rD8T+EvCNr4fXS/sWn6LaahdwwD7Hpls4llLHy1KPC6Hknkrxk8igDI0/4rGfS7y7utIhge20q/1JlS+3o7Wty8BjVzGMhigIbHG4DBq14B8X6nqFz4qu/ETabaaJZX4jgnkvArQK0Fu6xkGNV2/vCd5fO5tuCADW3pnw98MWWgadpE+j2Oo21gJPJa/topmUyMWkIyuF3MxJCgDtgDiqHiiPwVp8utXV9pNq+o6Xp0erXYt7UJM9vEzPEN42hwGt+ELYyi5AGKANLx74pk8MWlm1rbQXt7dSlIrV3nDyBVLMUWGCZ2IwM/KABySO/G2nxdub7TxqVj4djfTobCxv7t5L/ZJGtzI6bUQRkOVKE8soI9K9G1DStI8SWFt/a+l2WoW/E0cd7bpKEJHBAYEA4PUUQ+HdEgtntoNH02O3eOOF4ktUCMkZJRCAMFVLMQOgycdaAPPpfF+paz4/8LRWsK2ejDWr+wdlvm865aC2uFYSQBAAm9Awy5PCnaMivVayY/DWhRa0dYj0XTE1ZmLm9W0jE5YqVJ8zG7O0kdehIrQjuY5Lya2VZhJEqOxaFwhDZxtcjax+U5AJI4zjIyATUUUUAFUtZ0qy1mx+x6lD51t5sU2zcy/PHIsiHIIPDIp98c8VdooA891S58GQateWU2n6vc3dnqJvp/semX9ykd3JbgZLxIy5MUo+XOBuBwDWfa/8IRZy20llpXi61+z28VoFt9L1iJJIol2RrIqxgS4XjLhjiuo8G/8AIx+O/wDsNR/+m6zrqqAPLr4+B73TdMsJtG8VJbabbfYrbyNH1eF1g2qpiLpGGdCFXKsSDgZzViO88FRMzRaH4ij3XMF5hPD+pgCWBEjiIAhwAqxoMDjjkGvSaKAPIZdN+HkiIn9heK0jWOOFo4tK1mNJEjYugkVUAk2sxI3A4zWu1/4Na1W3bRfEbQrfSakEOgaoR9okZ2d/9TzkyP8AL93np0qfxf8AFLR9B1ifRrQf2hrFtsa5tlfyhEjYP3mGGchl2ouSSwHHJG9qFtLNdyR2+p6j5hOW2uqxw55xwvJ9vzobsBwMFn8ObRGtl0jxX89uluiy6brLtFFG4dFiLITGFYArs27T0xXTadpeka9o2jXemalfHQbG+kvJE1FriSaSaFmQK73LeZGI5EYlSOqDGBnO9pWn/YImV7q4vJXOWmuCpc+2QBx6CsbwDY2mpeDb601G2hurSXWNVEkMyB0cDUbg4Kng8gVEZczKcbBP4uutdka08B28d/yVk1efP2GDHXaw5nb/AGU49WWtbw14Zt9FluL2aeXUNZugBdahc48yQDoqgcJGOyLgD3OSd2NEijWONVRFAVVUYAA6ACnVZJzfjXdENCul+7b6rBu9hJuh/nKKp+DT/a3iLxF4hODC8w0uzbrmG3LB2H1maYcdQi1Q+OV3LF8Pb2ysFWTVNQZLeziOSS4YOz4H9xEdz/u/hXU+E7Oy0/wxpNrpefsMVrGsJbksu0YYnuT1J7k0AUZGN18Q4EUZTT9MdnOejTyKFH5QP+dJdYtviJYSO2FvNOmhX/fjkRsfiHY/8BNHhTZPrPii9UHL6gIAT3WKGNcfTdv/ADNL41Vo/wCw71BhrXVIMsOyykwn8P3tAHSVzfhtRL4l8VXKkFftUNuMf7FvGT+shH4V0lc18PsS+Hjf7SDqN1Pe891eRin/AI5soA6WiiigAooooAKKKKACiiigAooqpqup2Ok2hutTuobW3BxvlcKCewHqfYc0AW680+OeoNb6X4esld1F7qsYfZL5ZKIrvgNkYJZUwRyDggHGK2LH4meF795RZXd5cRx4DTR6dctHk9MP5eD07Vz/AMULu11/RNL1LQ7yC8is7+OO6VLgRhYpflKyMQTGCdoJwCASQR1oAd8IdFt3mudXlP2mRNnlSyYLCSaJZZHJwMttkjj3YBxGeBuIrf8AilplvdaBDqcqS+bo9wl6skEjRyJGDiba6kEfuy568kDOayvB0r+AbeTSPFN1LK07/ao9SKvJHMzKvmqzclSr5xu42svPBA19S+IPg9Ld47nVra5hlYW7JFG84ZnO0IQqnk5xg9c0AZkUej+DPHELy6qqHVbOU3k1/drvlkiaIRMxYjoruox2xXoEMsc0SSwuskTgMrochgehB7ivFb3w1oH/AAi+oeIvh/qyw29jFdK0X2dJ/LkK4dSXHmIRgHaxOOwFdJ8NNKOk+IL+20bU5LzQLe3WCULFHHbi6BA/dBBjcFB8wjjJX+INQBwX7Vf/ACGPB/8A1wv/AP0K1pun+NdAg0gxQ6x9lsj4cewGliKb5bw9XOF2Hd/ezn1xXueu+HND8QeR/b2jabqfkbvK+22qTeXuxu27gcZwM464FZX/AArjwP8A9Cb4b/8ABXB/8TWkaiSs0bRqpR5Wjgv2WP8AkTdf/wCw0/8A6S21ez1n6JomlaDava6Hpljpts7mRorOBIUZyACxVQBnAAz7CtCok7tszk+ZthRRRSJCiiigAooooAKKKKACiiigAooooAKKKKAPMvid8N38Y3+rXYi02SeTRfsNhJdZLW9z5jOJQQp24yPmHzdePWvdfDG4g1Vz4few0rTP7Vjv4YrfchhAsJbdmVQuN5d1bryASTnitX4g+Pr7wtfX8VnokGoW+n6X/at1LJfGBhGHZCqKI23N8ueSB7ju22+IN7Hr1vo2r6HDa3r6pFpshgvjNGgktXuFcMY1JPyFSuBzyCaAPNPCnge/1tL6ytdCtNHhSz0yCW6FvdWovJIbxZpJGM0MchkZEPOGwSuX546nUPhbqM3xBs9TtLXw5a6NbXkcipbQRQu1sI9jwuq2+9ydzdZthGBs4zWta/FC6uhpNwmhxQ6TeyNG+oz3UvkIwungCh44HXcdisPMMakyKoY8kVdU8XaxrvhvRdXtrSLTdKu9b0+OCWHUHa4ljN8kbJLGI1VAy7gV3t1wR1oA5d/gxrH/AAjmhaaltoMa6dFLBPDBMiJeMyoBdsZLOULNhCD8hYDGJOoPonjTwZLrvgzQ9NNtYaldaZPazmLVZN8c/lYDq8nlnll3At5fOfujOKxdI+K2paxBd3Gm+DdSuLYQSTWrolwBIUkC7HZrcICQSwEbS/dI64B7jwVrz+ItF+2zRW8EyyvDJDDJK/lsp5VvNiidW9VKDFAHEaP8PdSs/GNrqbW2i26RahJetfwSObswtEUWyC+Wo8pSQAd2MIPkB5qTx/8ADu513xJrmpWFhocr6noEmlrc3ZKT2k5SdRKmImyGEqIx3KQq/wAXAr1GigDx+++FdxDcz/2TZ6G2lNNY3DaPMWitrx4opkl80LGw5MkbhtrbjGNw6GpPD/w1urOUtfnRZ7mHTZYrOBw08NnO1xLLHtRxzHGJFVWPzYU4AzXrleefF/wEni7SvtVgiprVopMTdPOXr5ZP8j2P1NZ1ZSjFyirs68FRo168adefJF9bXt66rQ4jRPhH4hs4tR+0poD29xPY3D6UsipaXRhMvmJIIrWNVVt6Efu3OUAbcBW7qHw31K6muZ4NO8PWlpINO/4kkcz/AGOVbd7kvC5EI+Q+ejD92fmXlcdfAYdT1awneNb3ULZo2KyKkroynOCCM8HtX0l8PfiF4Un0u2sV1e6iulADf2vMTI7dz5jEqeegBH0FcmHx8az5WrfM+hzfhOvl1NVacnUT7Renm9Wdx4ds/sGiWlr/AGdYaZ5akfY7Bt0EXJ4Q7E47/dHJrRpsbpKivE6ujDIZTkEexp1d58nsFFFFAHK+Df8AkY/Hf/Yaj/8ATdZ101wJTbyi3ZVmKnYWGQGxwT7ZrmfBv/Ix+O/+w1H/AOm6zrqqAPl7xtpvxBsPtJ1L+1pk35+3i5JiVepdzGMRxjk9AQMDGea86sPE9/fWU6adf31zqU+37MBdsFjO5RudmbYqECRQDk7tg+v21qstjHYyJqksEdrMpifznCqwIOV59RmvkKTw9Avjyyg8Kos0t/qDvAvniVI03sVkbC7VwFDY5PHagC74c8HXPjG5j1DR7G10HStMl3ajqGryea8rAh5AykkPs25Jkbv0QfLX014a0W38PaNDptnLNLBEWKtMQW+Yk44AAHPAAwK5jxdotnpXw1HhuyT9xeywaZjndL586pK5PXJV5HJznrWt8Op5X8K29nduXvNMkk0yZmOSxgcxq592QI//AAKsZO6uaxVnY6WsH4Yf8izdf9hjVv8A04XFb1YPww/5Fm6/7DGrf+nC4op7hUOspHZUVmdgqqMkk4AFLXC+IZn8ZazN4YsGYaNasP7bukJAfjIs0I/iYEGQjoh29X42MiTwoh8Ua5P4ruV3acI2tNGjYcGAn95cYPeUgY/2FX+8a1Ph6XHg/T7eX/WWYeyb/ti7Rf8AsldBFGkMaRxIqRoAqqowFA6ADsK5zwTgS+IkjOYk1ebZ7EqjN/4+z0AO8BbX0S4nUf6/UL2U/jcyAfoBSfEcH/hCtTlXO6BUuBj1jdXH/oNJ4APlaNdWTZ82yv7qB8+8rOp/FHQ/jTviI+PBOrxAbpLmH7JGo7ySkRoP++nFAFzxhfNpvhTWL2M4lgtJXj/39p2/rirWh2I0zRdPsFOVtbeOAf8AAVC/0rJ8fL5uhQwN/qp7+zhk/wBxrmMEfj0/GujoAKKKKACiiigAooooAKKKKAM/XtVg0XS5r25DuEwqRRjLzSMdqRoO7MxAA9TXz/4w8UNqHiSPTYof+Eg8SMds9nakukG5WK20XRfKBUedJuUt93O3Kr3PxTs7jxP4hGjp4gi0Oy0uxbULkkkTSJIskZlTBBAjVW5HeTkjHOz8KPCdtounHVGglW8vY0WM3ODNHbqAI1bAADEAMwAABIUDCCgDnPEvw917VrQX2nmx0i6V1l+wWkjligJZo1mJ2o7bvvKmAVU9s1wvhLUrzT3szfWk9xGiiIg2xCfZlKR3ULeZjdAm7GwKwV9jAjcwH03XzL4qv54PH2t2WjypL9r1IWLQ3Mso8tJ3iEzQIcRt+8XnaxZSWJU9gD0/XfhFpt+t0NP1K9sTcKqEsEuDGigAJG0gLIpUBSA2CoA7DHM+OvAGpaHoeoa0vi+5KxXiai9vLaqYGnLgea+DvbbkEDdj5FGDivca5L4s20118OtcS3UNIkImwXZBhGVz8y8rwp5HI6jmgDnvhppuiWGpyaV4fuob7TodHt0umDB/Okd5HDSD+8VcnB7MO2K9JtbaC0t47e0hjggjG1I4lCqo9ABwBXlfwhu5INZnj1R1GpanamTY7q0iCCeZFVjgMw8tkKswyyqeSBXrNABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFK90nTr4zm+sLS5M8P2abzoVfzIsk+W2RyuSTtPHNQ6l4f0bVIrmPU9I068juWV50uLZJBKyjClgQdxA4BPStOigDCTwd4ZS4s7hPDmjLPZ/8AHtILGINB8xf5DtyvzMzcY5JPenxeFPDsV9NexaDpKXk0izSTrZxiR3Vg6szYySGAYE8ggHrW1RQBgP4M8LyT3k8nhvRWmvAVuZGsIi04LBiHO3LAkA855APatTS9NsdIsks9Ksraxs487ILaJYo1ycnCqABVuigAooooAKKKKAOYHgzTV8ZTeIFij8y5tHtriBkBSUlkIf64Ug+uR+OB4i+D3hbVy8ltby6ZOed1o2Ez/uHIx9MV6NRWMsPTkrOJ6NHNsbRkp06rTSS36LZPvbzPBX+EHivQ3Z/C3iYBeu0SSWzH8FyD+Jpdvxm0z5QTdxjvm3kz+fzV7zRWP1KC+CTj6M9T/WjE1P8AeaVOr5ygr/hY8HPiX4ur10UnPH/HoD/WtXwvrPxQuvEWnrq+mGPTPOUXJ8mNPkPBOSc8deK9joprCyTv7RmdTPaU4OKwlNXVr2enpqcr4N/5GPx3/wBhqP8A9N1nXVVwtpc6xoPiTxUy+FdX1K21DUI7uC4s5rMIUFnbREESzowIaJ/4fSp9Q8R69NatHbeBtdDP8ree+nupXuCovBn866z542tU8QaVZoRLf2RnDbVjadQd3vzx7mud8IeCrLQr19Se5kv7+SJYUnkVQIogPlRAOAMYGe+Pc5r6fqOr224v4B1nIARPIOnRqF68L9qOOffsK0B4g1ngf8IL4iA6f6/T/wD5KrOd3oi42WpHr7C/8b+G9MXlbUTatOPQInkxg/VpmYf9cval0ECz8c+KbMAhLlLTVF9Czo0DY/8AAZSf973rF8P6rfXGpar4ksvD2q6vb6m4t7OW0ktlVbWAsqf66ZD88jTSAgYKutStqmoL42ivP+Eb1VbqTSZVNg0lr57hJ4sMGE3l4/ev1fPHT1XK9h3W53tYPww/5Fm6/wCwxq3/AKcLioP+Eh1n/oRfEf8A3/0//wCSqPCek6wPAtzaO02hand319cKXWOaS3Sa8llXhWZC/luO7AE85xgkE1uE2mO8Sa5e6jqp8N+FJUGoDH9oX4wy6bEf0MzD7iHp95hjg9B4f0ay0DSLfTdMiMdtCONx3M7E5Z2Y8szEkljySSab4d0Ow8PaYljpcPlwhjI7MxZ5ZG5aR2PLOTyWPJrTrUzIru4htLWa5uZFit4UaSR2OAqgZJPsAKw/AcUy+HY7m5jaKW/mmvzEwwYxNI0iqfcBgD75qbxlpM+taFJaWrReb5sUvlT5EU4RwxikwCdrYweD16EcGvHr+qBALjwpqwm7iKa2dM+zGUHH1A+lADfAwzDrcp5MurXRz3O19nP/AHxj6AU74gN5fhzz+hgvLSbd/d23MZJ/LNSeELO8t11W6vrVbJr+8N0lqJBIYh5aIdzDjcxQsQMgbuppPHFvc3OixC1tnuliu7eee3jxvliSVXYLkgE/KDjPIBHegBfHlpPeeEtRjtEMlxGqzxoOrtGwkCj/AGjtwD6kVsafdwahYW15aOJLe4jWWNx/ErAEH8jWG3i61EeV0zXmk/55jSpwc+mSoX9cUvgexurHS7lbm3azhmupJ7ayZw7W0TYIQkcfe3NgEhd20EhRQB0VFFFABRRRQAUUUUAFFFFAHBfFXwYfE9vp91bQCa7s5NskasI5ZrdiDJHG5xtc7VwSQMbgeGJpmi69qnmvb2N3HrEkQzJp2oqLLUYhx7bJB77VB/vGvQKz9Y0bTdZiSPVLKC5CHKGRfmjPqrdVPuCKAMafxjaJZ36vb3Vnqtvay3CWV5FseQIpJKEZVx67CcV4n4MuYbrXvDB1u4iMv2+NUkjZ0guZkXPmLHMNxfzHyZo8IwlI5I491svCtnaalb3f2rUrgWxZreG6u3mjhYqVLDcSSdrMOScBjjrXjXxU8PWnhfXWMUd1FpGrqS72s4jkhVFx9lV3BSGBndG/hwzcEcUAfQtNdFkRkdQyMMFSMgj0Nch8K9VvtU8ME6nd299Pby+ULqAsVmQxpIpywBJAcLkgE7ckZrsaAPmjUfC+o+AdalSJr3y7eTzdHuYXUIYt0jtGF4HmIpJLSMwKtJhcMxHs/wAN/G1r4x0hJA0aagiBpY0ztdTkCSPPJQkH6EEHsT0mr6Zaavp8tlqEIlt5MZHQqQchlI5DA4II5BGRXgL6HrWi+KJRoF41z4h0bdKUZ1eTUVLL/rtzgnzInjVWAwgt5BzhMAH0VRVHQtSj1jR7PUIFZEuIxJsbqpPVT7g5H4VeoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMrXfEeh+H/I/t7WdN0zz93lfbbpIfM243bdxGcZGcdMisr/hY/gf/AKHLw3/4NIP/AIqjUv8Akqfh7/sC6n/6PsK5PUfjdo1lqd/Zf2F4gnazuprR5YkttjPFIyMV3TA4ypxkCgzqVadJc1SSS83Y6z/hY/gf/ocvDf8A4NIP/iqP+Fj+B/8AocvDf/g0g/8Aiq4e5+Puh21vLPP4d8SLFEpd22WpwAMk8T17FQKlWp1VenJP0dzlf+Fj+B/+hy8N/wDg0g/+Ko/4WP4H/wChy8N/+DSD/wCKrqqKDU5X/hY/gf8A6HLw3/4NIP8A4qj/AIWP4H/6HLw3/wCDSD/4quqooA5X/hY/gf8A6HLw3/4NIP8A4qj/AIWP4H/6HLw3/wCDSD/4quqooA5X/hY/gf8A6HLw3/4NIP8A4qj/AIWP4H/6HLw3/wCDSD/4quqooA5X/hY/gf8A6HLw3/4NIP8A4qj/AIWP4H/6HLw3/wCDSD/4quqooAxdE8WeHNeu3tdD1/SNSuUQyNFZ3sczhAQCxVWJxkgZ9xW1XK6l/wAlT8Pf9gXU/wD0fYV1VABXBSar4q1HxH4httK1DRLOy028jtI1udMluJHzbQTFiy3CDrMRjb0Heu9rhPDv/I0+Of8AsLxf+m+zrOrJxjdGlOKlKzJP+K4/6D3hv/wRz/8AyZR/xW//AEHfDf8A4I5//kyt2iuX20+50eyh2OV1XU/FWk2puNS8TeF7eHOAX0OfLH0AF3kn2FY41/WPEtrPo48R6R/ppEEjw6XcWMyRHBkMZklkDOVO0DAwXDZ4wYGiPiTxjdLK+Iop5LUBlBKRqCCUzwMlTz6lTzgY3dS0KGzuYEsDDb214jWkwnQyBTjcjKxYFSCp74zt781aqyW7IdOPRFq0tfF1jaw2mn6v4ags4EEUEQ0OciONRhV/4++wAFQnT/FDa5/aZ1PRRepYrapOdPlMZLSs8n7nz8j5Vh58w5IOR0rT8PahHeafEjXkFzdxApMY3UklWKlyB0yRn8a1an2011K9lB9DC/4rj/oO+G//AARz/wDyZWr4C1W+1nw4LrVTbNex3l5aSNbRNHG/k3MsIYKzMRkRg43HkmrFZnwt/wCRWuP+wxqv/pwuK1ozlJu5nVgorQ62vnb48fDmbTnuPE/hoSR20h339vESNjf89QB/Ce47demcfRNNdFdGR1DIwwVIyCPSvZyzMquXV1Wp6rqujX9bHFXoRrw5WfE3hLxLJZ65ay67qOtvpW79+lpdujuB2zuHHTPIOO4r638JeM/D3ieBBoepQzSBebdjtlUY7qefx5HvWfoXw50HSrHVtPa0hutLvrr7SlrPHuEGVAIUnnqCQeCPwzXDeKfgHp88huvCuoy6bcKdywzEyRg9sN95fr81fQ5hj8szepacpU2tna8fmt79P1OKjRr4ZaJS/M9tor5zXUfi34AG29t5Na06P+NlN0u0dTvX94o/3vyrf0D9oLR7jEevaXd2EvQvCRMn1PRh9MGvLqcO4rl58M1Vj3i7/hudEcbTvad4vzPbaK5bRviB4T1kL9g16wZm6JLJ5Tn/AIC+D+ldQrK6hkIZTyCDkGvGq0KtF8tWLi/NWOmM4yV4u4tFFFZFBRRRQAUUVHPNFbxGS4kSKMdWdgoH4mhK+iAkorjNb+J/g7R9wuddtZZB/Bakzkn0+TIH4kV5zrf7QCzSi28KaFPczucI913PtGmSf++hXq4bJMditadJ27vRfe7HPUxVKnvI95JwOa858bfF7w14Z3wxT/2pfjjyLRgVU/7T9B+GT7V5t/wjvxT+IuDrly+k6XJ1ilPkLj08pfmb/gf516B4L+C/hrw8Y576M6vfLz5lyo8tT/sx9P8AvrdXcsBl+B1xlX2kv5YfrL+mZe2rVdKUbLu/8j0PRtSttY0q01Gxcva3USzRkjB2sM8jsa8y+Of2prvQltZLiFPIvHlljuUt41RREW86VgdkeMnKgnIXtkj1hQFUBQABwAK5X4leDoPGvh37A8iwXcMq3FrOybxHKucZHccnI/wr52TTb5djsV7amP8AA25tX8DxwxbYruOeV7i3LSFotzkp/rAHKlNhBYZIrsL/AMQaNp7Yv9W0+2PTE1yiH9TXz3dfDfxJa3lvDPpE11tvZriSeO584SKViVSZWIds7HJRgoBYYI7WrD4Qa0dbhvrfTLazitrk3MCzTpGdwuvOQtHGHQsFJQ8ADjA45Qz1TxP8R9GstCuLrQ7611S44jia3fzYI3ZgitLIuVRQxGckeg5ryzwr4Z1DxBqLRXlt9p1m4LTalqmqQI7wjIVTb4PybXiZFHKuYi4wmA0h+EXiSd44pYrARRGPymknyvHnF942nfuMoyCCCFwRzXsPw+8Jx+EdCS0a4a8vXCm4uSu3ewGAFGTtUdhnuT1JoA3tNsoNN0+2srRNlvbxrFGuckKBgZPc+9WaKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDldS/wCSp+Hv+wLqf/o+wr5pvwG8Wa8p6HXL8f8Ak3LX0tqX/JU/D3/YF1P/ANH2Fed6l8EtRudZ1O9tfFVrBHd3s94sb6UztH5srSbdwnGcFsZwOlB5Wb4Spi6KhS3Tv+DPNfjXp8Wlan4msoDmOK2OD5aR9YAfuoqqOvYCvfvjbeR6f8NdWuX1GXTpYwhhnhvHtX37hgB1ZSc88Z5rgtZ+Bmt6zHdDUfG0E8lzGY5JX0l2cgrt6m5POPX0r3egeWYSph3Uc1bmd110PKbrxprlv4gu7fTJtJk0O01bT9Ji8yKWaaVbmCFhL53m4ODLn7p3AdQea4DRvGGt+CfC2kNbW+gi41mG41CXUJ7eO3W5lD4EUkk13GGfJJL7mIUgCMgE19K0UHqHiniPxzrOq6N4wtLfWNG0XUbawuRbaSFaTUZcWnmCWGRZl6kkqyIwAXOTUtt461O2ee/tr7S9dtrLR7G+u7mz87y3gNzcJOUQTOgdETJbkkqQeNoX2aigDwzxH8WPEunRadNHY6VawahbS39o960cKSxeaRDEXmuYQrmMK7EbyN4+TjJ7r4m+LL7wz4e0/ULOXSrRp5gs39oSxZVSjNiNXmhSRsgceYOMkbsYruaKAPB0+IeoaZf+I7+88R2CpLBYXFnZ3GnOHxLFGPMWKS6QRx7mIYswUE5ZxjktfjBq91o8E01z4f0o5v8AN/eRGSC5aAp5cUSx3BXzHD54lcfKdu7t7xWT4h8P2HiG3SDUzemFQwMdvfT2yuGGCHETrvGOzZHX1NAHlNn8VtfufFej6a1jpkMVyLDdHPLDC9ws8UbySQmS5VztLkBVikyUxuBOB7ZUdvDFbW8UFvGscMShERRgKoGAAPTFSUAcrqX/ACVPw9/2BdT/APR9hXVVyupf8lT8Pf8AYF1P/wBH2FdVQAVwnh7/AJGnxz/2GIv/AE32dd3XBaE6xeJfHjucIurRsT14Gn2dY1/hNaPxGhrmsQaTBukVpZSpZYkxkgYGST0GSBn1IAyTiuVuvHc+nXPlarY2sLscpFHcmRtvHJIXH8Q6evqcVm2uj6h4v1cS6zOkWlSFbswWc5YyxkMIkkccEY5AXp8x6tk9b4n0nT08I3cC21vDDawtLCoTCxsgyMbeR0wcckE1zWS0ZvdvVHMRTppl5ca/Al5MZZnKLt3wiNgGdWZSdrAjIPII27QdxpupePLfU0j09tBS8Ny4jFpPIQZSQpXGUxyW9cjax6DNa3wrnWfSL2SKJokW52HLbgzbFJZTk8cgde3POaveP7m7tLLTrizEpkjvFGUPI3I6j8Mn3+ho62DW1ynp/h9H1a0vbJbiO0HlzxyyXLExjLM0QXPO4sc5yME9TiuzrN8NFD4f08RuJAsKoWBBywGG6cdQelaVS3ctKwVmfC3/AJFa4/7DGq/+nC4rTrM+Fv8AyK1x/wBhjVf/AE4XFbYfdmNfZHW0UUV1nMFFFFABWFr3hDw/4g3HWNHs7pyMGRowJP8AvsYYfnW7RWlOrOlLmpyafloKUVJWaueQaz8AvC94GbTri/09z0VZBKg/Bhn/AMermm+BniXSXLeGvFixnIIJMtsfzQtX0JRXr0uI8xprldTmXaST/PU5pYKjLXlt6Hz0PDXxo0sYtNYa8x0/0tJM/wDf0U77b8coCUktjK3Xd5dof1XivoOitf8AWCUv4mHpS/7c/wCCT9TS2nJfM+fP+Ei+NMg8tdIKseN/2WMfqTij7V8c7r5Y4PJx1Oy0XP8A31/SvoOij+3YL4cLS/8AAb/qH1R9akvvPns+EfjHquRea+bMHr/p3l/+igadD8BNW1GUS+IvFPmOOuxHnJ/4E7DH5V9BUUf6y4yP8FRh/hil+dw+o038V36s8q0T4FeEdPKtere6k45IuJtq59gm39Sa9C0XQdJ0SLy9H02zslI58iJULfUgZP41p0V5eJzHFYr+PUcvnp92xvCjTp/BGwUUUVxmoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHK6l/yVPw9/2BdT/9H2FeJ+IPjd4wsvEetWVnB4fFtZ6hc2kXm2czOUjmdAWImAJIUE4Ar2zUv+Sp+Hv+wLqf/o+wr5w8Oroz/GfV18SGEad/bWo588gRb/tE23eT/DnHt68ZrWlFNu5tRjGTfMuh0Gs/GL4j6T4cttbubDw2LC6SV7Z/skv73y+GGBcEjnjkV9Harqdho9jJe6te2tjZx4Dz3MqxRrk4GWYgDJIH418r/GO/iuPhboFo91pUmoW6X32iHT5ISkWWyvyxfKAR+f1zX0N8UNPv9S8Lxx6VZyX11DqFjdfZ43RGdIrmORwC7KudqnGSKVSKVrIKsUrWRs2PiHRdQsor2w1fTrmzmlFvHPDco8byE4CBgcFs9hzWpXlZ0TxLd+I7nX7LTZtFW8vdPWWxF1GsskUMkhlmmMbFDuWRV2qzEqgzngDjmsviHYQa5qOom80jT2slaZJtY+RHFzGzrFNNdy7CYfNUSYhAOMqvBGZifQtFeGeA7XUvFriW1u/ECeGRrl1knXZJJPs4tIggE6TMXXzg/wBx2AOeetSWmh/EL7Ppw1Aa1Nqa2tkkFzFqyRwWro5883MYkHnErg52yZHGVPNAHtN5d21jB597cQ28O5U8yVwi7mYKoye5YgAdyQKSC7trie5gguIZZrZgk8aOGaJioYBgPukqynB7EHvXh+teEfFmqWuvWs9jrl1bm4guoHutVMUspS8jkMaIl28Q/dq+1tsOCE4z8w17vRvFhv5pPsniOTw8b6Fxp0OshL3yBYxoAJvPH3Zg+4eaCx+bLdSAewVBHd20l3NaR3EL3UKo8sKuC8atnaWXqAdrYJ67T6VyHjnT9TvfBFlb6LHrkF0jQnyYLlWuAoXlJZDcxFuwYrNuJ5ywzngU8L+KrK+1HU00HVJ9TvtItIYxD4glEUMsZmEiyk3SuzbHUrgsA2fnXJcgHulFfPLHxN4a0uCXx1ealBov9qXDLbtrqWVzLG1vH5QEr3jNtVxKSnns3IPIGKfomkfEXULPwtevfa0bd9OsHEschZ4pB80vno93CHLcZLpMcHAwRggHrOpf8lT8Pf8AYF1P/wBH2FdVXK6l/wAlT8Pf9gXU/wD0fYV1VABXC+Hf+Rp8c/8AYYi/9N9nXdVwnh3/AJGnxz/2F4v/AE32dY1/gNaPxFWLQZ9DluZNHMogmlaYpAVypPYxt8jKMcYKtjjnrVLxPf6ne+Hb+GK3cSQBJ3kWF1DRq2WUo6NzxnAD5AOOcV3FA6iuRS7nS4nG/DbULWTTpbBF8m7jkaVomJJYNj5sknOOFOC2CMZro9d0uDWtIudPuWdI51xvQ4ZGByrL7ggEfSuB8BrHF40u4gogRUmMMbdcCQjCk4OMbvlxtGMgmvRri8tbYZubmCEf9NJFX+Zpy0egltqecaZfXngjUjZ6tt/stlDvIm4qnYyrnPBPLDJIz3xmvTEZXRWRgysAQQcgg9xXnnjLWf7S1qysdMQSpayb3mRBIZZDjEKDpg5UkkjooHWu08O2LabolnZybA0SY2pnavJO1c9hnA+lEu4R7GjWZ8Lf+RWuP+wxqv8A6cLitOsz4W/8itcf9hjVf/ThcVrh92Z19kdbRRRXWcwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcL4s1vStB+JPhu61zU7HTbZ9J1KNZby4SFGczWJCgsQM4BOPY1xuoaH8D9Q1G7vrrW9Ca5u5pLiZk8TOgaR2LMdqzgDJJOAAOa9sooTtsNNrY8Kfwr8B3RkfWNEZGGCp8USkEen+vr0v/hY/gf8A6HLw3/4NIP8A4quqoou3uDbe5yv/AAsfwP8A9Dl4b/8ABpB/8VR/wsfwP/0OXhv/AMGkH/xVdVRQI5X/AIWP4H/6HLw3/wCDSD/4qj/hY/gf/ocvDf8A4NIP/iq6qigDlf8AhY/gf/ocvDf/AINIP/iqP+Fj+B/+hy8N/wDg0g/+KrqqKAOV/wCFj+B/+hy8N/8Ag0g/+Ko/4WP4H/6HLw3/AODSD/4quqooA5X/AIWP4H/6HLw3/wCDSD/4qj/hY/gf/ocvDf8A4NIP/iq6qigDgLTxHofiD4p6J/YOs6bqfkaNqPm/YrpJvL3T2O3dtJxnBxnrg139FFABXllt4p8P6J4y8b22ta7pWn3D6rFIsV3eRwuVNhaAMAxBxkEZ9jXqdFROHOrFQlyu559/wsHwZ/0N3h3/AMGUP/xVH/CwfBn/AEN3h3/wZw//ABVeg0Vl9XXc19u+x4H4k/4QfUdQuL3TvHPh22luCWljk1GIruJXLKQ+QSFwfr1GMVVWw8Atcy3Mvjnw0sz5wEu4Coy249X5yf5Cvoaiq9j5k+08jxDwndeAvD9814fHOh3dyVCgvqMChTjBbG/liPfjJwOa67/hYPgz/obvD3/gzh/+Kr0Gik6Ce7Gq1uh59/wsHwZ/0N3h3/wZQ/8AxVXvhHcQ3ng1rm0mjnt5tV1SSOWJgyOpv7ghlI4II5BFdnRVU6Sg7kzqOYUUUVqZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The vector for",
"    <em>",
"     Loa loa",
"    </em>",
"    filariasis are flies from two species of the genus",
"    <em>",
"     Chrysops",
"    </em>",
"    ,",
"    <em>",
"     C. silacea",
"    </em>",
"    and",
"    <em>",
"     C. dimidiata",
"    </em>",
"    . During a blood meal, an infected fly (genus",
"    <em>",
"     Chrysops",
"    </em>",
"    , day-biting flies) introduces third-stage filarial larvae onto the skin of the human host, where they penetrate into the bite wound",
"    <strong>",
"     (1)",
"    </strong>",
"    . The larvae develop into adults that commonly reside in subcutaneous tissue",
"    <strong>",
"     (2)",
"    </strong>",
"    . The female worms measure 40 to 70 mm in length and 0.5 mm in diameter, while the males measure 30 to 34 mm in length and 0.35 to 0.43 mm in diameter. Adults produce microfilariae measuring 250 to 300 &mu;m by 6 to 8 &mu;m, which are sheathed and have diurnal periodicity. Microfilariae have been recovered from spinal fluids, urine, and sputum. During the day, they are found in peripheral blood, but, during the noncirculation phase, they are found in the lungs",
"    <strong>",
"     (3)",
"    </strong>",
"    . The fly ingests microfilariae during a blood meal",
"    <strong>",
"     (4)",
"    </strong>",
"    . After ingestion, the microfilariae lose their sheaths and migrate from the fly's midgut through the hemocoel to the thoracic muscles of the arthropod",
"    <strong>",
"     (5)",
"    </strong>",
"    . There the microfilariae develop into first-stage larvae",
"    <strong>",
"     (6)",
"    </strong>",
"    and subsequently into third-stage infective larvae",
"    <strong>",
"     (7)",
"    </strong>",
"    . The third-stage infective larvae migrate to the fly's proboscis",
"    <strong>",
"     (8)",
"    </strong>",
"    and can infect another human when the fly takes a blood meal",
"    <strong>",
"     (1)",
"    </strong>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites: Filariasis. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/frames/a-f/filariasis/body_Filariasis_l_loa.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/html/frames/a-f/filariasis/body_Filariasis_l_loa.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_56_19335=[""].join("\n");
var outline_f18_56_19335=null;
var title_f18_56_19336="Use of botulinum toxin for treatment of non-neurogenic lower urinary tract conditions";
var content_f18_56_19336=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of botulinum toxin for treatment of non-neurogenic lower urinary tract conditions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/56/19336/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/56/19336/contributors\">",
"     Sangeeta T Mahajan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/56/19336/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/56/19336/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/56/19336/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/56/19336/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/56/19336/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum neurotoxin (BoNT) is a potent neurotoxin that is used for a variety of therapeutic indications (eg, dystonia, achalasia). Many clinicians are familiar with use of BoNT therapy for bladder and urethral dysfunction in patients with neurologic disorders (eg, spinal cord injury, multiple sclerosis). This agent is now gaining popularity for treatment of otherwise healthy patients with overactive bladder syndrome, benign prostatic hyperplasia, painful bladder",
"    <span class=\"nowrap\">",
"     syndrome/interstitial",
"    </span>",
"    cystitis, and urinary retention following anti-incontinence surgery.",
"   </p>",
"   <p>",
"    Use of BoNT for treatment of non-neurogenic lower urinary tract dysfunction is reviewed here. Treatment of neurogenic lower urinary tract dysfunction, other treatments for urge incontinence and urinary retention, and the pharmacology of BoNT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=see_link\">",
"     \"Chronic complications of spinal cord injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36985?source=see_link\">",
"     \"Comorbid problems associated with multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15962?source=see_link\">",
"     \"Management and prognosis of cerebral palsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A brief overview of the pharmacology of BoNT is presented here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;BoNT is produced by Clostridium botulinum, a gram-negative, anaerobic bacterium. BoNT acts by inhibiting calcium-mediated release of acetylcholine vesicles at the pre-synaptic neuromuscular junction in peripheral nerve endings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/1\">",
"     1",
"    </a>",
"    ]. This results in temporary flaccid muscle paralysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of BoNT for lower urinary tract indications has NOT been approved by the United States Food and Drug Association (FDA); therefore, patients should be counseled that insurance may not cover treatment with this expensive medication. Seven serologic forms of BoNT exist, including A, B, C, D, E, F and G2, although only serotypes A and B are commercially available.",
"   </p>",
"   <p>",
"    BoNT-A is the serotype used most commonly for treatment of lower urinary tract dysfunction. Currently, BoNT-A toxin is available within the United States as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    (Botox&reg;) and in Europe as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"     abobotulinumtoxinA",
"    </a>",
"    (Dysport&reg;). The two formulations have different potencies (1 U of onabotulinumtoxinA is equivalent to approximately 3 to 5 U of abobotulinumtoxinA). Attempts to convert dosages between the two drug formulations are not reliable and should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BoNT-B has also been studied for treatment of lower urinary tract dysfunction; it is available as Myobloc&reg;.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dosage and duration of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lethal dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    in humans is unknown; it is estimated that 2800 U would be lethal for a 70 kg person. The lethal dose for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"     abobotulinumtoxinA",
"    </a>",
"    is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/3\">",
"     3",
"    </a>",
"    ]. Most therapeutic doses of onabotulinumtoxinA range from 25 to 300 U and of abobotulinumtoxinA range from 250 to 1000 U. Doses used for lower urinary tract indications are discussed below (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Lower urinary tract indications'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Peak neuromuscular blockade is achieved within 24 to 72 hours after treatment and persists for several weeks to months, depending upon the dose administered and muscle treated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/4\">",
"     4",
"    </a>",
"    ]. A prospective cohort study of repeat BoNT-A injections reported that the median time between injections ranged from 8 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LOWER URINARY TRACT INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower urinary tract dysfunction is a well-known complication of spinal cord injury, cerebrovascular accident, multiple sclerosis, and other neurologic disorders. Use of BoNT to treat these patients is well established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=see_link&amp;anchor=H9#H9\">",
"     \"Chronic complications of spinal cord injury\", section on 'Bladder dysfunction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36985?source=see_link&amp;anchor=H16#H16\">",
"     \"Comorbid problems associated with multiple sclerosis in adults\", section on 'Spasticity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15962?source=see_link&amp;anchor=H5#H5\">",
"     \"Management and prognosis of cerebral palsy\", section on 'Botulinum toxin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Significant lower urinary tract dysfunction also occurs in patients without neurologic disease. The use of BoNT in otherwise healthy patients has provided an additional therapeutic option for the conditions discussed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Overactive bladder syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overactive bladder syndrome (OAB) is a constellation of symptoms, including urinary urgency and frequency, urge incontinence,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nocturia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/6\">",
"     6",
"    </a>",
"    ]. Detrusor overactivity, or involuntary contractions of the detrusor muscle, is the physiologic basis of these symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/6\">",
"     6",
"    </a>",
"    ]. Detrusor overactivity that is not due to neurologic disease is referred to as non-neurogenic or idiopathic.",
"   </p>",
"   <p>",
"    First-line therapy for OAB is anti-cholinergic therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    behavioral therapy (ie, bladder training or pelvic floor exercises). For patients whose symptoms are refractory to first-line therapy, the use of BoNT provides an effective alternative to more invasive and aggressive treatments (eg, sacral nerve stimulation via surgically implanted electrodes or augmentation cystoplasty). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intra-detrusor BoNT-A improves symptoms in patients with non-neurogenic OAB that is refractory to multiple first-line treatments, based upon data from a meta-analysis that included 19 randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/7\">",
"     7",
"    </a>",
"    ]. Use of BoNT-A compared with placebo resulted in a significant decrease in episodes of urinary frequency and incontinence after four to six weeks (frequency: 6.5 fewer episodes; incontinence: 1.6) and after 12 weeks (frequency: 3.4; incontinence: 2.7).",
"   </p>",
"   <p>",
"    In the systematic review of observational studies and one randomized trial, the average efficacy rate for improvement in OAB symptoms was 69 percent (range 36 to 89 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/8\">",
"     8",
"    </a>",
"    ]. In patients with urge incontinence, complete continence was achieved in an average of 58 percent (range 32 to 86 percent). The mean duration of clinical effect from a single treatment was 6 months (range 4 to 10 months). All randomized trials reported significant improvement of OAB symptoms with BoNT-A compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are fewer data regarding the use of BoNT-B to treat OAB; the duration of clinical effect appears to be shorter (six weeks in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Urinary retention rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major limitation to the use of intra-detrusor BoNT-A is the rate of post-treatment urinary retention. In randomized trials, 26 to 43 percent of participants had an elevated postvoid residual (&gt;150 to 200 mL) at four to six weeks after BoNT-A treatment; approximately 25 percent of these patients were symptomatic and required self-catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Symptoms of urinary retention",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevated postvoid residuals resolved in most patients within 9 to 12 weeks. &nbsp;",
"   </p>",
"   <p>",
"    Some data suggest that detrusor injection combined with urethral injection of BoNT-A decreases the rate of urinary retention, with a minimal increase in de novo stress urinary incontinence or spontaneous urinary leakage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/13\">",
"     13",
"    </a>",
"    ]. This approach requires further investigation.",
"   </p>",
"   <p>",
"    Further study is needed to determine the dose and technique of BoNT-A therapy that best reduces the rate of post-treatment self-catheterization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Comparison with other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to BoNT, options for treatment of refractory urge incontinence include sacral nerve stimulation via surgically implanted electrodes and augmentation cystoplasty. Augmentation cystoplasty is associated with high morbidity, which limits its use to individuals with severe incontinence; these are usually patients with neurogenic urge incontinence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no comparative studies of treatment outcomes of BoNT and sacral nerve stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/14\">",
"     14",
"    </a>",
"    ]. A systematic review of randomized trials and case series that evaluated sacral nerve simulation found that 67 to 80 percent of patients achieved continence or a greater than 50 percent improvement in symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/15\">",
"     15",
"    </a>",
"    ]. Common complications included pain at the implant or lead site (25 percent of patients), wound problems (7 percent), and adverse effects on bowel function (6 percent). These efficacy rates are similar to those for BoNT-A (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Efficacy'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Sacral nerve stimulation requires implantation of a device in the patient's buttock and an electrode into the S3 sacral foramina, which is more invasive than the cystoscopy procedure used for BoNT intra-detrusor injection. On the other hand, sacral nerve stimulation does not result in urinary retention.",
"   </p>",
"   <p>",
"    A cost-effectiveness analysis calculated that two years of treatment with BoNT-A is less expensive than sacral nerve stimulation (US$4392 versus $15,743) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prospective comparative data are needed regarding BoNT and sacral nerve stimulation. Given the similar efficacy of the two treatments according to existing studies, the invasive nature of nerve stimulation, and the possible lower cost of BoNT, we suggest BoNT for treatment of patients with OAB refractory to first-line therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Clinical regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;OAB has been treated with 100 to 300 U of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    in most studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]; the optimal dose is under investigation. Given that onabotulinumtoxinA is packaged in 100 U vials, many clinicians inject 100 U at the first treatment, given the lower potential for urinary retention than with higher doses. As noted above, the duration of action varies (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Dosage and duration of action'",
"    </a>",
"    above). Most clinicians repeat dosing every 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Different doses were investigated in a randomized trial in which 75 patients with non-neurogenic or neurogenic detrusor overactivity were assigned to either 100, 150, or 200 U of suburothelial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/17\">",
"     17",
"    </a>",
"    ]. At three-month follow-up, the rate of continence was similar for patients who received 100, 150, or 200 U (35, 36 and 41 percent). The patients who received 100 U had a significantly lower incidence of a large postvoid residual urine volume (&ge;150 mL) than did those who received 150 or 200 U (30.4 percent versus 52 percent and 72 percent). The duration of therapeutic effectiveness was significantly shorter for the patients treated with 100 U compared with those treated with 150 or 200 U (3.5 versus 5.5 and 6.7 months).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients often experience mild pain or discomfort at the injection site or in the suprapubic area for several days after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/8\">",
"     8",
"    </a>",
"    ]. Transient mild hematuria may also occur. Patients should call their clinician if they have any adverse effects from the injection, including urinary retention, severe or persistent hematuria, muscle weakness.",
"   </p>",
"   <p>",
"    Since urinary retention is a common adverse event of detrusor injection of BoNT, we give all patients preoperative instruction in intermittent self-catheterization along with an instruction sheet and necessary supplies. We review the symptoms of urinary retention with patients; these include: inability to voluntarily void",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a sensation that the bladder is persistently full.",
"   </p>",
"   <p>",
"    We see patients with symptoms of urinary retention in the office for evaluation. We advise these patients to self-catheterize after voiding at least three times daily (morning, afternoon, and bedtime) and to keep a diary of voided versus catheterized urine volume. We tell patients to stop self-catheterization when the catheterized volume is consistently &lt;100 cc. Patients with urinary retention often require self-catheterization for two to four weeks after BoNT injection. General principles of urinary catheterization are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/47/40697?source=see_link\">",
"     \"Placement and management of urinary bladder catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We see all patients for a four-week post-treatment follow-up visit. We selectively assess postvoid residual on all patients at this visit, or earlier if they have symptoms of urinary retention.",
"   </p>",
"   <p>",
"    Patients are then followed every three months until their symptoms are severe enough to repeat the BoNT injection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Benign prostatic hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transperineal or transurethral (via cystoscope) injection of BoNT-A into the prostate appears to be effective for reducing symptoms associated with benign prostatic hyperplasia. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=see_link&amp;anchor=H19#H19\">",
"     \"Surgical and other invasive therapies of benign prostatic hyperplasia\", section on 'Botulinum toxin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Interstitial cystitis/bladder pain syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravesical injection of BoNT-A may provide relief of symptoms in patients with interstitial",
"    <span class=\"nowrap\">",
"     cystitis/bladder",
"    </span>",
"    pain syndrome. However, the risk of urinary retention is particularly daunting in this population, since catheterization is likely to be poorly tolerated by patients with a painful bladder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43369?source=see_link\">",
"     \"Management of interstitial cystitis/bladder pain syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Urinary retention after anti-incontinence surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women who undergo surgery for stress urinary incontinence experience transient urinary retention. Persistent (longer than four weeks) voiding dysfunction after surgery occurs in 4 to 22 percent of patients; the rate varies by the type of procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is often assumed that urethral compression is the primary etiology of urinary retention in this setting. However, failure of relaxation of the external urethral sphincter also appears to contribute to retention, based on electromyographic results [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/19\">",
"     19",
"    </a>",
"    ]. Injection of BoNT into the external urethral sphincter has been used to treat sphincter hypertonia in patients with detrusor sphincter dyssynergia and benign prostatic hyperplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=see_link&amp;anchor=H9#H9\">",
"     \"Chronic complications of spinal cord injury\", section on 'Bladder dysfunction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=see_link&amp;anchor=H19#H19\">",
"     \"Surgical and other invasive therapies of benign prostatic hyperplasia\", section on 'Botulinum toxin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based on these findings, some experts have proposed the use of BoNT to treat women with urinary retention following anti-incontinence surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. There has only been one report of successful treatment of a functional urethral obstruction after suburethral sling with injection of 100 U of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    into the external urethral sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/22\">",
"     22",
"    </a>",
"    ]. Currently, use of BoNT for this indication should be considered experimental. Further study of this application is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of BoNT is contraindicated in patients with peripheral motor neuropathy (eg, amyotrophic lateral sclerosis), neuromuscular junction disorders (eg, myasthenia gravis, Lambert-Eaton syndrome), or who are taking medications that interfere with neuromuscular transmission, eg, aminoglycosides, curare-like compounds (neuromuscular blocking agents, eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19990?source=see_link\">",
"     pancuronium",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/21,23\">",
"     21,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PROCEDURE FOR ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration site of BoNT for lower urinary tract applications varies according to the indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of urinary retention as well as systemic absorption resulting in muscle weakness or respiratory collapse should be discussed with all patients planning BoNT injection; this discussion should be documented on the consent form and in the medical record.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pretreatment catheterization training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the risk of urinary retention, all patients in our practice who are receiving intradetrusor BoNT injection for OAB symptoms are instructed in intermittent self-catheterization and given the necessary supplies in case they experience voiding difficulty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;BoNT-A is supplied either as a liquid or as a powder that must be reconstituted in normal saline for injection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/21\">",
"     21",
"    </a>",
"    ]. Precautions should be taken to avoid systemic injection (eg, withdrawing the needle first to confirm an absence of blood before injecting).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Detrusor injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;For OAB, intra-detrusor injection of BoNT-A is the most commonly used route of administration. The toxin is injected via cystoscope into 10 to 20 sites throughout the detrusor muscle (",
"    <a class=\"graphic graphic_figure graphicRef64588 \" href=\"UTD.htm?12/58/13218\">",
"     figure 1",
"    </a>",
"    ). Use of either a rigid or flexible cystoscope has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Techniques to prevent backflow during injection of BoNT include: filling the bladder to near capacity or use of ultrafine needles [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/8,27,28\">",
"     8,27,28",
"    </a>",
"    ]. The general technique for cystoscopy is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29592?source=see_link\">",
"     \"Diagnostic cystourethroscopy for gynecologic conditions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some debate exists regarding whether suburothelial injections are more effective than intra-detrusor injections [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/8\">",
"     8",
"    </a>",
"    ]. Suburothelial administration alters sensory afferent transmission rather than causing motor-end plate paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/29\">",
"     29",
"    </a>",
"    ]. A randomized trial (n = 15) comparing detrusor with suburothelial injection in detrusor overactivity unresponsive to anticholinergic medications found no significant difference between the two injection sites in rates of treatment success (93 versus 80 percent) or elevated postvoid residual (33 versus 47 percent). The difference in outcome reported here appears to be clinically significant; lack of statistical significance is likely due to the small study size [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Prostate injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;For treatment of symptoms associated with benign prostatic hyperplasia, BoNT-A is injected into the prostate gland transperineally or transurethrally (via cystoscope).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     External urethral sphincter injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;For excessive tone of the external urethral sphincter, BoNT-A is injected into the external urethral sphincter. Transurethral, paraurethral, or transperineal with or without electromyographic (EMG) guidance have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/8\">",
"     8",
"    </a>",
"    ]. Transurethral injection may be performed via cystoscopy in both men and women, with multiple injections given circumferentially at the level of the bladder neck.",
"   </p>",
"   <p>",
"    Paraurethral injection is performed by using EMG with injection capability. The urethral sphincter muscle is identified using an EMB signal and then BoNT is injected. Unfortunately, this technique can be technically challenging, requires sophisticated EMG, and the urethral signal can easily be confused with the surrounding perineal musculature.",
"   </p>",
"   <p>",
"    Several authors have commented on the feasibility of transperineal injection facilitated by ultrasound guidance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     How to manage accidental overdose",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients planning to receive BoNT injection should be warned of potential muscle weakness and pulmonary collapse as rare complications of the therapy. The lethal dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    in humans is estimated to be 2800 units for a 70 kg person, as noted above (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Dosage and duration of action'",
"    </a>",
"    above). An antidote is available for overdoses, but is only useful acutely and will not help long-lasting symptoms of muscle paralysis. With the small amounts of BoNT used clinically, it is not generally recommended that physicians administering BoNT have the antitoxin on hand. However, adequate supportive care facilities (ie, intensive care unit) and a local health department that has a supply of antitoxin should be accessible on the rare chance that an overdose occurs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=see_link&amp;anchor=H23#H23\">",
"     \"Botulism\", section on 'Antitoxin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antitoxin should be reserved for patients who demonstrate significant cardiopulmonary compromise thought to be secondary to BoNT toxin overdose. Administration of antitoxin should be performed in an acute care setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Development of resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of patients undergoing repeat treatments with BoNT-A will develop antibody-mediated resistance. One study reported that 4 to 10 percent of patients had detectable antibodies to the toxin after repeated treatment for cervical dystonia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Risk factors for antibody development include: a history of shorter dosing intervals, increasing number of booster doses (multiple doses given at short intervals), and higher overall treatment doses [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The FDA recommends several precautions to prevent antibody development, including use of the minimal effective toxin dose and allowing at least eight weeks between repeat treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS AND COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Systemic absorption and FDA warning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic effects are rarely observed with lower urinary tract injection of BoNT. Weakness has been reported in 2 to 6 percent of patients treated with 1000 U",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"     abobotulinumtoxinA",
"    </a>",
"    , as well as in some patients treated with 750 U abobotulinumtoxinA or 300 U",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/8,21\">",
"     8,21",
"    </a>",
"    ]. The reported duration of such symptoms varies from two weeks to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although BoNT-A injection is generally safe, the FDA issued a warning in 2009 based upon reports of life-threatening systemic toxicity from local BoNT injections [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/35\">",
"     35",
"    </a>",
"    ]. These cases were similar to botulism, and were thought to occur due to spread of BoNT beyond the injection site. Symptoms in adult patients included dysphagia, ptosis, difficulty holding up the head, and leg weakness and numbness. The most severe cases were observed in children with cerebral palsy who received local BoNT injections for limb spasticity and developed difficulty swallowing or breathing. Because of these cases, the FDA recommends that practitioners who use BoNT be alert for potential systemic effects, which may occur as early as one day and as late as several weeks after treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Urinary retention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary retention occurs mainly following intra-detrusor injection of BoNT-A. As noted above, randomized trials have reported an elevated postvoid residual in 26 to 43 percent of patients, 25 percent of whom were symptomatic and required self-catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Symptoms of urinary retention",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevated postvoid residuals resolved in most patients within 9 to 12 weeks. Management of urinary retention is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35912?source=see_link\">",
"     \"Acute urinary retention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported rate of urinary tract infection following intra-detrusor BoNT injection varies from 6 to 35 percent. As expected, patients who are using urinary catheters have higher infection rates [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Other adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients have complained of transient constipation following BoNT treatment, particularly with BoNT-B [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19336/abstract/8\">",
"     8",
"    </a>",
"    ]. Other mild symptoms associated with BoNT injection include flu-like symptoms, dry mouth, and malaise.",
"   </p>",
"   <p>",
"    <strong>",
"     INFORMATION FOR PATIENTS",
"    </strong>",
"    &mdash; UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/36/43586?source=see_link\">",
"       \"Patient information: Treatments for urge incontinence in women (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Botulinum toxin (BoNT), an inhibitor of peripheral cholinergic nerve transmission, is increasingly used to treat both neurogenic and non-neurogenic lower urinary tract dysfunction. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      BoNT-A is the serotype most commonly used as a therapeutic medical agent, although BoNT-B is also now available. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Formulations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lower urinary tract applications of BoNT-A include refractory overactive bladder syndrome (OAB), benign prostatic hyperplasia, and painful bladder",
"      <span class=\"nowrap\">",
"       syndrome/interstitial",
"      </span>",
"      cystitis. Preliminary findings suggest that BoNT-A may also be useful to treat patients with urinary retention following anti-incontinence surgery. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Lower urinary tract indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intra-detrusor BoNT-A treatment is effective in approximately 70 percent of patients with OAB refractory to first-line treatments. However, urinary retention has occurred in 26 to 43 percent of patients, 25 percent of whom were symptomatic and required self-catheterization. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Urinary retention rates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with refractory OAB, we suggest treatment with BoNT-A rather than sacral neuromodulation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Comparison with other therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic effects of lower urinary tract injection of BoNT are rare, but muscle weakness and, rarely, respiratory depression can occur. Clinicians who administer this agent should counsel patients about these risks and monitor for systemic symptoms. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Systemic absorption and FDA warning'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/1\">",
"      Moynihan BG. I. Mesenteric Cysts. Ann Surg 1897; 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/2\">",
"      Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 2003; 44:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/3\">",
"      Binder WJ, Brin MF, Blitzer A, Pogoda JM. Botulinum toxin type A (BOTOX) for treatment of migraine. Dis Mon 2002; 48:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/4\">",
"      Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 1990; 71:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/5\">",
"      Sahai A, Dowson C, Khan MS, et al. Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology 2010; 75:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/6\">",
"      Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/7\">",
"      Duthie JB, Vincent M, Herbison GP, et al. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2011; :CD005493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/8\">",
"      Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 2009; 55:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/9\">",
"      Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008; 180:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/10\">",
"      Flynn MK, Amundsen CL, Perevich M, et al. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol 2009; 181:2608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/11\">",
"      Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007; 177:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/12\">",
"      Ghei M, Maraj BH, Miller R, et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 2005; 174:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/13\">",
"      Schulte-Baukloh H, Weiss C, Stolze T, et al. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol 2005; 48:984.",
"     </a>",
"    </li>",
"    <li>",
"     Hartmann, KE, McPheeters, ML, Biller, DH, et al. Treatment of overactive bladder in women. Evidence Report/Technology Assessment No. 187 (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2007-10065-I). AHRQ Publication No. 09-E017. Rockville, MD: Agency for Healthcare Research and Quality. August 2009. Available at file://www.ahrq.gov/clinic/tp/bladdertp.htm (Accessed March 22, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/15\">",
"      Brazzelli M, Murray A, Fraser C. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol 2006; 175:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/16\">",
"      Siddiqui NY, Amundsen CL, Visco AG, et al. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. J Urol 2009; 182:2799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/17\">",
"      Kuo HC. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology 2006; 68:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/18\">",
"      Natale F, La Penna C, Saltari M, et al. Voiding dysfunction after anti-incontinence surgery. Minerva Ginecol 2009; 61:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/19\">",
"      FitzGerald MP, Brubaker L. The etiology of urinary retention after surgery for genuine stress incontinence. Neurourol Urodyn 2001; 20:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/20\">",
"      Sahai A, Khan M, Fowler CJ, Dasgupta P. Botulinum toxin for the treatment of lower urinary tract symptoms: a review. Neurourol Urodyn 2005; 24:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/21\">",
"      Smith CP, Chancellor MB. Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 2004; 171:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/22\">",
"      Smith C, O'Leary M, Erickson J et al. Botulinum toxin urethral sphincter injection resolves urinary retention after pubovaginal sling Operation. Int J Urogyn 2002; 13:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/23\">",
"      Emmerson J. Botulinum toxin for spasmodic torticollis in a patient with myasthenia gravis. Mov Disord 1994; 9:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/24\">",
"      Schurch B, St&ouml;hrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/25\">",
"      Harper M, Popat RB, Dasgupta R, et al. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2003; 92:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/26\">",
"      Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004; 63:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/27\">",
"      Schulte-Baukloh H, Knispel HH. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2005; 95:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/28\">",
"      Apostolidis A, Dasgupta R, Fowler CJ, Dasgupta P. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2005; 96:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/29\">",
"      Kuo HC. Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology 2006; 67:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/30\">",
"      Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol 2007; 178:1359.",
"     </a>",
"    </li>",
"    <li>",
"     Greene, P, Fahn, S. Development on antibodies to botulinum toxin type A in patients with torticollis treated with injections of botulinum toxin type A. In: Botulinum and tetanus neurotoxins: Neurotransmission and biomedical aspects, DasGupta, B (Ed), Plenum Press, New York 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/32\">",
"      Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994; 9:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/33\">",
"      Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 1997; 6:S146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19336/abstract/34\">",
"      Del Popolo, G. Botulinum-A toxin in the treatment of detrusor hyperreflexia. Neurourol Urodyn 2001; 20: 522.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm175011.htm. (Accessed on March 17, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8089 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-558F5CFEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_56_19336=[""].join("\n");
var outline_f18_56_19336=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Formulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dosage and duration of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LOWER URINARY TRACT INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Overactive bladder syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Urinary retention rates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Comparison with other therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Clinical regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Interstitial cystitis/bladder pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Urinary retention after anti-incontinence surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PROCEDURE FOR ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pretreatment catheterization training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Detrusor injection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Prostate injection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - External urethral sphincter injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      How to manage accidental overdose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Development of resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ADVERSE EFFECTS AND COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Systemic absorption and FDA warning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Urinary retention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Other adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/8089\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/8089|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/58/13218\" title=\"figure 1\">",
"      Detrusor BoNT injection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35912?source=related_link\">",
"      Acute urinary retention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=related_link\">",
"      Botulism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=related_link\">",
"      Chronic complications of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36985?source=related_link\">",
"      Comorbid problems associated with multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29592?source=related_link\">",
"      Diagnostic cystourethroscopy for gynecologic conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15962?source=related_link\">",
"      Management and prognosis of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43369?source=related_link\">",
"      Management of interstitial cystitis/bladder pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/36/43586?source=related_link\">",
"      Patient information: Treatments for urge incontinence in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/47/40697?source=related_link\">",
"      Placement and management of urinary bladder catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=related_link\">",
"      Surgical and other invasive therapies of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_56_19337="Hypoxic-ischemic brain injury: Evaluation and prognosis";
var content_f18_56_19337=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypoxic-ischemic brain injury: Evaluation and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/56/19337/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/56/19337/contributors\">",
"     Gerald L Weinhouse, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/56/19337/contributors\">",
"     G Bryan Young, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/56/19337/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/56/19337/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/56/19337/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/56/19337/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/56/19337/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxic-ischemic brain injury most often results from insults such as cardiac arrest, vascular catastrophe, poisoning (such as carbon monoxide intoxication or drug overdose), or head trauma. While many patients expire without recovering awareness, improved techniques in resuscitation and artificial life support have resulted in greater numbers of patients surviving with variable degrees of brain injury. The evolution of hypothermic treatment for comatose survivors of cardiac arrest has furthered the potential to improve neurologic morbidity and lessen mortality following anoxic brain injury [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While progress has also been made in the early identification of patients at greatest risk of poor neurologic outcome after cardiac arrest, reliable prediction of good outcomes, with intact memory and independence, has lagged. The evaluation and prognosis of patients with non-traumatic hypoxic-ischemic brain injury are reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NOMENCLATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coma is defined as a state of pathologic unconsciousness; patients are unaware of their environment and are unarousable. It is caused by either dysfunction of the reticular activating system above the level of the mid-pons, or dysfunction of both cerebral hemispheres. Physical examination permits localization of the level of central nervous system dysfunction (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical assessment'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coma must be distinguished from the persistent vegetative state, which is also characterized by unawareness, but in which patients have normal sleep-wake cycles and are arousable. Patients in a coma may progress to a vegetative state, but this may not be associated with an improvement in their overall functional outcome. Both coma and persistent vegetative states must be distinguished from brain death, locked-in syndrome (a condition in which the patient is awake and aware but cannot move or communicate due to muscle paralysis), akinetic mutism (a condition resulting from frontal lobe injury in which the patient does not initiate speech or movements), and dementia (",
"    <a class=\"graphic graphic_table graphicRef54393 \" href=\"UTD.htm?2/21/2396\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=see_link&amp;anchor=H17#H17\">",
"     \"Stupor and coma in adults\", section on 'Conditions mistaken for coma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The vegetative and minimally conscious states are clinically defined syndromes. Importantly, prognosis for recovery can vary depending on the underlying etiology and differs between patients who have hypoxic ischemic versus traumatic brain injury [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Brain death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain death (death by brain criteria) is defined as the irreversible cessation of cerebral and brainstem function. There is no respiratory drive, and thus there are no spontaneous breaths regardless of hypercarbia or hypoxemia. There are no responses arising from the brain (including cranial nerve reflexes and motor responses) to stimuli, although spinal reflexes may persist [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/8\">",
"     8",
"    </a>",
"    ]. One is legally dead in the United States when criteria for brain death have been demonstrated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30761?source=see_link\">",
"     \"Diagnosis of brain death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some cases patients who meet brain death criteria may be potential organ donors; issues specific to the management of these individuals are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18566?source=see_link\">",
"     \"Management of the potential deceased donor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Persistent vegetative state",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in a persistent vegetative state (PVS) represent a subgroup of patients who suffer severe anoxic brain injury and progress to a state of wakefulness without awareness. A vegetative state may represent a transition between coma and recovery or between coma and death. The term was first used in 1972 and is defined as [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/4,6,9-12\">",
"     4,6,9-12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No evidence of awareness of self or environment and an inability to interact with others",
"     </li>",
"     <li>",
"      No evidence of sustained, reproducible, purposeful, or voluntary behavioral responses to visual, auditory, tactile, or noxious stimuli",
"     </li>",
"     <li>",
"      No evidence of language comprehension or expression",
"     </li>",
"     <li>",
"      Intermittent wakefulness manifested by the presence of sleep-wake cycles",
"     </li>",
"     <li>",
"      Sufficiently preserved hypothalamic and brainstem autonomic function to permit survival with medical and nursing care",
"     </li>",
"     <li>",
"      Bowel and bladder incontinence",
"     </li>",
"     <li>",
"      Variably preserved cranial nerve reflexes and spinal reflexes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a patient remains comatose, the usual outcome is to recovery, PVS, or death within two weeks. On the basis of available clinical data, PVS is judged to be permanent after three months if induced nontraumatically. For traumatic brain injury, a year in this state is generally required to be considered permanent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/7\">",
"     7",
"    </a>",
"    ]. Most data indicate that after three months in a PVS related to HIE, recovery is rare and is associated with moderate to severe disability at best [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. With the use of ancillary testing it is often possible to arrive at reliable prognostic conclusions in much shorter intervals of time following cardiac arrest (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Ancillary testing'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The distinction between PVS and the minimally conscious state can be difficult. Careful and repeated bedside testing has been reported to reveal evidence of awareness and voluntary responses in patients originally believed to be in a PVS.",
"   </p>",
"   <p>",
"    Functional magnetic resonance (fMRI) studies have revealed that a small proportion of patients with traumatic brain injury who satisfied the above criteria for vegetative state show evidence of awareness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. In these studies, patients were verbally instructed to either imagine a motor activity (playing tennis) or an imagined visual exercise (alternatively looking at rooms in their homes). Patients who responded showed increased blood oxygen level determination (BOLD) signal in the motor or visual centers in the cerebral hemispheres to the appropriate question [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/16\">",
"     16",
"    </a>",
"    ]. These binary responses were also used to generate",
"    <span class=\"nowrap\">",
"     yes/no",
"    </span>",
"    answers to questions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/15\">",
"     15",
"    </a>",
"    ]. Similarly, another study found electrophysiologic responses to an auditory cognitive paradigm in two patients with PVS after traumatic brain injury and acute disseminated encephalomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/18\">",
"     18",
"    </a>",
"    ]. Another small case series found that 3 of 16 patients with PVS were able to repeatedly and reliably generate appropriate EEG responses to two distinct commands, despite being behaviorally unresponsive [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/19\">",
"     19",
"    </a>",
"    ]. While these signs of awareness are more often observed in patients with PVS after TBI, they have been described in nontrauma cases as well, including at least one case of HIE [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. These studies have raised concern about the possibility of awareness in patients who are diagnosed with PVS, and it may be more appropriate to communicate predictions regarding outcome in terms of levels of disability, which can be reliably determined using clinical, radiological, and electrophysiological evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who continue in PVS, life expectancy is approximately two to five years, and most patients die from infection of the lungs or urinary tract, multiorgan system failure, sudden death of unknown cause, respiratory failure, or underlying disease. It is estimated that there are 10,000 to 25,000 adult patients in PVS in the United States, generating an estimated annual cost of care of up to seven billion dollars.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Minimally conscious state",
"    </span>",
"    &nbsp;&mdash;&nbsp;This term has been proposed to describe patients who do not meet criteria for persistent vegetative state [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/22\">",
"     22",
"    </a>",
"    ]. As with PVS, these patients have a severe alteration in consciousness. In contrast, they may intermittently demonstrate limited interaction with the environment by visually tracking, following simple commands, signaling yes or no (not necessarily accurately), or having intelligible verbalization or restricted purposeful behavior. In one series, patients in a minimally conscious state demonstrated sleep-wake cycles with both slow wave and rapid eye movement (REM) sleep, while patients in PVS did not [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Follow-up data on this group of patients are limited; they are believed to have a somewhat less severe injury and less dire prognosis than patients with PVS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. However, data on late recovery of patients in minimally conscious state are largely reported in traumatic, rather than anoxic, brain injury [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. One case series of 39 minimally conscious patients included seven with a primary etiology of hypoxic ischemic encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/13\">",
"     13",
"    </a>",
"    ]. Five years after coma-onset, only one of these seven patients had emerged from this state compared with one-third of the patient group overall. However, in this case series the best recovery from the minimally conscious state was characterized as severe disability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     THERAPEUTIC (INDUCED) HYPOTHERMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The induction of mild to moderate hypothermia (chill therapy) to a target temperature 32 to 34&ordm;C in the initial hours after cardiac arrest improves the neurologic outcome of resuscitated patients. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35274?source=see_link&amp;anchor=H9724176#H9724176\">",
"     \"Post-cardiac arrest management in adults\", section on 'Therapeutic (Induced) hypothermia'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Accumulating reports suggest that induced-hypothermia therapy impacts the prognostic utility of clinical examination findings and ancillary testing (such as SSEP and NSE) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Validated protocols for assessing prognosis in the setting of therapeutic hypothermia are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/32\">",
"     32",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical assessment'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12\">",
"     'Ancillary testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL ASSESSMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Clinical setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough history from the patient's family members or health care providers is essential to the assessment, although in some cases it may be impossible to obtain. The time and pace of onset, history of drug and medication use, prodromal symptoms, and the duration of resuscitation and presumed cerebral hypoxia assist in determining both the etiology and the prognosis of a given patient's condition [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/29\">",
"     29",
"    </a>",
"    ]. However, none of these factors is sufficiently reliable to differentiate those with poor outcomes (no greater than PVS) from those patients who regain awareness.",
"   </p>",
"   <p>",
"    The circumstances of cardiopulmonary resuscitation (CPR) can affect prognosis after a cardiac arrest in terms of both survival and quality of life. In one study of out of hospital cardiac arrest, 44 percent of patients receiving CPR survived initially, 30 percent were alive at 24 hours, 13 percent at one month, and only 6 percent were alive after six months. The duration of CPR significantly correlated with outcome; no patient who required more than 15 minutes of CPR survived more than six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30041?source=see_link\">",
"     \"Outcome of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In other studies, variables such as age &gt;70, stroke or renal failure prior to admission, fever within the first 48 hours, and recent congestive heart failure were associated with a poor prognosis; in contrast, factors such as a witnessed arrest and an initial rhythm of ventricular fibrillation (VF) or tachycardia have correlated with a better prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/29,34,35\">",
"     29,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prognosis based on clinical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some features of the physical and neurological examinations are helpful in determining prognosis (",
"    <a class=\"graphic graphic_table graphicRef69852 \" href=\"UTD.htm?15/47/16123\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef79948 \" href=\"UTD.htm?2/51/2876\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/33,36,37\">",
"     33,36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link\">",
"     \"The detailed neurologic examination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=see_link&amp;anchor=H5#H5\">",
"     \"Stupor and coma in adults\", section on 'Neurologic examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical assessment should include documentation of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence or absence of spontaneous movements",
"     </li>",
"     <li>",
"      Response to voice, light touch, and painful stimuli",
"     </li>",
"     <li>",
"      Pupillary size and response to light",
"     </li>",
"     <li>",
"      Other cranial nerve function, including corneal and oculovestibular reflexes",
"     </li>",
"     <li>",
"      Respiratory pattern (spontaneous, ataxic, etc)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of clinical series and systematic reviews have assessed the utility of specific clinical findings in predicting outcome from anoxic brain injury. A Glasgow Coma Scale (GCS) score (",
"    <a class=\"graphic graphic_table graphicRef81854 \" href=\"UTD.htm?28/62/29676\">",
"     table 4",
"    </a>",
"    ) of &le;4 within the first 48 hours has been associated with poor outcome (death, persistent coma) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In other series, absent corneal or pupillary light reflexes at 24 hours and absent motor responses at 24 or 72 hours have also been associated with poor prognosis (severe neurologic disability or death) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/29,36\">",
"     29,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For making decisions regarding withdrawal of life support, statistically significant associations are inadequate. Two systematic reviews have concluded that two clinical criteria have been found to be 100 percent specific for poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/29,40\">",
"     29,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Absent or extensor motor response on day three",
"     </li>",
"     <li>",
"      Absent pupillary or corneal reflexes on day three",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These assessments may be confounded, and their sensitivity and specificity for prognosis reduced, in the setting of specific treatments and comorbid conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Medications eg, anticholinergics used in resuscitation or sedative, paralytic agents used after arrest",
"     </li>",
"     <li>",
"      Acute metabolic derangements, especially acute renal or liver failure or shock",
"     </li>",
"     <li>",
"      Induced hypothermia may also impact test reliability (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35274?source=see_link&amp;anchor=H9724176#H9724176\">",
"       \"Post-cardiac arrest management in adults\", section on 'Therapeutic (Induced) hypothermia'",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, in a series of 111 patients treated with therapeutic hypothermia, neither of the above clinical criteria were 100 percent specific for poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/30\">",
"     30",
"    </a>",
"    ]. They did find that the presence of both of these criteria was specific for poor outcome. Two additional studies have shown that loss of motor responses better than extension on day three was not 100 percent prognostically reliable in this setting, while absent pupillary and corneal reflexes on day three remained predictive of no recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with one of these confounding variables, ancillary testing may be helpful (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Ancillary testing'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Myoclonic status epilepticus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent bilaterally synchronous myoclonus in the face, limbs, and axial musculature is usually associated with in-hospital death or poor outcome, even in patients with intact brainstem reflexes or some motor response [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. In a postmortem study, myoclonic status epilepticus (MSE) was associated with severe ischemic brain, brainstem, and spinal cord damage, a pattern that is distinct from the neuropathology of status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/47\">",
"     47",
"    </a>",
"    ]. Clinicians should be careful to distinguish myoclonic status epilepticus (bilaterally synchronous twitching of axial structures, often with eye opening and upward deviation of the eyes) from multifocal myoclonus and generalized tonic-clonic seizures, which are not reliably helpful in prognostication.",
"   </p>",
"   <p>",
"    However, increasing evidence suggests that the presence of MSE has insufficient negative prognostic power when considered in isolation. Cases with good recovery have been reported in patients with MSE in whom circulatory arrest was secondary to respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/29,48-50\">",
"     29,48-50",
"    </a>",
"    ]. In some of these, accumulation of sedative agents could have been confounders, and in others, the myoclonus was not clearly generalized and persistent, and may have been sporadic. One systematic review of three series which examined MSE as a prognostic factor found that it did not have sufficient predictive ability for poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/36\">",
"     36",
"    </a>",
"    ], while another concluded that in the setting of primary circulatory arrest, MSE within the first day reliably identifies patients with a poor neurologic outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/29\">",
"     29",
"    </a>",
"    ]. In another case series, the authors report functional recovery in six patients with MSE; all had received hypothermia treatment and had intact brainstem function at 36 hours, reactive background activity on EEG, and intact cortical responses on SSEP [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/51\">",
"     51",
"    </a>",
"    ]. In addition, two of four patients with only EEG evidence of MSE recovered, while 23 of 24 patients with electroclinical MSE did not awaken. Thus, the presence of MSE should be considered in the context of other clinical features in making decisions to withdraw or maintain care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ANCILLARY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several tests have been studied in the period after anoxic injury; these are often helpful at arriving at an earlier prognostic determination than would be possible with clinical testing alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Somatosensory evoked potentials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatosensory evoked potentials (SSEPs) are the averaged electrical responses in the central nervous system to somatosensory stimulation. Bilateral absence of the N20 component of the SSEP with median nerve stimulation at the wrist in the first week (usually between 24 and 72 hours) from the arrest has a pooled likelihood ratio of 12.0 (95% CI of 5.3 to 26.6) and a false positive rate of zero percent for an outcome no better than PVS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/29,40,45,52-57\">",
"     29,40,45,52-57",
"    </a>",
"    ]. Repeated testing should be considered when the N20 responses are present in the first two to three days from the cardiac arrest, as they may later disappear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27863?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical neurophysiology\", section on 'Somatosensory evoked potentials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a multicenter cohort, the interobserver agreement of SSEP interpretation in patients with hypoxic ischemic coma was only moderate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/58\">",
"     58",
"    </a>",
"    ]. Noise level strongly influenced interobserver disagreement. Despite this finding, an absent N20 was still 100 percent predictive of a dismal outcome, ie, no better than persistent coma [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of the N20 responses, however, does not assure a good outcome. About one-half of patients with a preserved N20 response on SSEP testing still die without recovering consciousness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/29\">",
"     29",
"    </a>",
"    ]. Although some studies have suggested that the presence or absence of the long latency response, N70, on SSEP can add to the prognostic ability of SSEP in this group of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/59\">",
"     59",
"    </a>",
"    ], a multicenter cohort study did not confirm this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Induced hypothermia may slow conduction velocities and alter the predictive ability of SSEP findings in patients with anoxic brain injury [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/29,31\">",
"     29,31",
"    </a>",
"    ]. While three studies have found that bilaterally absent N20 responses remains predictive of poor outcome in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/30,42,43,60\">",
"     30,42,43,60",
"    </a>",
"    ], another found that neurologic recovery was possible in a small number of patients (1 of 36 patients) who had absent N20 responses in the setting of cardiac arrest treated with induced hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35274?source=see_link&amp;anchor=H9724176#H9724176\">",
"     \"Post-cardiac arrest management in adults\", section on 'Therapeutic (Induced) hypothermia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical operating characteristics of other evoked potentials (brainstem, auditory, visual, middle latency, and event-related) have not been adequately evaluated. SSEPs are the best validated and most reliable of the ancillary tests currently available for clinical use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Electroencephalography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical value of the electroencephalogram (EEG) is unclear in the assessment of prognosis of anoxic brain injury because investigators have used different classification systems and variable intervals of recordings after resuscitation. Furthermore, the EEG is susceptible to subjective interpretation, the effects of sedative drugs, metabolic disturbances, and sepsis, which can invalidate the results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27863?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical neurophysiology\", section on 'Electroencephalogram'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EEG categories can be crudely classified into malignant and",
"    <span class=\"nowrap\">",
"     benign/types.",
"    </span>",
"    The former includes complete or near complete suppression, burst-suppression, generalized periodic complexes and the alpha-theta pattern. In one series, these malignant EEG findings were associated with a higher mortality (91 versus 54 percent) compared with those who did not have these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/62\">",
"     62",
"    </a>",
"    ]. Of these findings, complete, generalized suppression (&lt;20 microvolts) is the most specific for poor outcome; other patterns are less reliable for prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/29,30,53,63,64\">",
"     29,30,53,63,64",
"    </a>",
"    ]. The presence of variability and reactivity are relatively favorable features for recovery of awareness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/30,65\">",
"     30,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An EEG can also be helpful to evaluate for the possibility of status epilepticus, which may be clinically suppressed by sedation or neuromuscular junction blockade, medications sometimes used to control shivering in induced-hypothermia therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/66\">",
"     66",
"    </a>",
"    ]. Severe brain injury may also cause an electroclinical dissociation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Biochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predictive value of several chemical tests including neuron-specific enolase (NSE), the glial S-100 protein, creatine kinase, and lactate in blood and cerebrospinal fluid (CSF) has been evaluated after anoxic brain injury in a number of studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/67-72\">",
"     67-72",
"    </a>",
"    ]. Smaller studies have also examined the utility of CSF adenylate kinase, lactate dehydrogenase, acid phosphatase, and glutathione concentrations predicting neurologic outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/73\">",
"     73",
"    </a>",
"    ]. A meta-analysis of all reported biochemical tests in blood and CSF concluded that the combined results were not sufficiently predictive for clinical use [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/40,74\">",
"     40,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent studies have confirmed that markedly elevated serum levels of NSE and S-100 are associated with poor outcomes, but cut-off values vary among series [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/45,74-77\">",
"     45,74-77",
"    </a>",
"    ]. A prospective study of 407 consecutive patients after cardiopulmonary resuscitation used cut-off values derived from a previous meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/45,74\">",
"     45,74",
"    </a>",
"    ]. In this study, NSE &gt;33",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    was found to perform similarly to SSEP as a test of poor outcome with zero percent false-positive rate and a positive likelihood ratio of 23 (95% CI: 2-357) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/74\">",
"     74",
"    </a>",
"    ]. When combined with SSEP, the prevalence of an abnormal test result (either NSE or SSEP) was extended from 45 to 66 percent.",
"   </p>",
"   <p>",
"    The effect of induced hypothermia on the predictive value of these laboratory studies is uncertain. One study compared 97 cardiac arrest patients treated with hypothermia and 133 historical control patients who did not receive hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/78\">",
"     78",
"    </a>",
"    ]. NSE did not correlate with adverse outcome in the hypothermia patients until a cutoff of nearly 80",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    at the 72 hour mark. In other studies, NSE &gt;33",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    has had false positive rates of 8 to 29 percent in the prediction of poor outcome in the setting of hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/42,43,64\">",
"     42,43,64",
"    </a>",
"    ]. In contrast, a smaller study found that NSE &gt;33",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    was associated with failure to regain consciousness in 17 of 17 patients treated with hypothermia, while 6 of 17 patients with lower NSE levels were later able to obey verbal commands [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/79\">",
"     79",
"    </a>",
"    ]. Further studies are needed before NSE or other biological markers can be used prognostically in cardiac arrest patients treated with hypothermia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnetic resonance imaging (MRI) can identify an intracranial hemorrhage, especially subarachnoid hemorrhage, which is sometimes the cause of the arrest. &nbsp;Computed tomographic (CT) images are usually normal immediately after a cardiac arrest, but by day three, they often show brain swelling and inversion of the gray-white densities (with the use of quantitative measures) in patients with a poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI), especially with apparent diffusion coefficient (ADC) mapping can add greater precision in predicting a poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. There is a strong correlation between MRI findings and long-term outcome infants suffering hypoxic ischemic encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features, diagnosis, and treatment of neonatal encephalopathy\", section on 'Neuroimaging predictors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the future, larger studies may find a role for standard MRI as well as functional neuroimaging, such as positron emission tomography (PET) and functional MRI (fMRI), in the prognostic assessment of adults with anoxic-ischemic brain injury [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/83-85\">",
"     83-85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As mentioned above, fMRI studies have the potential to detect network processing of sensory and motor responses, showing some evidence of awareness in a small proportion of behaviorally unresponsive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/15,16,21,86\">",
"     15,16,21,86",
"    </a>",
"    ]. However, the performance and interpretation of these studies remains complex and is still investigational [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/4\">",
"     4",
"    </a>",
"    ]. There are also ethical issues regarding quality of life in decision-making that need to be resolved, namely whether patients who can generate such binary responses can participate in a decision-making process. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Persistent vegetative state'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive and preventive care remains the mainstay of therapy in all forms of anoxic brain injury [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/9,10,87\">",
"     9,10,87",
"    </a>",
"    ]. Efforts should be focused upon providing adequate nutritional support, reducing the potential for nosocomial infection, and providing adequate prophylaxis against venous thromboembolism and gastric stress ulceration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=see_link\">",
"     \"Stress ulcer prophylaxis in the intensive care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although pharmacologic stimulant therapy is recommended for some patients in a vegetative or minimally conscious state from traumatic and non-traumatic brain injury, there is no evidence to support their use in anoxic brain injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Myoclonic seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonic seizures may respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/88\">",
"     88",
"    </a>",
"    ]. In one case series, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    was successful in eliminating clinical myoclonus and suppressing the EEG manifestations in all 60 patients treated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19337/abstract/89\">",
"     89",
"    </a>",
"    ]. Given the overall poor prognosis associated with MSE following primary cardiac arrest, it does not seem justified to resort to general anesthesia to stop the seizures. Stopping the myoclonus does not improve the dismal outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Family counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family members of patients with severe neurologic injuries should be kept well informed about prognosis. They should be informed that patients in a coma are thought to experience no pain because there is no sense of awareness of self or environment, despite what may appear as grimaces, crying, or other expressions of discomfort. The perception of pain and suffering are conscious experiences governed by the cerebral cortex, while the expression of pain may be elicited at any level of the nervous system, including the",
"    <span class=\"nowrap\">",
"     motor/behavioral,",
"    </span>",
"    endocrinologic, and autonomic responses that may occur as reflexes in the absence of consciousness.",
"   </p>",
"   <p>",
"    Decision making regarding withdrawal of various levels of treatment is dependent on accurate prognostication. Once this is established, the autonomy of the patient is of prime concern and the level of care can be decided (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/60/26565?source=see_link\">",
"     \"Ethics in the intensive care unit: Informed consent\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=see_link\">",
"     \"Ethical issues near the end of life\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resuscitation from cardiac arrest or other cardiopulmonary catastrophe may be complicated by hypoxic ischemic brain injury. Obtundation or coma are frequent early on, followed by recovery or evolution to brain death or persistent vegetative state.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Certain clinical criteria have been demonstrated to be reliable in identifying individuals with a very poor prognosis. Absent pupillary or corneal reflexes at three days after cardiac arrest are invariably associated with a poor outcome. Motor responses at day three are not reliable indicators in patients treated with hypothermia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bilaterally absent somatosensory evoked responses bilaterally at 24 to 72 hours may be useful to identify those with a poor prognosis. While very specific, these signs are not very sensitive for poor neurologic outcome. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Somatosensory evoked potentials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biomarkers, eg, neuronal specific enolase, appear to be promising indicators of poor outcome, but have uncertain predictive value at least for those patients treated with hypothermia. Further research is needed to better define their cut-off values and sensitivity. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Biochemistry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is helpful to have two indicators of poor outcome before concluding that the patient will be severely disabled. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Ancillary testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential confounding factors in the clinical assessment of patients in hypoxic ischemic coma include acute metabolic derangements (eg, renal failure, liver failure, shock), the administration of sedative or neuromuscular agents, and induced-hypothermia therapy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Ancillary testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If no negative prognostic criteria apply, the patient should continue to be supported until a more definitive prognosis can be reached. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regular information sessions with substitute decision maker(s) and family are advisable. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Family counseling'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/1\">",
"      Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002; 346:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/2\">",
"      Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002; 346:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/3\">",
"      Mateen FJ, Josephs KA, Trenerry MR, et al. Long-term cognitive outcomes following out-of-hospital cardiac arrest: a population-based study. Neurology 2011; 77:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/4\">",
"      Laureys S, Owen AM, Schiff ND. Brain function in coma, vegetative state, and related disorders. Lancet Neurol 2004; 3:537.",
"     </a>",
"    </li>",
"    <li>",
"     Plum, F, Posner, JB. The Diagnosis of Stupor and Coma. 3rd ed, FA Davis Company, Philadelphia 1980. p.103.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/6\">",
"      Medical aspects of the persistent vegetative state (1). The Multi-Society Task Force on PVS. N Engl J Med 1994; 330:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/7\">",
"      Bernat JL. The natural history of chronic disorders of consciousness. Neurology 2010; 75:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/8\">",
"      Saposnik G, Maurino J, Saizar R, Bueri JA. Spontaneous and reflex movements in 107 patients with brain death. Am J Med 2005; 118:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/9\">",
"      Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet 1975; 1:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/10\">",
"      Levy DE, Bates D, Caronna JJ, et al. Prognosis in nontraumatic coma. Ann Intern Med 1981; 94:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/11\">",
"      Jennett B, Plum F. Persistent vegetative state after brain damage. A syndrome in search of a name. Lancet 1972; 1:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/12\">",
"      Medical aspects of the persistent vegetative state (2). The Multi-Society Task Force on PVS. N Engl J Med 1994; 330:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/13\">",
"      Luaut&eacute; J, Maucort-Boulch D, Tell L, et al. Long-term outcomes of chronic minimally conscious and vegetative states. Neurology 2010; 75:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/14\">",
"      Estraneo A, Moretta P, Loreto V, et al. Late recovery after traumatic, anoxic, or hemorrhagic long-lasting vegetative state. Neurology 2010; 75:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/15\">",
"      Monti MM, Vanhaudenhuyse A, Coleman MR, et al. Willful modulation of brain activity in disorders of consciousness. N Engl J Med 2010; 362:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/16\">",
"      Owen AM, Coleman MR, Boly M, et al. Detecting awareness in the vegetative state. Science 2006; 313:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/17\">",
"      Rodriguez Moreno D, Schiff ND, Giacino J, et al. A network approach to assessing cognition in disorders of consciousness. Neurology 2010; 75:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/18\">",
"      Faugeras F, Rohaut B, Weiss N, et al. Probing consciousness with event-related potentials in the vegetative state. Neurology 2011; 77:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/19\">",
"      Cruse D, Chennu S, Chatelle C, et al. Bedside detection of awareness in the vegetative state: a cohort study. Lancet 2011; 378:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/20\">",
"      Cruse D, Chennu S, Chatelle C, et al. Relationship between etiology and covert cognition in the minimally conscious state. Neurology 2012; 78:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/21\">",
"      Ropper, AH. Cogito ergo sum by MRI. N Eng J Med 2010; 362:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/22\">",
"      Giacino JT, Ashwal S, Childs N, et al. The minimally conscious state: definition and diagnostic criteria. Neurology 2002; 58:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/23\">",
"      Landsness E, Bruno MA, Noirhomme Q, et al. Electrophysiological correlates of behavioural changes in vigilance in vegetative state and minimally conscious state. Brain 2011; 134:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/24\">",
"      Laureys S, Perrin F, Faymonville ME, et al. Cerebral processing in the minimally conscious state. Neurology 2004; 63:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/25\">",
"      Coleman MR, Menon DK, Fryer TD, Pickard JD. Neurometabolic coupling in the vegetative and minimally conscious states: preliminary findings. J Neurol Neurosurg Psychiatry 2005; 76:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/26\">",
"      Voss HU, Ulu&ccedil; AM, Dyke JP, et al. Possible axonal regrowth in late recovery from the minimally conscious state. J Clin Invest 2006; 116:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/27\">",
"      Whyte J, Katz D, Long D, et al. Predictors of outcome in prolonged posttraumatic disorders of consciousness and assessment of medication effects: A multicenter study. Arch Phys Med Rehabil 2005; 86:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/28\">",
"      Lammi MH, Smith VH, Tate RL, Taylor CM. The minimally conscious state and recovery potential: a follow-up study 2 to 5 years after traumatic brain injury. Arch Phys Med Rehabil 2005; 86:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/29\">",
"      Wijdicks EF, Hijdra A, Young GB, et al. Practice parameter: prediction of outcome in comatose survivors after cardiopulmonary resuscitation (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 67:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/30\">",
"      Rossetti AO, Oddo M, Logroscino G, Kaplan PW. Prognostication after cardiac arrest and hypothermia: a prospective study. Ann Neurol 2010; 67:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/31\">",
"      Sunde K, Dunlop O, Rostrup M, et al. Determination of prognosis after cardiac arrest may be more difficult after introduction of therapeutic hypothermia. Resuscitation 2006; 69:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/32\">",
"      Perman SM, Kirkpatrick JN, Reitsma AM, et al. Timing of neuroprognostication in postcardiac arrest therapeutic hypothermia*. Crit Care Med 2012; 40:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/33\">",
"      Berek K, Jeschow M, Aichner F. The prognostication of cerebral hypoxia after out-of-hospital cardiac arrest in adults. Eur Neurol 1997; 37:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/34\">",
"      de Vos R, Koster RW, De Haan RJ, et al. In-hospital cardiopulmonary resuscitation: prearrest morbidity and outcome. Arch Intern Med 1999; 159:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/35\">",
"      Saklayen M, Liss H, Markert R. In-hospital cardiopulmonary resuscitation. Survival in 1 hospital and literature review. Medicine (Baltimore) 1995; 74:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/36\">",
"      Booth CM, Boone RH, Tomlinson G, Detsky AS. Is this patient dead, vegetative, or severely neurologically impaired? Assessing outcome for comatose survivors of cardiac arrest. JAMA 2004; 291:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/37\">",
"      Levy DE, Caronna JJ, Singer BH, et al. Predicting outcome from hypoxic-ischemic coma. JAMA 1985; 253:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/38\">",
"      Mullie A, Verstringe P, Buylaert W, et al. Predictive value of Glasgow coma score for awakening after out-of-hospital cardiac arrest. Cerebral Resuscitation Study Group of the Belgian Society for Intensive Care. Lancet 1988; 1:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/39\">",
"      Berek K, Schinnerl A, Traweger C, et al. The prognostic significance of coma-rating, duration of anoxia and cardiopulmonary resuscitation in out-of-hospital cardiac arrest. J Neurol 1997; 244:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/40\">",
"      Zandbergen EG, de Haan RJ, Stoutenbeek CP, et al. Systematic review of early prediction of poor outcome in anoxic-ischaemic coma. Lancet 1998; 352:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/41\">",
"      Al Thenayan E, Savard M, Sharpe M, et al. Predictors of poor neurologic outcome after induced mild hypothermia following cardiac arrest. Neurology 2008; 71:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/42\">",
"      Fugate JE, Wijdicks EF, Mandrekar J, et al. Predictors of neurologic outcome in hypothermia after cardiac arrest. Ann Neurol 2010; 68:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/43\">",
"      Bouwes A, Binnekade JM, Kuiper MA, et al. Prognosis of coma after therapeutic hypothermia: a prospective cohort study. Ann Neurol 2012; 71:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/44\">",
"      Wijdicks EF, Parisi JE, Sharbrough FW. Prognostic value of myoclonus status in comatose survivors of cardiac arrest. Ann Neurol 1994; 35:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/45\">",
"      Zandbergen EG, Hijdra A, Koelman JH, et al. Prediction of poor outcome within the first 3 days of postanoxic coma. Neurology 2006; 66:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/46\">",
"      Wijdicks EF, Young GB. Myoclonus status in comatose patients after cardiac arrest. Lancet 1994; 343:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/47\">",
"      Young GB, Gilbert JJ, Zochodne DW. The significance of myoclonic status epilepticus in postanoxic coma. Neurology 1990; 40:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/48\">",
"      Arnoldus EP, Lammers GJ. Postanoxic coma: good recovery despite myoclonus status. Ann Neurol 1995; 38:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/49\">",
"      Harper SJ, Wilkes RG. Posthypoxic myoclonus (the Lance-Adams syndrome) in the intensive care unit. Anaesthesia 1991; 46:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/50\">",
"      Krumholz A, Stern BJ, Weiss HD. Outcome from coma after cardiopulmonary resuscitation: relation to seizures and myoclonus. Neurology 1988; 38:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/51\">",
"      Rossetti AO, Oddo M, Liaudet L, Kaplan PW. Predictors of awakening from postanoxic status epilepticus after therapeutic hypothermia. Neurology 2009; 72:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/52\">",
"      Carter BG, Butt W. Review of the use of somatosensory evoked potentials in the prediction of outcome after severe brain injury. Crit Care Med 2001; 29:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/53\">",
"      Chen R, Bolton CF, Young B. Prediction of outcome in patients with anoxic coma: a clinical and electrophysiologic study. Crit Care Med 1996; 24:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/54\">",
"      Robinson LR, Micklesen PJ, Tirschwell DL, Lew HL. Predictive value of somatosensory evoked potentials for awakening from coma. Crit Care Med 2003; 31:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/55\">",
"      Pohlmann-Eden B, Dingethal K, Bender HJ, Koelfen W. How reliable is the predictive value of SEP (somatosensory evoked potentials) patterns in severe brain damage with special regard to the bilateral loss of cortical responses? Intensive Care Med 1997; 23:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/56\">",
"      Zandbergen EG, Koelman JH, de Haan RJ, et al. SSEPs and prognosis in postanoxic coma: only short or also long latency responses? Neurology 2006; 67:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/57\">",
"      Lee YC, Phan TG, Jolley DJ, et al. Accuracy of clinical signs, SEP, and EEG in predicting outcome of hypoxic coma: a meta-analysis. Neurology 2010; 74:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/58\">",
"      Zandbergen EG, Hijdra A, de Haan RJ, et al. Interobserver variation in the interpretation of SSEPs in anoxic-ischaemic coma. Clin Neurophysiol 2006; 117:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/59\">",
"      Madl C, Kramer L, Domanovits H, et al. Improved outcome prediction in unconscious cardiac arrest survivors with sensory evoked potentials compared with clinical assessment. Crit Care Med 2000; 28:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/60\">",
"      Bouwes A, Binnekade JM, Zandstra DF, et al. Somatosensory evoked potentials during mild hypothermia after cardiopulmonary resuscitation. Neurology 2009; 73:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/61\">",
"      Leithner C, Ploner CJ, Hasper D, Storm C. Does hypothermia influence the predictive value of bilateral absent N20 after cardiac arrest? Neurology 2010; 74:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/62\">",
"      Rossetti AO, Logroscino G, Liaudet L, et al. Status epilepticus: an independent outcome predictor after cerebral anoxia. Neurology 2007; 69:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/63\">",
"      Young GB. The EEG in coma. J Clin Neurophysiol 2000; 17:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/64\">",
"      Rossetti AO, Carrera E, Oddo M. Early EEG correlates of neuronal injury after brain anoxia. Neurology 2012; 78:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/65\">",
"      Thenayan EA, Savard M, Sharpe MD, et al. Electroencephalogram for prognosis after cardiac arrest. J Crit Care 2010; 25:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/66\">",
"      Hovland A, Nielsen EW, Kl&uuml;ver J, Salvesen R. EEG should be performed during induced hypothermia. Resuscitation 2006; 68:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/67\">",
"      Vaagenes P, Kjekshus J, Torvik A. The relationship between cerebrospinal fluid creatine kinase and morphologic changes in the brain after transient cardiac arrest. Circulation 1980; 61:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/68\">",
"      K&auml;rkel&auml; J, Pasanen M, Kaukinen S, et al. Evaluation of hypoxic brain injury with spinal fluid enzymes, lactate, and pyruvate. Crit Care Med 1992; 20:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/69\">",
"      Tirschwell DL, Longstreth WT Jr, Rauch-Matthews ME, et al. Cerebrospinal fluid creatine kinase BB isoenzyme activity and neurologic prognosis after cardiac arrest. Neurology 1997; 48:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/70\">",
"      M&uuml;llner M, Sterz F, Domanovits H, et al. The association between blood lactate concentration on admission, duration of cardiac arrest, and functional neurological recovery in patients resuscitated from ventricular fibrillation. Intensive Care Med 1997; 23:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/71\">",
"      Fogel W, Krieger D, Veith M, et al. Serum neuron-specific enolase as early predictor of outcome after cardiac arrest. Crit Care Med 1997; 25:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/72\">",
"      Ros&eacute;n H, Rosengren L, Herlitz J, Blomstrand C. Increased serum levels of the S-100 protein are associated with hypoxic brain damage after cardiac arrest. Stroke 1998; 29:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/73\">",
"      Edgren E, Terent A, Hedstrand U, Ronquist G. Cerebrospinal fluid markers in relation to outcome in patients with global cerebral ischemia. Crit Care Med 1983; 11:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/74\">",
"      Zandbergen EG, de Haan RJ, Hijdra A. Systematic review of prediction of poor outcome in anoxic-ischaemic coma with biochemical markers of brain damage. Intensive Care Med 2001; 27:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/75\">",
"      Meynaar IA, Oudemans-van Straaten HM, van der Wetering J, et al. Serum neuron-specific enolase predicts outcome in post-anoxic coma: a prospective cohort study. Intensive Care Med 2003; 29:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/76\">",
"      Zingler VC, Krumm B, Bertsch T, et al. Early prediction of neurological outcome after cardiopulmonary resuscitation: a multimodal approach combining neurobiochemical and electrophysiological investigations may provide high prognostic certainty in patients after cardiac arrest. Eur Neurol 2003; 49:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/77\">",
"      Tiainen M, Roine RO, Pettil&auml; V, Takkunen O. Serum neuron-specific enolase and S-100B protein in cardiac arrest patients treated with hypothermia. Stroke 2003; 34:2881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/78\">",
"      Steffen IG, Hasper D, Ploner CJ, et al. Mild therapeutic hypothermia alters neuron specific enolase as an outcome predictor after resuscitation: 97 prospective hypothermia patients compared to 133 historical non-hypothermia patients. Crit Care 2010; 14:R69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/79\">",
"      Cronberg T, Rundgren M, Westhall E, et al. Neuron-specific enolase correlates with other prognostic markers after cardiac arrest. Neurology 2011; 77:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/80\">",
"      Wijman CA, Mlynash M, Caulfield AF, et al. Prognostic value of brain diffusion-weighted imaging after cardiac arrest. Ann Neurol 2009; 65:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/81\">",
"      Wu O, Sorensen AG, Benner T, et al. Comatose patients with cardiac arrest: predicting clinical outcome with diffusion-weighted MR imaging. Radiology 2009; 252:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/82\">",
"      Rutherford M, Pennock J, Schwieso J, et al. Hypoxic-ischaemic encephalopathy: early and late magnetic resonance imaging findings in relation to outcome. Arch Dis Child Fetal Neonatal Ed 1996; 75:F145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/83\">",
"      Laureys S, Antoine S, Boly M, et al. Brain function in the vegetative state. Acta Neurol Belg 2002; 102:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/84\">",
"      Wartenberg KE, Patsalides A, Yepes MS. Is magnetic resonance spectroscopy superior to conventional diagnostic tools in hypoxic-ischemic encephalopathy? J Neuroimaging 2004; 14:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/85\">",
"      Mlynash M, Campbell DM, Leproust EM, et al. Temporal and spatial profile of brain diffusion-weighted MRI after cardiac arrest. Stroke 2010; 41:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/86\">",
"      Coleman MR, Davis MH, Rodd JM, et al. Towards the routine use of brain imaging to aid the clinical diagnosis of disorders of consciousness. Brain 2009; 132:2541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/87\">",
"      Grubb NR. Managing out-of-hospital cardiac arrest survivors: 1. Neurological perspective. Heart 2001; 85:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/88\">",
"      Patel R, Jha S. Intravenous valproate in post-anoxic myoclonic status epilepticus: a report of ten patients. Neurol India 2004; 52:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19337/abstract/89\">",
"      Th&ouml;mke F, Weilemann SL. Poor prognosis despite successful treatment of postanoxic generalized myoclonus. Neurology 2010; 74:1392.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4833 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-5849588C53-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_56_19337=[""].join("\n");
var outline_f18_56_19337=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NOMENCLATURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Brain death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Persistent vegetative state",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Minimally conscious state",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      THERAPEUTIC (INDUCED) HYPOTHERMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Clinical setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prognosis based on clinical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Myoclonic status epilepticus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ANCILLARY TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Somatosensory evoked potentials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Electroencephalography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Biochemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Myoclonic seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Family counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4833\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4833|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/21/2396\" title=\"table 1\">",
"      Clinical features of PVS coma and others",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/47/16123\" title=\"table 2\">",
"      Poor prognostic features after cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/51/2876\" title=\"table 3\">",
"      Neurologic predictors of prognosis after cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/62/29676\" title=\"table 4\">",
"      Glasgow coma scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=related_link\">",
"      Clinical features, diagnosis, and treatment of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27863?source=related_link\">",
"      Clinical neurophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30761?source=related_link\">",
"      Diagnosis of brain death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=related_link\">",
"      Ethical issues near the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/60/26565?source=related_link\">",
"      Ethics in the intensive care unit: Informed consent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18566?source=related_link\">",
"      Management of the potential deceased donor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30041?source=related_link\">",
"      Outcome of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35274?source=related_link\">",
"      Post-cardiac arrest management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=related_link\">",
"      Stress ulcer prophylaxis in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=related_link\">",
"      Stupor and coma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_56_19338="Malignancy-related superior vena cava syndrome";
var content_f18_56_19338=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Malignancy-related superior vena cava syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/56/19338/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/56/19338/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/56/19338/contributors\">",
"     Dmitry J Rabkin, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/56/19338/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/56/19338/contributors\">",
"     Arthur T Skarin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/56/19338/contributors\">",
"     Eduardo Bruera, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/56/19338/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/56/19338/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/56/19338/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superior vena cava (SVC) syndrome results from any condition that leads to obstruction of blood flow through the SVC. Obstruction can be caused by invasion or external compression of the SVC by adjacent pathologic processes involving the right lung, lymph nodes, and other mediastinal structures, or by thrombosis of blood within the SVC. In some cases, both external compression and thrombosis coexist [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the preantibiotic era, syphilitic thoracic aortic aneurysms, fibrosing mediastinitis, and other complications of untreated infection were frequent causes of the SVC syndrome. In the postantibiotic era, malignancy became the most common cause, accounting for 90 percent of cases. More recently, the incidence of SVC syndrome due to thrombosis has risen, largely because of increased use of intravascular devices such as catheters and pacemaker wires. In the present era, benign causes now account for 20 to 40 percent of cases of SVC syndrome.",
"   </p>",
"   <p>",
"    This review will focus on the etiology, clinical presentation, diagnosis, and treatment of SVC syndrome, emphasizing management in patients with malignancy. The management of SVC thrombosis in the setting of hemodialysis and other indwelling intravascular catheters in patients who do not have cancer is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15722?source=see_link\">",
"     \"Thrombosis associated with chronic hemodialysis vascular access: Catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39432?source=see_link\">",
"     \"Central vein stenosis associated with dialysis access\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link\">",
"     \"Catheter-induced upper extremity venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstruction of the SVC can be caused by invasion or external compression by adjacent pathologic processes involving the right lung, lymph nodes, or other mediastinal structures, or by thrombosis of blood within the SVC. As the flow of blood within the SVC becomes obstructed, venous collaterals form, establishing alternative pathways for the return of venous blood to the right atrium (",
"    <a class=\"graphic graphic_figure graphicRef81142 \" href=\"UTD.htm?42/61/43990\">",
"     figure 1",
"    </a>",
"    ). Collateral veins may arise from the azygos, internal mammary, lateral thoracic, paraspinous, and esophageal venous systems (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70515 \" href=\"UTD.htm?10/34/10784\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The venous collaterals dilate over several weeks. As a result, upper body venous pressure is markedly elevated initially but decreases over time. However, even when well-developed collateral drainage patterns are present, central venous pressures remain elevated, producing the characteristic signs and symptoms of SVC syndrome.",
"   </p>",
"   <p>",
"    The rapidity of onset of symptoms and signs from SVC obstruction depends upon the rate at which complete obstruction of the SVC occurs in relation to the recruitment of venous collaterals. Patients with malignant disease may develop symptoms of SVC syndrome within weeks to months because rapid tumor growth does not allow adequate time to develop collateral flow. In contrast, fibrosing mediastinitis due to an infection such as histoplasmosis may not become symptomatic for years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15526?source=see_link\">",
"     \"Fibrosing mediastinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The interstitial edema of the head and neck is visually striking but generally of little clinical consequence. However, edema may narrow the lumen of the nasal passages and larynx, potentially compromising the function of the larynx or pharynx and causing dyspnea, stridor, cough, hoarseness, and dysphagia. In addition, cerebral edema can also occur and lead to cerebral ischemia, herniation, and possibly death.",
"   </p>",
"   <p>",
"    Cardiac output may be diminished transiently by acute SVC obstruction, but within a few hours, blood return is reestablished by increased venous pressure and collaterals. Hemodynamic compromise, if present, more often results from mass effect on the heart than from SVC compression [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the preantibiotic era, syphilitic thoracic aortic aneurysms, fibrosing mediastinitis, and other complications of untreated infection were frequent causes of the SVC syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Subsequently, malignancy became the most common cause, accounting for 90 percent of cases by the 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. More recently, the incidence of SVC syndrome due to thrombosis has risen, largely because of increased use of intravascular devices such as catheters and pacemakers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Benign causes now account for 20 to 40 percent of cases of SVC syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intrathoracic malignancy is responsible for 60 to 85 percent of cases of SVC syndrome, and SVC obstruction is the presenting symptom of a previously undiagnosed tumor in up to 60 percent of these cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/4,5,7\">",
"     4,5,7",
"    </a>",
"    ]. Non-small cell lung cancer (NSCLC) is the most common malignant cause of SVC syndrome, accounting for 50 percent of all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/4,5,8\">",
"     4,5,8",
"    </a>",
"    ], followed by small cell lung cancer (SCLC, 25 percent of all cases) and non-Hodgkin lymphoma (NHL, 10 percent of cases). Together, lung cancer and NHL are responsible for approximately 95 percent of cases of SVC syndrome that are caused by malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=see_link\">",
"     \"Evaluation of mediastinal masses\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32392?source=see_link\">",
"     \"Anterior mediastinal mass lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 2 to 4 percent of patients with lung cancer develop SVC syndrome at some point during their disease course [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. SVC syndrome is more common with SCLC, occurring in approximately 10 percent of cases at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/11-16\">",
"     11-16",
"    </a>",
"    ]. This is presumably because SCLC develops and grows rapidly in central rather than peripheral airways. Fewer than 2 percent of patients presenting with NSCLC have SVC syndrome as a complication, but because of the higher incidence, NSCLC is a more frequent cause of SVC syndrome than is SCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Venous obstruction in these cases results from extrinsic compression of the SVC by either the primary tumor or enlarged mediastinal lymph nodes, or as a result of direct tumor invasion of the SVC (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56308 \" href=\"UTD.htm?7/49/7967\">",
"     image 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the risk factors, pathology, and clinical manifestations of lung cancer\", section on 'Intrathoracic effects of the cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;SVC syndrome develops in 2 to 4 percent of cases of NHL [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]. For unclear reasons, Hodgkin lymphoma is rarely a cause of SVC syndrome despite its common presentation with mediastinal lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=see_link\">",
"     \"Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence and pathogenesis of SVC varies in different NHL subtypes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffuse large cell and lymphoblastic lymphomas are the most common subtypes that are associated with SVC syndrome. In one series of 915 patients with NHL, 36 presented with SVC syndrome, and all but one had either diffuse large cell or lymphoblastic subtype [",
"      <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/17\">",
"       17",
"      </a>",
"      ]. Among patients diagnosed with lymphoblastic (n = 56) or diffuse large cell lymphoma (n = 339), the incidence of SVC syndrome at presentation was 21 and 7 percent, respectively. The incidence in other subtypes was 0 to 3.9 percent.",
"     </li>",
"     <li>",
"      SVC syndrome is even more common in patients with primary mediastinal large B-cell lymphoma with sclerosis, an unusual and aggressive NHL subtype that represents 3 to 7 percent of all diffuse large-cell lymphomas. Patients typically present with a rapidly enlarging anterior mediastinal mass, frequently with associated SVC syndrome. In one report of 30 patients, 17 (57 percent) had SVC syndrome at presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/19\">",
"       19",
"      </a>",
"      ]. In addition, other patients who did not meet the clinical criteria for SVC syndrome had radiologic evidence of compression of this vessel by computed tomography (CT). Overall, 80 percent had some evidence of SVC compromise. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link&amp;anchor=H22#H22\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'Primary mediastinal large B cell lymphoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although most NHLs cause SVC syndrome by extrinsic compression due to enlarged lymph nodes (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59806 \" href=\"UTD.htm?28/9/28816\">",
"       image 3",
"      </a>",
"      ), patients with intravascular (angiotropic) lymphoma have intravascular occlusion as the primary pathogenic mechanism [",
"      <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13511?source=see_link\">",
"       \"Intravascular large cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other malignant tumors that are less commonly associated with the SVC syndrome include thymoma and other thymic neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], primary mediastinal germ cell neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/23\">",
"     23",
"    </a>",
"    ], mesothelioma, and solid tumors with mediastinal lymph node metastases (eg, breast cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/24\">",
"     24",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nonmalignant disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonmalignant conditions account for 15 to 40 percent of SVC obstructions in contemporary retrospective series [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/4,5,7,25\">",
"     4,5,7,25",
"    </a>",
"    ]. Although the incidence of SVC syndrome due to infections such as tuberculosis and syphilis has decreased, there has been an increase in SVC thrombosis associated with the presence of intravascular devices such as central venous catheters and cardiac pacemaker leads [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombosis of the SVC accounts for a significant proportion of the nonmalignant causes of SVC obstruction. Most cases are related to the presence of indwelling intravascular devices [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/5,26\">",
"     5,26",
"    </a>",
"    ]. However, considering the frequency of use of central venous access catheters, the incidence of catheter-related SVC thrombosis appears to be low [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39432?source=see_link\">",
"     \"Central vein stenosis associated with dialysis access\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link\">",
"     \"Catheter-induced upper extremity venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although uncommon, pulmonary embolism can result from these thrombi, especially if they are attached to the catheter (sleeve thrombi) rather than the vessel wall (mural thrombi) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Fibrosing mediastinitis and fungal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as 50 percent of cases of SVC syndrome not due to malignancy are attributable to fibrosing mediastinitis, of which the most common cause is an excessive host response to a prior infection with Histoplasma capsulatum. A number of other infections have been associated with fibrosing mediastinitis, including tuberculosis, actinomycosis, aspergillosis, blastomycosis, and Bancroftian filariasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15526?source=see_link\">",
"     \"Fibrosing mediastinitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=see_link\">",
"     \"Pathogenesis and clinical features of pulmonary histoplasmosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, infection with nocardiosis can cause SVC syndrome by contiguous spread from a pulmonary, pleural, or cutaneous focus of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16489?source=see_link\">",
"     \"Clinical manifestations and diagnosis of nocardiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Postradiation fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postradiation local vascular fibrosis should be included in the differential diagnosis of SVC syndrome in patients who have received prior thoracic radiation therapy (RT), even if it predated the condition by several years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17129?source=see_link\">",
"     \"Clinical manifestations and treatment of radiation-induced fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical diagnosis of SVC syndrome is made on the basis of characteristic signs and symptoms of central venous obstruction. Regardless of etiology, dyspnea is the most common symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/8,9,30\">",
"     8,9,30",
"    </a>",
"    ]. In addition, patients frequently complain of facial swelling or head fullness, which may be exacerbated by bending forward or lying down. Other symptoms include arm swelling, cough, chest pain, or dysphagia. Patients with cerebral edema may have headaches, confusion, or possibly coma.",
"   </p>",
"   <p>",
"    On physical examination, the most common findings are facial edema and venous distension in the neck and on the chest wall (",
"    <a class=\"graphic graphic_picture graphicRef76917 \" href=\"UTD.htm?4/21/4432\">",
"     picture 1",
"    </a>",
"    ). Arm edema, cyanosis, and facial plethora are less frequent.",
"   </p>",
"   <p>",
"    In most cases, symptoms are gradually progressive over several weeks and then get better over time, due to the development of venous collaterals. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with SVC syndrome have an abnormal chest radiograph since malignancy is the most common underlying disorder. In an early series of 86 patients with SVC syndrome, 84 percent had an abnormal chest film [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/25\">",
"     25",
"    </a>",
"    ]. The most common findings were mediastinal widening and pleural effusion, occurring in 64 and 26 percent of cases, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most useful imaging study is a contrast-enhanced chest CT. CT can define the level and extent of venous blockage, identify and map collateral pathways of venous drainage, and often permits identification of the underlying cause of venous obstruction. The presence of collateral vessels on CT is a strong indicator of SVC syndrome, with a specificity of 96 percent and sensitivity of 92 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications, including excessive bleeding from venipuncture sites, are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/5,34\">",
"     5,34",
"    </a>",
"    ]. However, contrast-enhanced blood from the collateral circulation draining into the inferior vena cava can simulate the appearance of a liver \"hot spot\" on CT (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75771 \" href=\"UTD.htm?13/21/13653\">",
"     image 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Venography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral upper extremity venography is the gold standard for identification of SVC obstruction and the extent of associated thrombus formation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/35\">",
"     35",
"    </a>",
"    ]. It is superior to CT for defining the site and extent of SVC obstruction and for visualizing collateral pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/31,36\">",
"     31,36",
"    </a>",
"    ]. However, it does not identify the cause of SVC obstruction unless thrombosis is the sole etiology. Similarly, radionuclide technetium-99m venography to assess SVC patency and venous flow patterns does not provide the important diagnostic information that is supplied by chest CT [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Helical CT with bilateral upper extremity contrast injection (helical CT phlebography) appears to combine the diagnostic benefit of CT with the same degree of enhanced vascular detail as digital venography, as long as appropriate techniques for intravenous injection of contrast material are used to minimize flow artifacts arising from unopacified blood [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neither approach is warranted unless an intervention (placement of an endovascular stent, surgery) is planned [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/2,40\">",
"     2,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     MR venography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance venography (MRI) is an alternative approach that may be useful for patients with contrast dye allergy or those for whom venous access cannot be obtained for contrast enhanced studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Histologic diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical history combined with CT imaging will generally differentiate between benign causes of SVC obstruction (particularly caval thrombosis) and extrinsic compression related to malignancy. Histologic diagnosis is a prerequisite for choosing appropriate therapy for the patient with SVC syndrome associated with malignancy, particularly since as many as 60 percent of patients present without a prior diagnosis of cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Minimally invasive techniques can often be used to establish a tissue diagnosis for patients who present without a prior diagnosis of malignancy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sputum cytology, pleural fluid cytology, and biopsy of enlarged peripheral lymph nodes (eg, supraclavicular) may be diagnostic in up to two-thirds of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bone marrow biopsies may provide both diagnostic and staging information for patients with suspected NHL or SCLC.",
"     </li>",
"     <li>",
"      More invasive procedures (bronchoscopy, mediastinoscopy, video-assisted thoracoscopy, thoracotomy) may be indicated when a definitive diagnosis cannot otherwise be established. Such procedures may be particularly useful in establishing the subtype for patients with lymphoma.",
"      <br/>",
"      <br/>",
"      Although some studies report a higher rate of complications from mediastinal procedures among patients who have SVC syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/43\">",
"       43",
"      </a>",
"      ], most report low rates of complications [",
"      <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/4,5,15,34,44-46\">",
"       4,5,15,34,44-46",
"      </a>",
"      ]. The safety of invasive procedures in most patients with SVC syndrome can be illustrated by the following observations:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In one series, 80 consecutive patients underwent cervical mediastinoscopy because of diagnostic uncertainty (n = 51), lack of response to chemotherapy or radiation therapy (RT, n = 17), or as part of their initial management (n = 12) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/45\">",
"       45",
"      </a>",
"      ]. There was little morbidity, and no perioperative mortality; five patients had significant bleeding, but only one required sternotomy. A definitive diagnosis was obtained in all patients.",
"     </li>",
"     <li>",
"      A review of 319 patients with SVC syndrome found major hemorrhage in 3 percent of patients undergoing mediastinoscopy or mediastinotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/34\">",
"       34",
"      </a>",
"      ]. Bronchoscopy was associated with a low risk of bleeding and respiratory distress (0.5 percent each).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are some factors that increase the risk of invasive procedures and anesthesia in patients with SVC syndrome. As examples, the presence of tracheal obstruction can lead to complications from intubation or the presence of a pericardial effusion can increase the risk of hemodynamic collapse due to cardiac tamponade [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/7,47\">",
"     7,47",
"    </a>",
"    ]. Such tumor-associated complications can be anticipated based upon the history and physical examination and the thoracic CT findings. These patients are more safely approached with upfront stenting and immediate RT (or chemotherapy) followed by an attempt to obtain diagnostic tissue. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Endovascular stents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Percutaneous transthoracic CT-guided biopsy or endoscopic ultrasound-directed biopsy is an alternative to mediastinoscopy or thoracotomy to establish a definitive diagnosis in high-risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/16/12552?source=see_link\">",
"     \"Endoscopic ultrasound-guided fine-needle aspiration in the mediastinum\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, it may not be possible to obtain sufficient material for histology, particularly if a lymphoma is suspected. In such cases, a core needle biopsy is preferable if an excisional lymph node biopsy is not possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following sections will emphasize the management of malignancy-related SVC syndrome. Management of SVC syndrome caused by indwelling venous catheters is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39432?source=see_link\">",
"     \"Central vein stenosis associated with dialysis access\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link\">",
"     \"Catheter-induced upper extremity venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of management for SVC syndrome associated with malignancy are to alleviate symptoms and treat the underlying disease. Treatment of the underlying cause depends upon the type of cancer, the extent of disease, and the overall prognosis, which is closely linked to histology and whether or not prior therapy has been administered [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/4\">",
"     4",
"    </a>",
"    ]. These factors all influence the choice of treatment.",
"   </p>",
"   <p>",
"    The average life expectancy among patients who present with malignancy-associated SVC syndrome is approximately six months, but there is wide variability depending on the underlying malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/4,7,49-52\">",
"     4,7,49-52",
"    </a>",
"    ]. For some patients, treatment of SVC syndrome and its underlying cause results in long-term relapse-free survival and cure. This is most likely to be achieved in chemotherapy-sensitive malignancies using a combined modality treatment approach.",
"   </p>",
"   <p>",
"    Evidence-based guidelines for management of SVC syndrome are not available. A general recommendation supporting radiotherapy or stent placement for symptomatic SVC syndrome from lung cancer has been made by both the National Comprehensive Cancer Network (NCCN) and the American College of Chest Physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Beyond this, specific recommendations for management are lacking.",
"   </p>",
"   <p>",
"    Initial management should be guided by the severity of symptoms and the underlying malignant condition as well as the anticipated response to treatment. A system for grading the severity of SVC syndrome (",
"    <a class=\"graphic graphic_table graphicRef72401 \" href=\"UTD.htm?11/11/11452\">",
"     table 1",
"    </a>",
"    ) and a treatment algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef54461 \" href=\"UTD.htm?4/1/4114\">",
"     algorithm 1",
"    </a>",
"    ) based upon the symptom severity and the underlying malignancy have been proposed by clinicians at Yale University [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Need for emergent RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, SVC syndrome due to malignant disease was considered a potentially life-threatening medical emergency requiring immediate RT as the quickest way to relieve the obstruction. Emergency RT is no longer considered necessary for most patients for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic obstruction is often a prolonged process developing over a period of weeks or longer prior to clinical presentation. The duration of symptoms has no influence on treatment outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/7\">",
"       7",
"      </a>",
"      ]. Deferring therapy until a full diagnostic work-up has been completed does not pose a hazard for most patients, provided the evaluation is efficient and the patient is clinically stable. This was illustrated in a review of 107 cases of SVC syndrome, in which no serious complication resulted from the SVC obstruction itself or investigative procedures leading to the diagnosis despite a prolonged period between the onset of symptoms and the initiation of therapy in some cases [",
"      <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      RT prior to biopsy may obscure the histologic diagnosis. As an example, in one study of 19 patients with symptomatic mediastinal masses who received emergency RT, a histologic diagnosis could not be established in eight (42 percent) from a biopsy obtained after such treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Current management guidelines stress the importance of accurate histologic diagnosis prior to starting therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/53\">",
"     53",
"    </a>",
"    ], and the upfront use of endovascular stents in severely symptomatic patients to provide more rapid relief than can be achieved using RT.",
"   </p>",
"   <p>",
"    Important exceptions to this general approach are patients who present with stridor due to central airway obstruction or severe laryngeal edema, and those with coma from cerebral edema.",
"    <strong>",
"     These situations represent a true medical emergency, and these patients require immediate treatment (stent placement and RT) to decrease the risk of sudden respiratory failure and death.",
"    </strong>",
"    &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link\">",
"     \"Diagnosis and management of central airway obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Supportive care and medical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no data documenting the effectiveness of this maneuver, the head should be raised to decrease hydrostatic pressure and head and neck edema.",
"   </p>",
"   <p>",
"    Obstruction of blood flow through the SVC slows venous return. This can result in local irritation or thrombosis of veins in the upper extremities, or delayed absorption of drugs from the surrounding tissues. Thus, the use of intramuscular injections in the arms should be avoided.",
"   </p>",
"   <p>",
"    For patients who have obstruction of the SVC resulting from intravascular thrombus associated with an indwelling catheter, removal of the catheter is indicated, in conjunction with systemic anticoagulation. This subject is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link\">",
"     \"Catheter-induced upper extremity venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H700934\">",
"    <span class=\"h4\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two settings in which systemic administration of glucocorticoids may be helpful. Glucocorticoids can be effective in reversing symptomatology due to SVC syndrome caused by steroid-responsive malignancies such as lymphoma or thymoma. Their effectiveness in patients with SVC obstruction due to other malignancies such as NSCLC has never been studied, and they are not indicated in these situations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/11\">",
"     11",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    In patients undergoing RT, particularly if laryngeal edema is present, glucocorticoids are commonly prescribed to reduce swelling. However, their efficacy has never been formally studied, and there are only case reports to suggest benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H700944\">",
"    <span class=\"h4\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretics are also commonly recommended, although it is unclear whether venous pressures distal to the obstruction are affected by small changes in right atrial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/2\">",
"     2",
"    </a>",
"    ]. In a retrospective series of 107 patients with SVC syndrome from a variety of causes, the rate of clinical improvement was similar among patients receiving glucocorticoids, diuretics, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Chemotherapy for small cell lung cancer, NHL, and germ cell tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with SCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/53\">",
"     53",
"    </a>",
"    ], NHL, or germ cell cancer (and possibly breast cancer), initial chemotherapy is the treatment of choice for patients with symptomatic SVC syndrome. In these settings, the clinical response to chemotherapy alone is usually rapid. Furthermore, these patients can often achieve long-term remission and durable palliation with standard treatment regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/12-17\">",
"     12-17",
"    </a>",
"    ]. When chemotherapy is the initial intervention of choice and the SVC obstruction is unrelieved, chemotherapy should be administered through a dorsal foot vein [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptomatic improvement usually occurs within one to two weeks of treatment initiation. In a review of treatment for SVC obstruction in patients with lung cancer, chemotherapy alone relieved symptoms of SVC obstruction in 77 percent of those with SCLC, although 17 percent had a later recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=see_link\">",
"     \"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For these malignancies, use of RT alone usually yields poorer long-term results and may compromise the subsequent results of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/14,17\">",
"     14,17",
"    </a>",
"    ]. However, in certain situations (eg, limited stage SCLC, some subtypes of NHL), the addition of RT to systemic chemotherapy may decrease local recurrence rates and improve overall survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=see_link\">",
"     \"Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With these treatment-responsive tumors, presentation with SVC syndrome does not necessarily portend an adverse outcome compared to patients without SVC obstruction. As an example, among patients with SCLC, some series noted paradoxically better survival among those presenting with SVC syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/13,16,57\">",
"     13,16,57",
"    </a>",
"    ], while others found no impact [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/12,14,15\">",
"     12,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with SVC syndrome and NHL, symptoms suggesting involvement of other mediastinal structures (eg, dysphagia, hoarseness or stridor) and shorter symptom duration appear to be adverse prognostic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Non-small cell lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;As compared with more therapy-sensitive malignancies, the degree and rapidity of response to chemotherapy is less in NSCLC. Symptom relief in this setting is more rapidly achieved by the use of an endovascular stent. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Endovascular stents'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/36/40520?source=see_link\">",
"     \"Second-line therapy for patients with previously treated advanced non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SVC obstruction is a strong predictor of poor prognosis in patients with NSCLC, with a median survival of only five months in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/58\">",
"     58",
"    </a>",
"    ]. Although long-term relapse-free survival has been rarely reported in patients with locally advanced disease and SVC syndrome treated with chemotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/59\">",
"     59",
"    </a>",
"    ] or a combined modality approach that includes both RT and chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/60\">",
"     60",
"    </a>",
"    ], therapy of SVC syndrome in patients with NSCLC is most often directed toward palliation of symptoms rather than long-term remission. For previously unirradiated patients, palliation is most often achieved with external beam irradiation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/36/40520?source=see_link&amp;anchor=H16#H16\">",
"     \"Second-line therapy for patients with previously treated advanced non-small cell lung cancer\", section on 'Symptom palliation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) is widely advocated for SVC syndrome caused by radiosensitive tumors in patients who have not been previously irradiated. When effective, RT provides considerable relief by reducing tumor burden [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the malignancies causing SVC syndrome are radiation-sensitive, and at least in lung cancer, symptomatic improvement is usually apparent within 72 hours. In a systematic review, RT was associated with complete relief of symptoms of SVC obstruction within two weeks in 78 and 63 percent of patients with SCLC and NSCLC, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/11\">",
"     11",
"    </a>",
"    ]. The rates of relapse post-treatment were 17 and 19 percent for SCLC and NSCLC, respectively.",
"   </p>",
"   <p>",
"    Objective measurement of the change in vena caval obstruction may not parallel measures of symptomatic improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/2\">",
"     2",
"    </a>",
"    ]. In an autopsy series [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/34\">",
"     34",
"    </a>",
"    ], complete and partial SVC patency was found in only 14 and 10 percent of patients after RT for SVC syndrome, despite reported relief of symptoms in 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/34\">",
"     34",
"    </a>",
"    ]. These data have led some to suggest that the development of collateralization may have contributed more to symptomatic improvement than the effect of RT, and to question the value of urgent RT in patients with SVC syndrome from chemotherapy sensitive malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Need for emergent RT'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39498?source=see_link\">",
"     \"Management of stage III non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Relief of symptoms may not be achieved for up to four weeks, and approximately 20 percent of patients do not obtain symptomatic relief from RT [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/9,11,24,52,62\">",
"     9,11,24,52,62",
"    </a>",
"    ]. Furthermore, the benefits of RT are often temporary, with many patients developing recurrent symptoms before dying of the underlying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/52,63\">",
"     52,63",
"    </a>",
"    ]. Particularly if symptoms are severe, more rapid palliation can be achieved through the use of an intraluminal stent, followed by RT for disease control. Stent placement is also effective in relieving symptoms in patients who fail to respond to RT [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Endovascular stents'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Endovascular stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The placement of a self-expanding endovascular stent restores venous return and provides rapid and sustained symptom palliation in patients with SVC syndrome. The technical success rate is in the range of 95 to 100 percent, and over 90 percent of patients report relief of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/35,51,64-72\">",
"     35,51,64-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The stent is placed percutaneously via the internal jugular, subclavian, or femoral vein, under local anesthetic. A guide wire is manipulated through the stenosis or obstruction in order to deploy the metal stent across the lesion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69106 \" href=\"UTD.htm?36/8/36992\">",
"     image 5",
"    </a>",
"    ). Many interventionalists administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    as a bolus of 5000 units during the procedure, although this is not universal [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/35,73\">",
"     35,73",
"    </a>",
"    ]. One stent may not be sufficient to bridge the entire extent of the stenotic area, particularly with involvement of the brachiocephalic veins. Sometimes two or even three stents in series (\"kissing stents\") are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Total occlusion of the SVC is not necessarily a contraindication to intraluminal stent placement nor is the presence of thrombus within a stenotic area [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. In such cases, balloon angioplasty or catheter-directed thrombolysis or mechanical thrombectomy could be considered prior to stent placement. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Angioplasty'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H27\">",
"     'Thrombolytic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There appears to be no significant difference in the published outcomes of the three most commonly used stainless steel stents (Gianturco Z stent, the Palmaz stent, or the Wallstent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/35\">",
"     35",
"    </a>",
"    ]. There are newer self-expanding stents (Luminex, Smart, Protege) made from nitinol (a nickel-titanium alloy) that exhibit shape memory effect and superelasticity. They have some advantages over the first-generation stents including a greater precision in placement within a stenotic area, lower thrombogenicity, and a higher radial force that allows them to withstand extrinsic compression and better maintain long-term patency [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/75\">",
"     75",
"    </a>",
"    ]. Covered stents may have higher long-term patency rates as compared to uncovered stents [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/76\">",
"     76",
"    </a>",
"    ], but additional experience is needed. &nbsp;",
"   </p>",
"   <p>",
"    There are no randomized trials comparing the efficacy of endovascular stents with palliative RT or systemic chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/77\">",
"     77",
"    </a>",
"    ]. The best data on the comparative efficacy of these approaches come from a systematic review of the literature of patients with SVC obstruction due to lung cancer (either SCLC or NSCLC) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/11\">",
"     11",
"    </a>",
"    ]. Of the 159 patients who underwent stent placement, 95 percent had relief of symptoms, and the incidence of reocclusion (usually due to thrombosis or tumor ingrowth into the stent) was only 11 percent. In contrast, of the over 600 patients with SCLC, chemotherapy alone, chemoradiotherapy, and RT resulted in complete or partial relief of symptoms in 84, 94, and 78 percent of cases, respectively. Among 150 patients with NSCLC, approximately 60 percent had relief with chemotherapy or RT. Overall, relapse rates were lower with SVC stenting (11 versus 17 to 19 percent with RT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy) in both SCLC and NSCLC.",
"   </p>",
"   <p>",
"    Reported recurrence rates range from 0 to 40 percent (averaging 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/35\">",
"     35",
"    </a>",
"    ]), but in a high proportion of these cases, patency can be restored with reintervention. Long-term outcomes after stent placement have been addressed in the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One series included 30 patients with SVC syndrome (16 malignancy-associated) who had a total of 49 stents placed [",
"      <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/72\">",
"       72",
"      </a>",
"      ]. Reocclusion developed in 13, eight of whom had SVC syndrome in the setting of an indwelling hemodialysis catheter. The primary patency rate for patients with malignant SVC syndrome was 74 percent at one year.",
"     </li>",
"     <li>",
"      A second series included 56 patients who underwent stent placement for SVC syndrome, 40 for malignant, and 16 for benign conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/74\">",
"       74",
"      </a>",
"      ]. A single stent was deployed in 38, while nine (16 percent) required more than one stent to bridge the stenotic area. Patency rates at one year in malignant and benign cases were 64 and 76 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the stent can be placed before a tissue diagnosis is available, it is a useful procedure for patients with severe symptoms who require urgent intervention. An endovascular stent is particularly appropriate for rapid symptom palliation in patients with NSCLC and mesothelioma and for those with recurrent disease who have previously received systemic therapy or RT. The role of endovascular stenting in patients presenting with chemotherapy sensitive tumors (ie, SCLC, NHL, germ cell tumors) and SVC obstruction is uncertain. In this setting, we reserve the use of endovascular stents for patients who have severe symptomatology. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Chemotherapy for small cell lung cancer, NHL, and germ cell tumors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Thrombolytic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When extensive thrombosis occurs as a complication of SVC stenosis, local catheter-directed thrombolytic therapy may be of value to reduce the length of the obstruction and the number and length of stents required, and also reduce the risk of embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/35,52,53,69,78\">",
"     35,52,53,69,78",
"    </a>",
"    ]. The thrombus may also be removed by mechanical thrombectomy, although this is used less often than thrombolysis.",
"   </p>",
"   <p>",
"    Thrombolytic therapy has also been administered following placement of an endovascular stent in an attempt to decrease secondary reocclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/71,79\">",
"     71,79",
"    </a>",
"    ]. However, the benefit of thrombolytics in this setting remains unclear, and these agents increase the risk of hematoma, gastrointestinal hemorrhage, hemoptysis and epistaxis. In a systematic review, the morbidity of stent insertion was greatest when thrombolytics were also administered, and there was no evidence that reocclusion rates were lower [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, this approach is not generally recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Angioplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no durable benefit from percutaneous balloon angioplasty as a sole therapeutic maneuver in patients with malignancy-related stenosis of the SVC [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/35\">",
"     35",
"    </a>",
"    ]. However, it is sometimes necessary to perform a predilatation to enlarge the vascular lumen in order to properly place a stent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/71\">",
"     71",
"    </a>",
"    ]. Venous rupture is an uncommon, though occasionally catastrophic, complication of angioplasty in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Need for long-term anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-term anticoagulation is often recommended after stent placement [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/35,49-51,65,67,72\">",
"     35,49-51,65,67,72",
"    </a>",
"    ], but whether long-term anticoagulation is necessary is an area of uncertainty [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/2,35,66,71\">",
"     2,35,66,71",
"    </a>",
"    ]. Full systemic anticoagulation is recommended by many after thrombolysis of existing thrombus, but there is little consensus on the indications for anticoagulation after stent placement in the absence of thrombus. To prevent stent reocclusion, some advocate anticoagulation for periods of one to nine months [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/51,65,78,80,81\">",
"     51,65,78,80,81",
"    </a>",
"    ] while others suggest antiplatelet therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/73,82\">",
"     73,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no data upon which to form an evidence-based recommendation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/35,50,67\">",
"     35,50,67",
"    </a>",
"    ]. Because it is well tolerated with minimal risk of bleeding,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    1 mg daily with the goal of maintaining an INR of less than 1.6 is a reasonable approach [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/83\">",
"     83",
"    </a>",
"    ]. An alternative approach is dual antiplatelet therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    75 mg daily plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) for three months after stent placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Complications of stent placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of stent placement are reported in 3 to 7 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/2\">",
"     2",
"    </a>",
"    ]. Early complications include infection, pulmonary embolus, stent migration, hematoma at the insertion site, bleeding, and rarely, perforation or rupture of the SVC [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/51,84,85\">",
"     51,84,85",
"    </a>",
"    ]. Late complications include bleeding (1 to 14 percent) and death (1 to 2 percent) from anticoagulation and stent failure with reocclusion.",
"   </p>",
"   <p>",
"    Stent failure is most often caused by thrombus or tumor ingrowth. However, since most patients with malignancy-related SVC syndrome have a short life expectancy, the stent usually remains patent until death [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/1\">",
"     1",
"    </a>",
"    ]. If reocclusion does occur, it can be treated with a second stent or thrombolytic therapy, with good secondary patency rates [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/1,11,73\">",
"     1,11,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Surgical intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although effective and associated with relatively few complications [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/86,87\">",
"     86,87",
"    </a>",
"    ], surgical bypass is rarely performed in patients with malignant cause of SVC syndrome because of the success of endovascular stenting. Surgical management is more often undertaken in patients with benign causes of SVC syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15526?source=see_link\">",
"     \"Fibrosing mediastinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical resection of mediastinal tumor and reconstruction of the SVC is rarely considered in view of its morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/88-90\">",
"     88-90",
"    </a>",
"    ] and the limited life expectancy of most patients who present with this complication. One possible exception is malignant thymoma and thymic carcinoma, which are relatively resistant to chemotherapy and radiation. Surgical resection could be considered in highly selected cases as a component of a multimodality approach to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/56/19338/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8474?source=see_link\">",
"     \"Clinical presentation and management of thymoma and thymic carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superior vena cava (SVC) syndrome results from obstruction of blood flow in the SVC. The majority of cases are due to malignancy, and approximately 95 percent of these are due to lung cancer or non-Hodgkin lymphoma (NHL). The SVC syndrome can also be caused by benign causes such as fibrosing mediastinitis and thrombosis associated with intravascular devices. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathophysiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignancy-related SVC syndrome was previously considered a potentially life-threatening medical emergency requiring immediate radiation therapy (RT) to rapidly relieve the obstruction. Emergency RT is no longer considered necessary for most patients. Current management guidelines stress the importance of accurate histologic diagnosis prior to starting therapy, and the upfront use of endovascular stents in severely symptomatic patients to provide more rapid symptom relief than can be achieved using RT.",
"     </li>",
"     <li>",
"      Important exceptions to this general approach are patients who present with stridor due to central airway obstruction or severe laryngeal edema causing respiratory compromise, and those with depressed central nervous system status from cerebral edema. These situations represent",
"      <strong>",
"       true medical emergencies",
"      </strong>",
"      , and these patients require both endovascular stenting and emergent RT to decrease the risk of sudden respiratory failure and death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Treatment recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment aims are to relieve symptoms and treat the underlying cause of the SVC syndrome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with clinical SVC syndrome who present with stridor, respiratory compromise, or depressed central nervous system function, we recommend emergent treatment with endovascular stenting followed by radiation therapy (RT) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Need for emergent RT'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients receiving RT on an emergency basis for severe airway obstruction, we suggest a short course of high-dose corticosteroids to minimize the risk of central airway obstruction (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Malignancy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Supportive care and medical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For other cases, if the imaging studies are consistent with a malignancy, a histologic diagnosis is required prior to initiating specific antitumor therapy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Imaging studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Histologic diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a previously undiagnosed chemotherapy sensitive malignancy (small cell lung cancer [SCLC], non-Hodgkin lymphoma [NHL], germ cell tumor, and possibly breast cancer), we recommend systemic chemotherapy as would be used for other tumors of that type (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). If patients are severely symptomatic, an endovascular stent can be used to provide rapid relief of symptoms. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Chemotherapy for small cell lung cancer, NHL, and germ cell tumors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Endovascular stents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with previously undiagnosed non-small cell lung cancer (NSCLC), we suggest placement of an endovascular stent for relief of symptoms (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Following stent placement, we suggest RT either alone or as part of a combined modality approach to treat the mediastinal disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Non-small cell lung cancer'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39498?source=see_link\">",
"       \"Management of stage III non-small cell lung cancer\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H25\">",
"       'Endovascular stents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For previously treated patients with recurrent or progressive malignancy and symptomatic SVC, we suggest placement of an endovascular stent for relief of symptoms (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Specific treatment against the tumor must be individualized, based upon antecedent therapy and overall prognosis. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Endovascular stents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who undergo placement of an endovascular stent, we suggest long-term anticoagulation with low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (1 mg daily) unless there is a contraindication to such therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A reasonable alternative is a three-month course of dual antiplatelet therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Need for long-term anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/1\">",
"      Garc&iacute;a M&oacute;naco R, Bertoni H, Pallota G, et al. Use of self-expanding vascular endoprostheses in superior vena cava syndrome. Eur J Cardiothorac Surg 2003; 24:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/2\">",
"      Wilson LD, Detterbeck FC, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med 2007; 356:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/3\">",
"      SCHECHTER MM. The superior vena cava syndrome. Am J Med Sci 1954; 227:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/4\">",
"      Yellin A, Rosen A, Reichert N, Lieberman Y. Superior vena cava syndrome. The myth--the facts. Am Rev Respir Dis 1990; 141:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/5\">",
"      Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology. Medicine (Baltimore) 2006; 85:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/6\">",
"      Chee CE, Bjarnason H, Prasad A. Superior vena cava syndrome: an increasingly frequent complication of cardiac procedures. Nat Clin Pract Cardiovasc Med 2007; 4:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/7\">",
"      Schraufnagel DE, Hill R, Leech JA, Pare JA. Superior vena caval obstruction. Is it a medical emergency? Am J Med 1981; 70:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/8\">",
"      Markman M. Diagnosis and management of superior vena cava syndrome. Cleve Clin J Med 1999; 66:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/9\">",
"      Armstrong BA, Perez CA, Simpson JR, Hederman MA. Role of irradiation in the management of superior vena cava syndrome. Int J Radiat Oncol Biol Phys 1987; 13:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/10\">",
"      Salsali M, Cliffton EE. Superior vena caval obstruction in carcinoma of lung. N Y State J Med 1969; 69:2875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/11\">",
"      Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. Clin Oncol (R Coll Radiol) 2002; 14:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/12\">",
"      Dombernowsky P, Hansen HH. Combination chemotherapy in the management of superior vena caval obstruction in small-cell anaplastic carcinoma of the lung. Acta Med Scand 1978; 204:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/13\">",
"      Spiro SG, Shah S, Harper PG, et al. Treatment of obstruction of the superior vena cava by combination chemotherapy with and without irradiation in small-cell carcinoma of the bronchus. Thorax 1983; 38:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/14\">",
"      Sculier JP, Evans WK, Feld R, et al. Superior vena caval obstruction syndrome in small cell lung cancer. Cancer 1986; 57:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/15\">",
"      Urban T, Lebeau B, Chastang C, et al. Superior vena cava syndrome in small-cell lung cancer. Arch Intern Med 1993; 153:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/16\">",
"      W&uuml;rschmidt F, B&uuml;nemann H, Heilmann HP. Small cell lung cancer with and without superior vena cava syndrome: a multivariate analysis of prognostic factors in 408 cases. Int J Radiat Oncol Biol Phys 1995; 33:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/17\">",
"      Perez-Soler R, McLaughlin P, Velasquez WS, et al. Clinical features and results of management of superior vena cava syndrome secondary to lymphoma. J Clin Oncol 1984; 2:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/18\">",
"      Presswala RG, Hiranandani NL. Pleural effusion and superior vena cava canal syndrome in Hodgkin's disease. J Indian Med Assoc 1965; 45:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/19\">",
"      Lazzarino M, Orlandi E, Paulli M, et al. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol 1993; 11:2306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/20\">",
"      Savarese DM, Zavarin M, Smyczynski MS, et al. Superior vena cava syndrome secondary to an angiotropic large cell lymphoma. Cancer 2000; 89:2515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/21\">",
"      Airan B, Sharma R, Iyer KS, et al. Malignant thymoma presenting as intracardiac tumor and superior vena caval obstruction. Ann Thorac Surg 1990; 50:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/22\">",
"      Dib HR, Friedman B, Khouli HI, et al. Malignant thymoma. A complicated triad of SVC syndrome, cardiac tamponade, and DIC. Chest 1994; 105:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/23\">",
"      Holbert BL, Libshitz HI. Superior vena caval syndrome in primary mediastinal germ cell tumors. Can Assoc Radiol J 1986; 37:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/24\">",
"      Chen JC, Bongard F, Klein SR. A contemporary perspective on superior vena cava syndrome. Am J Surg 1990; 160:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/25\">",
"      Parish JM, Marschke RF Jr, Dines DE, Lee RE. Etiologic considerations in superior vena cava syndrome. Mayo Clin Proc 1981; 56:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/26\">",
"      Rozmus G, Daubert JP, Huang DT, et al. Venous thrombosis and stenosis after implantation of pacemakers and defibrillators. J Interv Card Electrophysiol 2005; 13:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/27\">",
"      Otten TR, Stein PD, Patel KC, et al. Thromboembolic disease involving the superior vena cava and brachiocephalic veins. Chest 2003; 123:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/28\">",
"      Sivaram CA, Craven P, Chandrasekaran K. Transesophageal echocardiography during removal of central venous catheter associated with thrombus in superior vena cava. Am J Card Imaging 1996; 10:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/29\">",
"      Van Putten JW, Schlosser NJ, Vujaskovic Z, et al. Superior vena cava obstruction caused by radiation induced venous fibrosis. Thorax 2000; 55:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/30\">",
"      Bell DR, Woods RL, Levi JA. Superior vena caval obstruction: a 10-year experience. Med J Aust 1986; 145:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/31\">",
"      Bechtold RE, Wolfman NT, Karstaedt N, Choplin RH. Superior vena caval obstruction: detection using CT. Radiology 1985; 157:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/32\">",
"      Kim HJ, Kim HS, Chung SH. CT diagnosis of superior vena cava syndrome: importance of collateral vessels. AJR Am J Roentgenol 1993; 161:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/33\">",
"      Eren S, Karaman A, Okur A. The superior vena cava syndrome caused by malignant disease. Imaging with multi-detector row CT. Eur J Radiol 2006; 59:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/34\">",
"      Ahmann FR. A reassessment of the clinical implications of the superior vena caval syndrome. J Clin Oncol 1984; 2:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/35\">",
"      Uberoi R. Quality assurance guidelines for superior vena cava stenting in malignant disease. Cardiovasc Intervent Radiol 2006; 29:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/36\">",
"      Engel IA, Auh YH, Rubenstein WA, et al. CT diagnosis of mediastinal and thoracic inlet venous obstruction. AJR Am J Roentgenol 1983; 141:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/37\">",
"      Podoloff DA, Kim EE. Evaluation of sensitivity and specificity of upper extremity radionuclide venography in cancer patients with indwelling central venous catheters. Clin Nucl Med 1992; 17:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/38\">",
"      Conte FA, Orzel JA. Superior vena cava syndrome and bilateral subclavian vein thrombosis. CT and radionuclide venography correlation. Clin Nucl Med 1986; 11:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/39\">",
"      Qanadli SD, El Hajjam M, Bruckert F, et al. Helical CT phlebography of the superior vena cava: diagnosis and evaluation of venous obstruction. AJR Am J Roentgenol 1999; 172:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/40\">",
"      Stanford W, Jolles H, Ell S, Chiu LC. Superior vena cava obstruction: a venographic classification. AJR Am J Roentgenol 1987; 148:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/41\">",
"      Lin J, Zhou KR, Chen ZW, et al. Vena cava 3D contrast-enhanced MR venography: a pictorial review. Cardiovasc Intervent Radiol 2005; 28:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/42\">",
"      Thornton MJ, Ryan R, Varghese JC, et al. A three-dimensional gadolinium-enhanced MR venography technique for imaging central veins. AJR Am J Roentgenol 1999; 173:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/43\">",
"      Dosios T, Theakos N, Chatziantoniou C. Cervical mediastinoscopy and anterior mediastinotomy in superior vena cava obstruction. Chest 2005; 128:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/44\">",
"      Ferrari LR, Bedford RF. General anesthesia prior to treatment of anterior mediastinal masses in pediatric cancer patients. Anesthesiology 1990; 72:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/45\">",
"      Mineo TC, Ambrogi V, Nofroni I, Pistolese C. Mediastinoscopy in superior vena cava obstruction: analysis of 80 consecutive patients. Ann Thorac Surg 1999; 68:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/46\">",
"      Porte H, Metois D, Finzi L, et al. Superior vena cava syndrome of malignant origin. Which surgical procedure for which diagnosis? Eur J Cardiothorac Surg 2000; 17:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/47\">",
"      Pullerits J, Holzman R. Anaesthesia for patients with mediastinal masses. Can J Anaesth 1989; 36:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/48\">",
"      Cosmo L, Haponik EF, Darlak JJ, Summer WR. Neoplastic superior vena caval obstruction: diagnosis with percutaneous needle aspiration. Am J Med Sci 1987; 293:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/49\">",
"      Greillier L, Barl&eacute;si F, Doddoli C, et al. Vascular stenting for palliation of superior vena cava obstruction in non-small-cell lung cancer patients: a future 'standard' procedure? Respiration 2004; 71:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/50\">",
"      Marcy PY, Magn&eacute; N, Bentolila F, et al. Superior vena cava obstruction: is stenting necessary? Support Care Cancer 2001; 9:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/51\">",
"      Nagata T, Makutani S, Uchida H, et al. Follow-up results of 71 patients undergoing metallic stent placement for the treatment of a malignant obstruction of the superior vena cava. Cardiovasc Intervent Radiol 2007; 30:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/52\">",
"      Kee ST, Kinoshita L, Razavi MK, et al. Superior vena cava syndrome: treatment with catheter-directed thrombolysis and endovascular stent placement. Radiology 1998; 206:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/53\">",
"      Kvale PA, Selecky PA, Prakash UB, American College of Chest Physicians. Palliative care in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:368S.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/55\">",
"      Yu JB, Wilson LD, Detterbeck FC. Superior vena cava syndrome--a proposed classification system and algorithm for management. J Thorac Oncol 2008; 3:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/56\">",
"      Loeffler JS, Leopold KA, Recht A, et al. Emergency prebiopsy radiation for mediastinal masses: impact on subsequent pathologic diagnosis and outcome. J Clin Oncol 1986; 4:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/57\">",
"      Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/58\">",
"      Martins SJ, Pereira JR. Clinical factors and prognosis in non-small cell lung cancer. Am J Clin Oncol 1999; 22:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/59\">",
"      Citron ML, Fossieck BE Jr, Krasnow SH, et al. Superior vena cava syndrome due to non--small-cell lung cancer. Resolution with chemotherapy alone. JAMA 1983; 250:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/60\">",
"      Roberts JR, Bueno R, Sugarbaker DJ. Multimodality treatment of malignant superior vena caval syndrome. Chest 1999; 116:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/61\">",
"      Levitt SH, Jones TK Jr, Kilpatrick SJ Jr, Bogardus CR Jr. Treatment of malignant superior vena caval obstruction. A randomized study. Cancer 1969; 24:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/62\">",
"      Mose S, Stabik C, Eberlein K, et al. Retrospective analysis of the superior vena cava syndrome in irradiated cancer patients. Anticancer Res 2006; 26:4933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/63\">",
"      Baker GL, Barnes HJ. Superior vena cava syndrome: etiology, diagnosis, and treatment. Am J Crit Care 1992; 1:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/64\">",
"      Tanigawa N, Sawada S, Mishima K, et al. Clinical outcome of stenting in superior vena cava syndrome associated with malignant tumors. Comparison with conventional treatment. Acta Radiol 1998; 39:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/65\">",
"      Urruticoechea A, Mes&iacute;a R, Dom&iacute;nguez J, et al. Treatment of malignant superior vena cava syndrome by endovascular stent insertion. Experience on 52 patients with lung cancer. Lung Cancer 2004; 43:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/66\">",
"      Oudkerk M, Kuijpers TJ, Schmitz PI, et al. Self-expanding metal stents for palliative treatment of superior vena caval syndrome. Cardiovasc Intervent Radiol 1996; 19:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/67\">",
"      Nicholson AA, Ettles DF, Arnold A, et al. Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy. J Vasc Interv Radiol 1997; 8:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/68\">",
"      Baltayiannis N, Magoulas D, Anagnostopoulos D, et al. Percutaneous stent placement in malignant cases of superior vena cava syndrome. J BUON 2005; 10:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/69\">",
"      Crowe MT, Davies CH, Gaines PA. Percutaneous management of superior vena cava occlusions. Cardiovasc Intervent Radiol 1995; 18:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/70\">",
"      Courtheoux P, Alkofer B, Al Refa&iuml; M, et al. Stent placement in superior vena cava syndrome. Ann Thorac Surg 2003; 75:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/71\">",
"      Schindler N, Vogelzang RL. Superior vena cava syndrome. Experience with endovascular stents and surgical therapy. Surg Clin North Am 1999; 79:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/72\">",
"      Smayra T, Otal P, Chabbert V, et al. Long-term results of endovascular stent placement in the superior caval venous system. Cardiovasc Intervent Radiol 2001; 24:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/73\">",
"      Lanciego C, Chac&oacute;n JL, Juli&aacute;n A, et al. Stenting as first option for endovascular treatment of malignant superior vena cava syndrome. AJR Am J Roentgenol 2001; 177:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/74\">",
"      Barshes NR, Annambhotla S, El Sayed HF, et al. Percutaneous stenting of superior vena cava syndrome: treatment outcome in patients with benign and malignant etiology. Vascular 2007; 15:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/75\">",
"      Thierry B, Merhi Y, Bilodeau L, et al. Nitinol versus stainless steel stents: acute thrombogenicity study in an ex vivo porcine model. Biomaterials 2002; 23:2997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/76\">",
"      Gwon DI, Ko GY, Kim JH, et al. Malignant superior vena cava syndrome: a comparative cohort study of treatment with covered stents versus uncovered stents. Radiology 2013; 266:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/77\">",
"      Wilson P, Bezjak A, Asch M, et al. The difficulties of a randomized study in superior vena caval obstruction. J Thorac Oncol 2007; 2:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/78\">",
"      Stock KW, Jacob AL, Proske M, et al. Treatment of malignant obstruction of the superior vena cava with the self-expanding Wallstent. Thorax 1995; 50:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/79\">",
"      Chatziioannou A, Alexopoulos T, Mourikis D, et al. Stent therapy for malignant superior vena cava syndrome: should be first line therapy or simple adjunct to radiotherapy. Eur J Radiol 2003; 47:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/80\">",
"      Hennequin LM, Fade O, Fays JG, et al. Superior vena cava stent placement: results with the Wallstent endoprosthesis. Radiology 1995; 196:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/81\">",
"      Dinkel HP, Mettke B, Schmid F, et al. Endovascular treatment of malignant superior vena cava syndrome: is bilateral wallstent placement superior to unilateral placement? J Endovasc Ther 2003; 10:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/82\">",
"      Gross CM, Kr&auml;mer J, Waigand J, et al. Stent implantation in patients with superior vena cava syndrome. AJR Am J Roentgenol 1997; 169:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/83\">",
"      Boraks P, Seale J, Price J, et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol 1998; 101:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/84\">",
"      Martin M, Baumgartner I, Kolb M, et al. Fatal pericardial tamponade after Wallstent implantation for malignant superior vena cava syndrome. J Endovasc Ther 2002; 9:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/85\">",
"      Smith SL, Manhire AR, Clark DM. Delayed spontaneous superior vena cava perforation associated with a SVC wallstent. Cardiovasc Intervent Radiol 2001; 24:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/86\">",
"      Doty JR, Flores JH, Doty DB. Superior vena cava obstruction: bypass using spiral vein graft. Ann Thorac Surg 1999; 67:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/87\">",
"      Dhaliwal RS, Das D, Luthra S, et al. Management of superior vena cava syndrome by internal jugular to femoral vein bypass. Ann Thorac Surg 2006; 82:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/88\">",
"      Bacha EA, Chapelier AR, Macchiarini P, et al. Surgery for invasive primary mediastinal tumors. Ann Thorac Surg 1998; 66:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/89\">",
"      Chen KN, Xu SF, Gu ZD, et al. Surgical treatment of complex malignant anterior mediastinal tumors invading the superior vena cava. World J Surg 2006; 30:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/90\">",
"      Inoue M, Minami M, Shiono H, et al. Efficient clinical application of percutaneous cardiopulmonary support for perioperative management of a huge anterior mediastinal tumor. J Thorac Cardiovasc Surg 2006; 131:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/91\">",
"      Shimizu N, Moriyama S, Aoe M, et al. The surgical treatment of invasive thymoma. Resection with vascular reconstruction. J Thorac Cardiovasc Surg 1992; 103:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/56/19338/abstract/92\">",
"      Charokopos N, Antonitsis P, Klimatsidas M, et al. Secondary endovascular repair of a reconstructed superior vena cava in a patient with a malignant thymic epithelial neoplasm. Thorac Cardiovasc Surg 2007; 55:267.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2832 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-E708425CE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_56_19338=[""].join("\n");
var outline_f18_56_19338=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Lung cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Lymphoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nonmalignant disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Fibrosing mediastinitis and fungal infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Postradiation fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - CT scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Venography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - MR venography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Histologic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Need for emergent RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Supportive care and medical management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H700934\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H700944\">",
"      Diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Chemotherapy for small cell lung cancer, NHL, and germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Endovascular stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Thrombolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Angioplasty",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Need for long-term anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Complications of stent placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Surgical intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2832\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2832|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?4/1/4114\" title=\"algorithm 1\">",
"      Rx algorithm SVC synd",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2832|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/34/10784\" title=\"diagnostic image 1\">",
"      SVC syndrome SCLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/49/7967\" title=\"diagnostic image 2\">",
"      SVC invasion by lung ca MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/9/28816\" title=\"diagnostic image 3\">",
"      SVC syndrome mediast lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/21/13653\" title=\"diagnostic image 4\">",
"      Collateral circulation SVC syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/8/36992\" title=\"diagnostic image 5\">",
"      SVC stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2832|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/61/43990\" title=\"figure 1\">",
"      SVC veins mediastinum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2832|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/21/4432\" title=\"picture 1\">",
"      Vein distention SVC syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2832|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/11/11452\" title=\"table 1\">",
"      Grading system SVC synd",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32392?source=related_link\">",
"      Anterior mediastinal mass lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=related_link\">",
"      Catheter-induced upper extremity venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39432?source=related_link\">",
"      Central vein stenosis associated with dialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=related_link\">",
"      Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16489?source=related_link\">",
"      Clinical manifestations and diagnosis of nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17129?source=related_link\">",
"      Clinical manifestations and treatment of radiation-induced fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8474?source=related_link\">",
"      Clinical presentation and management of thymoma and thymic carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=related_link\">",
"      Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/16/12552?source=related_link\">",
"      Endoscopic ultrasound-guided fine-needle aspiration in the mediastinum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=related_link\">",
"      Evaluation of mediastinal masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=related_link\">",
"      Extragonadal germ cell tumors involving the mediastinum and retroperitoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15526?source=related_link\">",
"      Fibrosing mediastinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=related_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13511?source=related_link\">",
"      Intravascular large cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39498?source=related_link\">",
"      Management of stage III non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=related_link\">",
"      Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=related_link\">",
"      Pathogenesis and clinical features of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/36/40520?source=related_link\">",
"      Second-line therapy for patients with previously treated advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15722?source=related_link\">",
"      Thrombosis associated with chronic hemodialysis vascular access: Catheters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_56_19339="Phytophotodermatitis agents";
var content_f18_56_19339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Plants causing phytophotodermatitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Limes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lemons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Celery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grasses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oranges",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parsley",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parsnips",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sagebrush",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Goldenrod",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chrysanthemum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ragweed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cocklebur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tobacco",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Figs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Garlic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hot peppers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyacinth bulbs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Daffodil bulbs",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Bergeson, PS, Weiss, JC. Arch Pediatr Adolesc Med 2000; 154:201.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_56_19339=[""].join("\n");
var outline_f18_56_19339=null;
var title_f18_56_19340="Indications for discontinuation of exercise testing";
var content_f18_56_19340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for discontinuation of exercise testing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Absolute",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderately severe angina (defined as 3 on a standard scale)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drop in systolic blood pressure of &gt;10 mmHg from baseline blood pressure*, despite an increase in workload, when accompanied by other evidence of ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sustained ventricular tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Signs of poor perfusion (eg, pallor or cyanosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ST elevation (+1.0 mm) in leads without diagnostic Q waves (other than V1 or aVR)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increasing nervous system symptoms (eg, ataxia, dizziness, near syncope, or confusion)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Technical difficulties monitoring the ECG or systolic blood pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subject's desire to stop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Relative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ST or QRS changes such as extensive ST depression (&gt;2 mm of horizontal or downsloping ST-segment depression) or marked axis shift",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drop in systolic blood pressure of &gt;10 mmHg from baseline blood pressure*, despite an increase in workload, in the absence of other evidence of ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrhythmias other than sustained ventricular tachycardia, including multifocal PVCs, triplets of PVCs, supraventricular tachycardia, heart block, or bradyarrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Development of bundle-branch block or intraventricular conduction delay that cannot be distinguished from ventricular tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest pain that is increasing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fatigue, shortness of breath, wheezing, leg cramps, or claudication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertensive response (systolic BP &gt;250 mmHg and/or diastolic BP &gt;115 mmHg)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Baseline refers to a measurement obtained immediately before the test and in the same posture as the test is being performed.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_56_19340=[""].join("\n");
var outline_f18_56_19340=null;
var title_f18_56_19341="N0M0 nephrectomized patie";
var content_f18_56_19341=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Assignment of NOMO nephrectomized patients into risk groups",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 184px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Progress from top to bottom using 1997 American Joint Committee on Cancer (AJCC) T stage, Furhman's grade, and ECOG performance status (PS).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_56_19341=[""].join("\n");
var outline_f18_56_19341=null;
var title_f18_56_19342="TcR V genes in Hashimotos";
var content_f18_56_19342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F69608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F69608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    T-cell receptor V gene use in Hashimoto's thyroiditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 425px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Many different V genes coding for the TcR are present in T cells from the thyroid of patients with Hashimoto's thyroiditis, suggesting that many antigens are involved in the pathogenesis of the disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn with permission from Davies, TF, Concepcion, ES, Ben-Nun, A, et al. autoimmune thyroid disease: Direct assessment by thyroid aspiration. J Clin Endocrinol Metab 1993; 76:660.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_56_19342=[""].join("\n");
var outline_f18_56_19342=null;
var title_f18_56_19343="Insertion Mirena IUD";
var content_f18_56_19343=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Insertion Mirena IUD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 239px; height: 450px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The IUD is retracted into the insertion tube by laying the device's free arms flat (horizontal) on the sterile inside plastic surface of the package and pulling the strings firmly until the IUD slides into the tube.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Berlex. Copyright &copy;Berlex.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_56_19343=[""].join("\n");
var outline_f18_56_19343=null;
